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PKR has been shown to play an essential role against VSV infection by 
phosphorylating eIF2a leading to the inhibition of protein synthesis. Through this 
capacity PKR is thought to be a mediator of the anti-viral and anti-proliferative actions of 
IFNs. In addition to translational control, PKR has been shown to modulate the 
transcriptional activities of NF-KB, Stats and p53. However, experiments with two 
different PKR-1- mouse mode1s have failed to verify many of the biological functions 
attributed to PKR. Here, we show that the two PKR-1- MEFs express different PKR 
truncated proteins suggesting that both PKR-1- models are incomplete knockouts. The 
expression of the PKR variants may account for the significant signaling differences 
between cells from the two PKR-1- mice. 
We also demonstrate· that another eIF2a kinase, PERK contributes to cellular 
resistance towards VSV infection. We demonstrate that PERK-1- MEFs are more 
susceptible to VSV -mediated apoptosis than PERK+1+ MEFs. The higher replication 
capacity of VSV in PERK-1- MEFs results from their inability to attenuate viral protein 
synthesis due to an impaired eIF2a phosphorylation. We also show that VSV-infected 
PERK-1- MEFs are unable to fully activate PKR suggesting a cross-talk between the two 
eIF2a kinases in virus infected cells. These findings further implicate PERK in virus 
infection, and provide evidence that the anti-viral and anti-apoptotic roies of PERK are 
mediated, at least in part, via the activation of PKR. 
Despite the translational control function of eIF2a kinases, we demonstrate their 
implications in p53 inactivation. Specifically, we show that PERK activation is 
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responsible for the proteasomal degradation of p53 in a manner that is independent of 
translational control. This role is not specific for PERK, since the PKR also promotes p53 
de gradation in response to dsRNA transfection. We established that activation of eIF2a 
kinases leads to the activation of GSK313 thus promoting the Mdm2-dependent 
de gradation of p53. That is, induction of eIF2a kinases leads to the nuc1ear localization 
of GSK3p, and the nuc1ear export and proteasomal degradation of p53. Our findings 
establish a novel cross-talk between the eIF2a kinases and p53 with significant 
implications in stress responses that control cell proliferation and tumorigenesis. 
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La protéine kinase PKRjoue un rôle essentiel contre l'infection virale par le VSV, 
elle phosphoryle eIF2a, provoquant l'inhibition de la synthèse des protéines. De cette 
action, PKR est perçue comme un médiateur des actions anti-virale et anti-proliférative 
des IFNs. En plus du contrôle traductionnel, PKR intervient dans la régulation des 
activités transcriptionnelles des facteurs NF-KB, Stats et p53. Cependant, des expériences 
avec deux modèles différents de souris PKR-1- n'ont pas permis de mettre en évidence 
certaines fonctions biologiques attribuées à PKR. Ici, nous montrons que les deux types 
de cellules PKR-1- expriment différentes protéines PKR tronquées, suggérant que les deux 
modèles de PKR-1- sont des knock-out incomplets. L'expression de ces variants de PKR 
peut justifier les différences significatives de signalisation observées dans les deux types 
de souris. 
Nous démontrons aussi qu'une autre kinase phosphorylant eIF2a, PERK, 
contribue à la résistance cellulaire consécutive à l'infection par le VSV. Nous 
démontrons que les MEFs PERK-1- sont plus susceptibles à l'apoptose induite par VSV 
par rapport aux MEFs PERK+1+. La plus forte capacité réplicative du VSV dans les MEFs 
PERK-1- résulte de leur incapacité d'atténuer la synthèse de protéine virale due au manque 
de phosphorylation de eIF2a. Nous montrons également que les MEFs PERK-1- infectés 
par VSV sont incapables d'activer totalement PKR, suggérant un lien étroit entre les deux 
kinases dans les cellules infectées par le virus. Ces travaux impliquent PERK dans 
l'infection virale, et fournissent la preuve que les rôles anti-virals et anti-apoptotiques de 
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PERK en réponse à l'infection virale sont régulés, au moins en partie, via l'activation de 
PKR. 
En plus des fonctions dans le contrôle traductionnel des kinases phosphorylant 
eIF2a, nous démontrons leurs implications dans l'inactivation de p53. Nous montrons 
que l'activation de PERK est responsable de la dégradation de p53 via le protéasome, et 
ce, indépendamment du contrôle traductionnel. Ce rôle n'est pas spécifique de PERK, 
puisque PKR induit aussi la dégradation de p53 en réponse au traitement dsRNA. Nous 
avons également établi que l'activation des kinases phosphorylant eIF2a active GSK3p, 
permettant ainsi la dégradation de p53 d'une manière dépendante de Mdm2. En effet, 
l'induction des kinases eIF2a mène à la localisation nucléaire de GSK3p, à l'exportation 
nucléaire et à la dégradation de p53. Nos travaux établissent un nouveau lien étroit entre 
les kinases phosphorylant eIF2a et p53, avec des implications significatives dans les 
réponses aux stress qui contrôlent la prolifération cellulaire et la tumorigenèse. 
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The tumor suppressor protein p53 was first identified in 1979 by its ability to 
associate with the simian virus 40 (SV40) large T antigen (LTAg) and by its 
overexpression in chemically induced sarcomas or other transformed mouse cells 
(80,210,211). Other viral proteins were found to associate or bind to p53, such as the 
adenoviral EIB 55 kDa protein (285) and the HPV E6 protein (237). This suggested that 
DNA tumor viruses utilize common pathways in order to induce the transforming 
phenotype. 
Although p53 was initially thought to be a tumor antigen further experiments 
suggested that p53 expression possesses oncogenic properties. Transfection of c10ned p53 
cDNA into primary mouse cells resulted in their immortalization (161) and co-
transfection with the activated ras oncogene transformed primary rat fibroblasts (255). 
AIso, p53 chromosomal translocations were detected in various tumors, such as acute 
promyelocytic leukemia (195). These studies favored the hypothesis that p53 behaved 
like an oncogene due to its overexpression in transformed cell lines. However, most of 
these experiments were misleading because this overexpressed p53 was in fact a mutated 
.protein instead of the wild type protein (331). 
The exact cellular role that p53 played still remained unc1ear until studies showed 
that p53 production was increased after nontransformed cells were exposed to ultraviolet 
(UV) radiation (223). This upregulation was explained by the fact that p53 undergoes 
post-translational modifications in order to bypass its degradation or to stabilize it (251). 
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Future experiments elucidated the cellular function of p53 when studies in colorectal 
carcinomas were done. Mutations commonly occurred in the p53 gene in combination 
with wild type p53 allelic deletions in colorectal carcinomas suggesting a tumor 
suppressor function ofp53 (8,10). This hypothesis was tested and confirmed when wild 
type p53 was able to inhibit the growth of various cancer cells (9) and to suppress the 
transformation capacity of many oncogenes (102). These historical key experiments led 
to an explosion of research in determining the tumor suppressor function of p53 and it 
was shown to be the most commonly mutated gene in diverse human tumors (241). 
Subsequent work during the 1990's showed that p53 was a transcription factor that 
regulates many genes involved in cell cycle arrest, DNA repair, and apoptosis (130). 
To date, great knowledge has been gathered regarding the mechanisms of 
activation and cellular functions of p53. Databases have been formed to categorize p53 
alterations found in many human malignancies as well as the consequences of its 
inactivation (29,123,138,208). Applying this knowledge effectively into patient care such 
as early diagnosis, clinical outcome or prognosis as well as patient response to various 
treatmetlts will be beneficial for designing novel anticancer therapies that are currently 
under investigation. 
The tumor suppressor protein p53, also known as tumor protein 53 (TP53), is a 
sequence-specific DNA-binding transcription factor that regulates a large number of 
target genes. These genes mediate cell cycle arrest, differentiation, senescence, DNA 
repair, inhibition of metastasis (angiogenesis), and apoptosis (130). Its primary function 
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is to suppress cancer via the activation of several cellular pathways targeted by its 
transcriptional activity (318,345). p53 has been described as "the guardian of the 
genome" due to its role in conserving genomic stability by preventing mutations. Its 
name is derived from its corresponding molecular weight of 53 kDa (193,201). 
The importance of p53 in tumorigenesis was demonstrated by the fact that p53 is 
highly mutated in many different cancers and is rendered inactive in other types of 
cancers (194); and that mice homozygous for the p53 null allele are prone to spontaneous 
neoplasms by 6 months of age (90). In about 50% of these tumours, p53 is directly 
inactivated as a result of mutations in the p53 gene (TP53) (145,146). Whereas in the 
remaining tumours, it is inactivated indirectly as a result of alterations in gene products 
that interact with or signal to p53 (146,337). Mutation or inactivation of p53 renders 
cancer cells resistant to CUITent cancer therapies due to the lack ofp53-mediated signaling 
pathways that are required to suppress the tumorigenesis process (318). 
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The human p53 gene (TP 5 3) is located on the chromosome band 17p 13.1, and 
stretches up to 20 kb containing Il exons (Fig. lA). The first exon is non-coding and is 
spaced sorne 10 kb from the other 10 exons. The fully processed and spliced mRNA is 
2.5 kb in size and is expressed in all cells in the body (21,22,250). Although the p53 
mRNA levels have been shown to be relatively low in normal tissues (270), studies 
regardingp53 mRNA transcription have shown that a number of transcription factors can 
maintain basallevels, enhance or repress p53 mRNA expression (107,176,315,330). Most 
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transcription factors, particularly those from the AP-l family (c-Jun, JDP-2), have been 
shown to repress p53 expression at the· transcriptional leve1 upon UV radiation 
(257,292,295). Although little is known about the promoter sequence regulating the 
transcription of p53, the highest level of p53 mRNA was detected in the spleen and 
thymus (213,249,270). 
The human p53 gene (TP53) encodes for a 53 kDa protein consisting of 393 
amino acids in which five evolutionary conserved regions have been described (Fig. lB) 
(307). The first is located near the amino terminus and spans codons 13-19. The other 
four conserved regions are localized in the central area of the protein between codons 
100-300. Functionally, the p53 protein is divided into three domains: the amino-terminus 
(N-terminus) domain; the central core domain; and the carboxy-terminus (C-terminus) 
domain (Fig. 1 C) (131). The functional domains are further sub-divided into several other 
domains that possess specific functions that enable p53 to act as a transcription factor 
and/or tumor suppressor (131). Although p53 functions mainly as a transcription factor, 
p53 has been shown to form protein complexes by binding to heterologous proteins in 
order to modulate its activity (41). However, the biological functions ofthese complexes 
are still under investigation. Nevertheless, the regulation of the biochemical and 
biological outcomes of p53 are determined by combinatorial site specific modifications 
mediated byprecise modulators (130). 
23 
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The N-Terminus domain consists of the transactivation domain (TAD) and the 
proline-rich domain (PRD) (Fig. 1C). The transactivation domain (aa 1-44) is required for 
the transactivation activity of p53 in order to interact with various transcription factors 
and specific regulators, such as acetyltransferases and the Mdm2 ubiquitin ligase (131). 
Aiso a putative nuc1ear export signal (NES) has been identified within the transactivation 
domain (aa 11-24). The proline-rich domain (PRD) is a Src-homology 3-like (SH3) 
domain (aa 58-101) (Fig. 1C) and can mediate the interaction ofp53 with Sin3a (238) in 
order to prevent its degradation (369) as well as to mediate the apoptotic function of p53 
upon DNA damage. 
The central core domain consists of the sequence-specific DNA-binding domain 
(DBD: aa 102-292) (Fig. 1 C) (131). This is where most of the interactions between p53 
and its target proteins occur. The DNA-binding domain contains a variety of structural 
motifs and is the target of 90% of p53 mutations found in human cancers. A single point 
mutation can cause serious conformational changes in p53 rendering it inactive in its 
ability to bind target DNA sequences. 
The C-terminus domain consists of the oligomerization or tetramerization domain 
(TET), and the regulatory domain (REG) (Fig. 1 C). The tetramerization domain (aa 325-
356) is composed of a p-strand, which interacts with another p53 monomer to form a 
dimer, fOllowed by a a-helix which mediates the dimerization of two p53 dimers to form 
a tetramer. Three nuc1ear localization signaIs (NLS) have been identified in the C-
terminal domain. The first NLS (NLSI: aa 316-324) consists ofthree consecutive lysine 
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residues to a basic core, and is the most active and conserved domain: The regulatory 
domain (aa 363-393) comprises the other two NLS. NLSII is located between amino 
acids 370-376, whereas the NLSIII is between amino acids 380-386. A leucine-rich C-
terminus NES has been identified within the tetramerization domain. The NES (aa 340-
351) is highly conserved and it is believed that 61igomerization can result in masking of 
the NES, resulting in p53 nuc1ear retention (131). 
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Figure 1. Structure of p53. 
(A) The TP53 gene spans sorne 20 kb, and comprises 11 exons (El-Ell) and 
10 introns (11-110) of various length in which El is non-coding. The fully 
spliced p53 mRNA is 2.5 kb. The numbers underneath the exons or above the 
introns indicate the length of that corresponding exon or intron in base pairs. 
(B) The p53 mRNA (exons shown in black) encode for a 53 kDa protein in 
which five conserved regions can be found (I-V). 
(C) The p53 protein is a transcription factor containing 393 amino acids. The 
N-terminus contains the transactivation do main (TAD) and the proline-rich 
domain (PRD) both playing key roles in p53 activation. The central core 
domain consists of the DNA-binding do main (DBD) and is required for 
binding to promoters of genes with p53 responsive elements. The C-terminus 
con tains the tetramerization do main (TET) in which the nuclear localization 
(NLS) and nuclear export (NES) signaIs have been described. AIso, the 
regulatory domain (REG) is Iocated at the very end of the protein, and is the 
region that undergoes many post-transiationai modifications that negatively 
regulate p53. 
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Intrinsic and extrinsic stresses to the cell are capable of inducing the activation of 
p53. These stresses are categorized in three different groups: genotoxic, non-genotoxic 
and oncogenic stresses. The most studied stress capable of activating p53 is the cellular 
response upon DNA damage or any damage that affects the integrity of the genome 
(genotoxic stress). Damaging agents such as, gamma or UV irradiation, alkylation or 
depurination of DNA, reactive oxidative free radicals, and exposure to nitric oxide(NO) 
(104) can alter the DNA template in different ways that ultimate1y lead to the stability 
and activation of p53. The stabilization and activation of p53 is achieved by different 
modulators that are capable of sensing specifie stresses in order to modify p53 at the 
post-translationallevel (35). 
Different types of DNA damage activate different enzymes that modify p53 at 
specifie amino acid residues capable of transmitting a specifie cellular response 
according to the type of stress. The transmittance of the signal is dependent upon the 
post-translational modifications that p53 underwent once activated by specifie 
modulators. These modifications can be phosphorylation on serine/threonine sites mainly 
in the N-terminus transactivation domain of p53, and acetylation, methylation, 
sumoylation or ubiquitination on different epsilon amino groups of lysine residues in the 
C-terminus domain (35). For instance different p53 modulators can modify p53 
depending upon the type of DNA damage-inducing agent (Fig. 2). For example, gamma-
radiation can induce the activation of ATM and CHIC kinases, in which both can 
phosphorylate p53, whereas UV-radiation activates ATR and CHKI kinases and modify 
p53 on different sites of phosphorylation. The combination of phosphorylation, 
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acetylation or other post-translational modifications of p53 will induce specific 
downstream signaling pathways upon the specific stress acting up on the cell (35). 
The accumulation of genomlc mutations is the key factor leading to 
carcinogenesis. The rapid induction of p53 activity in response to genotoxic stress thus 
serves to ensure that cells carrying such mutations are dealt with in order to avoid tumor 
progression. Furthermore, p53 also contributes, directly or indirectly, to repair the 
afflicted DNA (246), hence its nickname "guardian of the genome" (193). 
Despite the activation of p53 upon DNA damage, a variety of other non-genotoxic 
conditions can lead to rapid induction of p53 stability (Fig. 2) (259). Although these 
conditions represent various types of stress (oxidizing or physical stress), they all have a 
common factor which is to favor the emergence of cancer-susceptible cells. Such 
conditions inc1ude ribonuc1eotide depletion (209), hypoxia (185), heat shock (247). 
In addition, p53 activity is triggered by oncogemc stress. This response is 
mediated by a variety of oncogenic proteins, inc1uding myc (136), Ras (293), and p-
catenin (74) for example, providing a direct link between oncogenic processes and the 
tumor suppressor action ofp53. 
Although most stress signaIs induce p53 protein accumulation, DNA synthesis 
inhibitors (116) and hypoxia (117,185) impair its transactivation function. Also our lab 
was the firstto show that a particular type of stress inactivates p53 by downregulating its 
protein levels upon ER stress (263). These data show that despite stresses that induce p53 
accumulation, its function is impaired under certain circumstances and that there may be 
other stresses that promote p53 degradation similar to the ER stress response (Fig.2). 
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Figure 2. Mediators of p53 core regulation. 
Diverse stress signaIs (DNA damage, oncogene activation, etc.) that activate 
p53 contribute to the regulation of the central core by inducing the tumor 
suppressor activity of the p53 protein by activating a wide range of specifie 
p53 mediators such as kinases, and acetyltransferases or other modifiers. 
However, sorne conditions promote p53 degradation such as ER stress. Other 
stress conditions, such as hypoxia, have remained controversiai as to how it 
regulates p53 activation or degradation. 
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The transcriptional activity of p53 is controlled at the cellular level, its DNA-
bi:t;lding ability, and its subcellular localization. AH these mechanisms are dependent on 
the different post-translational modifications imposed on the p53 protein itself. 
l 
For more than a decade, p53 protein turnover has been shown to be mediated by 
an ubiquitination-dependent mechanism mediated by the 26S proteasome pathway 
(55,222). A molecule of ubiquitin is first sequentiaHy transferred through the ubiquitin-
activating enzyme (El), ubiquitin-conjugating enzyme (E2), and the ubiquitin-protein 
ligase (E3). The E3 ligase also transfers ubiquitin molecules to one or more lysine 
residues of the target substrate. When multiple ubiquitin molecules are attached to one 
another they form a polyubiquitin chain. This chain is sufficient to target the substrate 
protein for destruction by the proteasome (58). 
One of the first E3 ubiquitin ligases identified to promote p53 degradation was 
Mdm2 (Fig. 3A) (147,221). It has been shown thatMdm2 can regulate the stability ofp53 
through the ubiquitin proteolysis pathway (36,133,187). More studies have demonstrated 
that Mdm2 has intrinsic E3 ligase activity suggesting that it can ubiquitinate p53 and 
Mdm2 itself (148). 
The hydrophobic pocket domain in the N-terminus of Mdm2 binds to the N-
terminus ofp53. The Mdm2-binding site in p53 has been mapped within residues 19-26 
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(Fig. 3A) (232). Upon binding to p53, Mdm2 transfers monoubiquitin molecules onto 
lysine residues located mainly in the C-terminus of p53. Figure 4 shows the various C-
terminus lysine residues of p53 modified by Mdm2. This monoubiquitination is sufficient 
to promote the nuc1ear export of p53, but not its degradation by the 26S proteasome 
pathway (204,355). It was recently shown that the histone acetyl transferase (HAT) p300 
possesses intrinsic E3 ligase activity and is critical in the addition of polyubiquitin chains 
to p53 (Fig. 3A) (118,119). However, the mechanism that govems the switch between the 
HAT and ubiquitin ligase activity ofp300 is not known. 
Another study suggests that p53 ubiquitination can be reversible by the Herpes 
virus-associated ubiquitin-specific protease (HAUSP). Not only was HAUSP identified 
as a p53 binding protein, but it can also bind and stabilize Mdm2 by deubiquitinating it as 
well (150,203,205). Although HAUSP is not induced by DNA damage, its effect on p53 
stability has not been determined yet. This suggests that perhaps other deubiquinating 
enzymes, such as the USPIUBP family of ubiquitin-specific processing proteases (7), 
may have a functional significance in regulating p53 activity. 
As mentioned earlier, Mdm2 is one of the well known E3 ligases that control p53 
stability (36). The identification of several other E3 ligases or proteins has been shown to 
mediate p53 ubiquitination and degradation. The list inc1udes Pirh2 (200), COPI (92), 
CHIP (99), ARF-BPI (45), Topors (265), and the recently described ER-resident 
ubiquitin ligase Synoviolin (352). Since most of these E3 ligases have been recently 
discovered, the regulation and mechanism of activation that mediates p53 degradation 
still remains elusive. However, it is apparent that more E3 ligases remain to be 
discovered and that the cell utilizes different ubiquitin ligases to degrade p53 upon 
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specific types of stress. For example, while Mdm2 degrades p53 in unstressed conditions 
(Fig. 3A), Synoviolin induces the ubiquitination and degradation of p53 upon ER stress 
(352). Perhaps the cell has acquired more than one single ubiquitin ligase to compensate 
for the loss of another. 
Ruman p53 has 23 phosphorylationldephosphorylation sites most of which are 
outside the DNA-binding domain (Fig. 4). These inc1ude serines 6, 9, 15,20, 33, 37, 46, 
149,215,313, 314, 315, 366, 376, 378, 392, and threonines 18, 55, 150, 155, 377, 378, 
387. Most residues are phosphorylated by several different kinases in response to specific 
stresses that are associated with p53 activation. Several kinases can phosphorylate one 
specific residue (Ser15 is phosphorylated by 8 different kinases), and one specific kinase 
can phosphorylate several residues (CRK2 phosphorylates 7 different residues) (Fig. 4). 
This redundancy amongst different kinases and phosphorylation sites may provide a 
safety mechanism to allow various stresses to activate p53 (35). Although sorne residues 
appear to be phosphorylated by a unique kinase, the phosphorylation patterns imposed 
upon p53 determines its cellular and biological responses or functions (35). 
In contrast, sorne residues that undergo dephosphorylation appear to activate p53 
as well upon ionizing radiation (IR). Such is the case with the dephosphorylation of 
Ser376 and stabilization of p53 correlating with the binding to 14-3-3 proteins (312). 
Conversely, not all kinases that phosphorylate p53 can stabilize and activate its 
transcriptional activity. We previously showed that glycogen synthase kinase 3 beta 
(GSK313) can phosphorylate p53 on Ser315/376 (Fig. 4) and induce its degradation upon 
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ER stress (263). However, other conditions that induce GSK3p kinase function can 
stabilize and activate p53 after Ser33 phosphorylation (332). This vast and complex 
pattern of phosphorylationldephosphorylation is under intense study, and reflects our lack 
ofknowledge that governs the regulation ofthe biological functions ofp53. 
The p53-Mdm2 interaction can be disrupted upon certain specific phosphorylated 
serine and threonine residues in the N-terminus of p53 (Fig. 3B) (35,341,349). The 
conformation of p53 is believed to be hindered once phosphorylated thereby preventing 
the binding of Mdm2 and thus promoting the buildup of p53 protein levels (Fig. 3B). In 
response to DNA damage (IR or UV irradiation), Ser15/20/37 and Thr18 are 
phosphorylated by either ATM (155), ATR (328) or CHK1/CHK2 (300) (Fig. 4). More 
so, the tetramerization of p53 is required for its N-terminus phosphorylation (301) and 
subsequent transactivation (Fig. 3D, 5). 
The phosphorylation of Ser15 and Ser20 alone does not impede the binding of 
Mdm2 whereas the phosphorylation on Thr18 does. However, since p53 undergoes 
sequential phosphorylation, Ser15/20 phosphorylation is required first before inducing 
Thr18 phosphorylation in order to inhibit Mdm2 binding. Despite the weIl studied IR and 
UV pathways leading to p53 stabilization (Fig. 5), there is a plethora of phosphorylation 
cascades catalyzed by specific kinases which differentially regulate p53 (35) (Fig. 4). 
Since p53 ubiquitination occurs within its C-terminus lysine residues (Fig. 4), any 
other modification on these residues would then hinder p53-Mdm2 interaction. The 
p300/CBP histone acetyltransferase acetylates Lys372/373/381/382 of p53 upon DNA 
damage thereby promoting its accumulation by competing with Mdm2-mediated 
ubiquitination of these same residues (Fig. 3C and Fig. 4) (212,282). These studies 
suggest that the N-terminus phosphorylation of p53 is required to promote C-terminus 
acetylation in order to stabilize and activate the transcriptional activity of p53 (Fig. 5). 
However a recent study demonstrated that by mutating six C-terminus lysine residues of 
endogenous mouse p53, the stabilization of p53 appeared normal before or after DNA 
damage (101). This indicates that ubiquitination of these lysine residues is not required 
for efficient p53 degradation. However the transcriptional activity of this mutant form of 
p53 was affected suggesting that the C-terminus post-translational modifications may 
contribute to the outcome of the p53 response rather to its stability. This matter still 
remains debatable and would require much more insight before generalizing such a 
statement. 
The p300lCBP proteins mediate histone acetylation and function as co-activators 
for many transcription factors (43), induding p53 (121). About a decade ago, p300lCBP 
was shown to also acetylate the C-terminus of p53, and promote its ability to bind DNA 
(Fig. 3C) (120,282). This increase in the DNA-binding function of p53 mediated by 
acetylation was later shown to enhance its transcriptional activity on selected target genes 
(216). However, when several acetylation sites were mutated in the C-terminus of p53, 
the mutant p53 was able to bind to the p2I promoter to the same extent as the wild type 
p53 protein using a ChIP assay (16). This study demonstrated that p53 acetylation may 
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not favor its DNA-binding ability but rather to promote co-activator recruitment and 
histone acetylation in order to induce its transcriptional activity on selected target genes. 
Although the enhancement of DNA-binding of p53 by acetylation remains controversial, 
these data suggest that C-tenninus acetylation modifies or induces confonnational 
changes in the structure of p53 in order to activate its transcriptional activity. 
Although p300/CBP acetylates lysines on p53 associated with Mdm2-mediated 
ubiquitination (Lys 372/373/381/382), the E4F1 ubiquitin ligase has recently been shown 
to ubiquitinate Lys320 (Fig. 4). This lysine residue is a distinct site than those targeted by 
Mdm2 and conipetes with the acetylation induced by PCAF on p53 (196). In contrast to 
Mdm2-dependent ubiquitination, E4Fl does not promote p53 degradation but instead it 
inhibits cell growth by arresting the cell cycle. However, this response does not induce 
pro-apoptotic target genes, as seen with the acetylation of Lys320 by PCAF (282,324). It 
appears that most acetylation that occurs on p53 has a positive effect on its transcriptional 
activity regardless the controversy surrounding the effect on its DNA-binding activity. 
Although p300/CBP stabilizes p53 by competing with the ubiquitination ofMdm2, E4Fl-
mediated ubiquitination has no effect on the lysine residues recognized by p300/CBP 
(196). 
It was previously discovered that histone deacetylases (HDAC) dowmegulate 
the transcriptional activity of p53 (167). HDACs deacetylate lysine residues on p53 
similar to those that are acetylated by p300/CBP. However, p53 and HDACs do not 
directly interact to promo te deacetylation. This is mediated by another protein called 
metastasis-associated protein 2 (MTA2) which is a component of the NuRD ATP-
dependent chromatin remodeling and histone deacetylase complex (357). MTA2 likely 
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recruits HDACs to p53 in order to reduce the acetylation levels of p53 (218). Other 
studies have shown that the Sin3a co-repressor recruits HDACs to p53 as well and 
inhibits its apoptotic function (238). Subsequent work has also identified that Sir2a, a 
NAD-dependent histone deacetylase, can physically bind and attenuate p53 function 
through deacetylation and repress its transcriptional activity upon DNA damage (217). 
Other lysine covalent modifications on p53 have been described such as 
sumoylation (289,290) and methylation (57), both of which stabilize and induce p53 
transcriptional activity (Fig. 4). In contrast, Mdm2-mediated neddylation (348) seems to 
inhibit its trrulsactivation. The mechanisms by which these modifications affect p53 
activity remains to be determined and the modifiedresidues are briefly described in 
Figure 4. 
Thus it appears that acetylation stabilizes p53 upon DNA damage and that the 
acetylated p53 is inactivated by deacetylation once the genomic damage has been 
repaired. These data suggest that a single post-translational modification does not 
determine the fate or function of p53, and that multiple covalent modifications encode for 
specific p53 biological outcomes; This "p53-code" would pro vide new insight as to how 
p53 chooses between the cell cycle or apoptotic transcriptional program. 
Although the phosphorylation effect of p53 on its DNA-binding activity remains 
unclear (101), p53 phosphorylation can recruit the interaction of certain proteins such as 
Pinl, a peptidyl-prolyl isomerase which regulates the function ofmany pro teins involved 
in cell cycle control and apoptosis (362). Upon DNA damage, p53 interacts with Pinl and 
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is strictly dependent on p53 phosphorylation. Serine 33, Thr8l and Ser3l5 are required 
for this interaction (362). Proline 82 of the polyproline region of p53 was identified to be 
essential for its interaction with Chk2 and consequent phosphorylation of p53 on serine 
20, following DNA damage. These physical and functional interactions are regulated by 
Pinl through cis.:.trans isomerization ofproline 82 (24). 
It was previously shown that the p53 protein lacking the polyproline region has 
impaired apoptotic activity and altered specificity for certain apoptotic target genes (25). 
AIso, p53 lacking the polyproline region was identified to be more susceptible to 
ubiquitination, nuclear export, and Mdm2-mediated degradation (25). These studies 
explain how Pinl protects p53 from Mdm2-mediated prote as orne degradation. Upon 
binding, Pinl generates conformational changes in p53, enhancing its transactivation 
activity and impairing its association with Mdm2. 
These are the first studies that provide a novel mechanism to the regulation of p53 
DNA-binding activity in which p53 phosphorylation indirectly controls its cellular 
response upon DNA damage. 
The activation and cellular functions of p53 are dependent on its localization. In 
unstressed cells, p53 is translated and localizes in the nucleus via its nuclear localization 
signal (NLS) (207,296). Nuclear p53 binds to and is ubiquitinated by Mdm2 thereby 
promoting its nuclear export and degradation (Fig. 5). The translation, nuclear 
translocation and degradation of p53 are dynamic processes that normal cells utilize to 
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maintain p53 levels relatively low. Any disturbance in this dynamic process would result 
in the stabilization and accumulation ofp53 in the nucleus. 
Recently the Parkin-like ubiquitin ligase, Parc has been shown to physically 
interact with p53 (242). Parc and p53 form a large cytoplasmic complex in unstressed 
cells and sequesters p53 in the cytoplasm and inhibits its apoptotic function (242). Our 
lab has shown that GSK3p binds and phosphorylates p53 on Ser315/376.in the nucleus, 
and enhances its cytoplasmic localization and degradation in cooperation with Mdm2 
upon ER stress (Fig. 5) (260,263). 
Another study demonstrated the role of REeT domain E3 ligase, WWP1, in 
regulating p53 localization and activity. WWP1 associates with p53 and induces p53 
ubiquitination. Unlike other E3 ligases, WWPI increased p53 stability in the cytoplasm 
with a concomitant decrease in its transcriptional activities. Although WWPI limits p53 
activity, p53 reduces the expression of WWPI, indicating a possible negative feedback 
loop mechanism. This finding identifies the first instance where an ubiquitin ligase 
stabilizes p53 while inactivating its transcriptional activities (192). 
In conclusion, all the CUITent p53 research suggests that a specific stress activates 
a different pool of p53 which in turn regulates a subset of target genes. AlI the different 
stresses employ various signaling pathways that differentially regulate the transcriptional 
activity of p53 in order to achieve a particular biological outcome. The enormous 
challenge that remains is to fully understand the dynamic processes that regulate or 
integrate these pathways together. 
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Figure 3. Regulation of p53 transcription al activity. 
(A) The transcriptional activity of p53 is regulated by the stability of the 
protein. In unstressed ceUs p53 is targeted for degradation by Mdm2-
mediated ubiquitination. The p300 acetyltransferase has been shown to 
promote ubiquitin (U) chain additions to the Mdm2-directed mono-
ubiquitinated p53 molecules. 
(B, C, D) In stressed ceUs, p53 undergoes post-translational modifications 
such as phosphorylation (P), acetylation (A) thus promoting its stabilization, 
and its DNA-binding activity by tetramerization in order to induce its 
transcriptional activity. 
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Figure 4. Post-translation al modification of p53. 
The p53 protein consists of several different domains (TAD: transactivation 
domain; PRD: proline-rich domain; DBD: DNA-binding domain; TET: 
tetramerization domain; REG: regulatory do main) that are post-
translationally modified by phosphorylation (P), acetylation (A), 
ubiquitination (U), neddylation (N), methylation (M) and sumoylation (S). 
Residues for each of these modifications are indicated, including the kinases, 
acetyltransferases or E3 ligases responsible for specific modifications that 
have been previously described. 
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Figure 5. Regulation of p53-Mdm2 interaction. 
In unstressed ceUs, p53 is kept inactive and at low levels by the action of 
Mdm2, which inhibits p53 by quenching its transcriptional activity, and 
through its ubiquitin-ligase activity to promote p53 degradation by the 
proteasome pathway. After various cellular stresses, stress-induced kinases 
phosphorylate p53 on several serine and threonine residues in the 
transactivation do main (TAD) thus reducing the binding of Mdm2. This leads 
to p53 accumulation, to form tetramers thus masking the nuclear export 
signal, so that stabilized p53 remains in the nucleus. The phosphorylation of 
the p53 TAD promotes the interaction with acetyltransferases such as p300. 
This leads to the acetylation of lysine residues in the p53 regulatory do main 
to promote p53 stabilization, and increase specifie DNA binding at p53 target 
genes. Although accumulated p53 is located in the nucleus, sorne studies 
suggest that foUowing stress, a pool of the p53 molecules remain in the 
cytoplasm to promote apoptosis by inhibiting the anti-apoptotic Bcl-2 or Bcl-
xL proteins. The apoptotic response is also mediated by the pro-apoptotic 
proteins Bax, Bak, and PUMA. In contrast, since most stress conditions 
stabilize p53, we have previously shown that ER stress promotes the 
degradation of p53. These p53 molecules are targeted for degradation in the 
cytoplasm by phosphorylation of p53 on Ser315/376 mediated by the 
activation of GSK3p and the cooperative action of Mdm2. 
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Since the demonstration of the DNA-binding activity of p53, intense p53-
regulated gene expression patterns have been analyzed using the help ofDNA microarray 
methods. The nature of the p53 response depends on the type of inducing agent, p53 
protein levels, cell type, and the length of treatment (366). The p53-regulated genes fall 
into either induced or repressed gene clusters that have different cellular functions. These 
. include cell cycle arrest, DNA repair, apoptosis, and feedback regulation just to name a 
few. Selected activated target genes will be discussed below and are summarized in 
Figure 6. 
Upon activation of p53 in response to stress signaIs, it binds to p53-responsive 
DNA sequence elements in the genome in order to transcribe target genes. The function 
of the p53-regulated genes falls into several categories (Fig. 6). The first are involved in 
Gl/S or G2/M phase cell cycle arrest such as p21 (96), 14-3-3cr (137), Cdc25C (310), and 
GADD45 (303) in conjunction with DNA repair genes (p21, GADD45, p48 XPE) (304). 
The second set of genes is involved in apoptosis which in itself comprises the intrinsic 
and extrinsic apoptotic pathways (132). For the extrinsic pathway, genes such as Fas, 
KILLERlDR5 have been described, whereas Bax, PUMA, and Noxa comprise the 
intrinsic apoptotic pathway. Several p53-regulated genes such as Perp, Scotin, PIG3, and 
p53-AIP have been shown to enhance the apoptotic function ofp53, but their mechanism 
of action remains unresolved (Fig. 6) (132). 
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Although the regulation and activation of apoptosis by p53 is still unelear, several 
groups have shown that p53 itself can localize to the mitochondria and promote apoptosis 
through the release of cytochrome c. This is partially mediated by the interaction of p53 
with Bel-2, Bel-xL or Bax (53,233) and the involvement of PUMA (Fig. 5) (52). 
Finally, the cell needs to assess whether its DNA has been repaired and re-enter 
the cell cyele or to reinforce the p53 response. For this, another set of p53-regulated 
genes initiate a positive or negative feedback loop that affect p53 and its core regulator of 
that specific pathway. These genes inelude the negative modulators such as Mdm2, Pirh2, 
COPI, WIP-I, SIAR-I, Cyelin G, and the positive modulator PTEN (Fig. 6) (132). 
MC?re and more p53-regulated genes are being discovered every year although 
their function or mechanisms of action are not fully elucidated. Rowever, the discovery 
of new target genes emphasizes new p53 functions never before seen or thought. For 
instance, three new p53-regulated genes have recently been discovered and reveal new 
roles of p53 in glucose metabolism and autophagy (Fig. 6). The DRAM· protein is 
regulated by p53 and may participate in the fusion of autophagosomes with lysozomes 
during autophagy (70). The pathways regulating glucose metabolism and mitochondrial 
respiration are regulated by p53-target gene products, TIGAR (23) and SC02 (227). 
TIGAR blocks glycolysis, whereas SC02 enhances oxygen consumption and 
mitochondrial respiration. Since aIl these pathways are regulated by metabolism, the data 
suggest that p53 may link aIl three metabolic pathways to ensure cell survival. . 
The identification of novel p53-target genes will help elarify sorne of the 
biological effects, cellular processes and phenotypes observed by the activation of p53. 
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However the regulation of the p53-gene expression profiles will have to be investigated 
further in order to understand these outcomes and find ways to control them regarding 
cancer therapy and drug treatment of patIents. 
AND 
Several reports have suggested that translational control may contribute to p53 
regulation. The p53 protein was suggested to negatively regulate its own translation by 
direct binding to its 5'UTR stem-Ioop structure (235). A translation suppressor element 
was also reported in the 3'UTR of the p53 mRNA (l05). A recent study revealed that in 
response to DNA damage, the ribosomal protein L26 (RPL26) and nuc1eolin were found 
to bind to p53 mRNA in cens and to compete with each other to regulate p53 synthesis 
through binding to the 5'UTR of p53 mRNA (319). AIso, two independent studies 
identified an InternaI Ribosomal Entry Site (IRES) in the 5'UTR of the p53 mRNA 
(268,354). They showed that p53 synthesis can be induced when cens are exposed to 
etoposide through a cap-independent translational mechanism mediated by IRES activity 
(354). 
Recently, it was reported that dsRNA downregulates p53 in a PKRltranslational-
dependent manner (226), and that lack of p53 sensitizes cens to dsRNA-dependent 
apoptosis. Despite suggestions that translational control of p53 might be important, the 
extent and mechanism of p53 translational regulation has remained unc1ear. 
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Figure 6. Downstream targets of p53. 
A variety of p53 target genes have been identified and play roles in the 
various cellular responses mediated by p53, such as DNA repair, cell cycle 
arrest, apoptosis, negative or positive feedback regulation, glucose 
metabolism, and autophagy. Each of these genes has been shown to contain 
p53 binding sites within its regulatory regions. 
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The regulation of gene expression at the translationallevel plays an important role 
in cell growth, proliferation, and development (343). Translation is controlled by many 
mechanisms notably at the level of initiation, elongation and termination (229). However, 
most of the regulation is modulated at the level of initiation. This step is crucial for the 
initiation codon to be recruited along with the ribosome onto an mRNA. Many initiation 
factors (eIFs) are involved in this recruitment process. The mammalian initiation steps 
consist first of the formation of the temary complex (TC) composed of eIF2-GTP-
tRNAMet. Then, the TC binds to the 40S small ribosomal subunit facilitated by the 
initiation factors elFl, eIFIA, and eIF3, forming the 43S pre-initiation complex. The 
elF4F complex composed of eIF4A, eIF4G, and elF4E binds to the 7-methylguanosine 
cap structure located on the 5'end of the mRNA and facilitates the loading of the 43S 
complex. The latter complex then scans along the mRNA, 5' to 3', in order to recognize 
the initiator AUG start codon. Once the start codon has been identified, the hydrolysis of 
GTP of elF2 occurs promoted by e1F5, thus generating an eIF2-GDP complex in which it 
dissociates from the TC leaving behind the tRNAMet in the P-site of the 40S ribosomal 
subunit. The 60S ribosomal subunit then joins the 40S subunit via eIF5B, yielding an 80S 
initiation complex (lC) waiting for the next aminoacyl-tRNA to be delivered in the A-site 
of the IC in order to begin elongation (229). 
In order to recycle to its active form and initiate another round of translation, 
eIF2-GDP must be converted to eIF2-GTP through the catalyzed reaction by e1F2B. The 
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hydrolysis of GTP to GDP as well as the recyc1ing of eIF2 is tightly controlled by the 
phosphorylation of the alpha (a) subunit of eIF2, which prevents eIF2 recyc1ing, thereby 
inhibiting translational initiation and protein synthesis (Fig. 7 A) (229). 
Although most mRNAs are inhibited by eIF2a phosphorylation, translation of 
several mRNAs is enhanced by this stress response. Such is the case for the yeast GCN4 
mRNA (87), and the ATF3 (122), ATF4 (215), and CAT-l (351) mRNAs in mammalian 
cells. In non-stressed cells, translation of these mRNAs is inhibited by upstream open 
reading frames (ORFs) in which ribosomes are stalled prematurely (110). This restricts 
the re-initiation and scanning of other ribosomes attempting to bind to the ORFs and thus 
preventing the translation of these mRNAs. When eIF2a is phosphorylated and limits the 
number of active 43S ribosomal complexes, only then can re-initiation occur and promote 
mRNA translation (110) (Fig. 7B). 
Phosphorylation of the a subunit on serine 51 by certain specific eIF2a protein 
kinase family members (see section 2.2) results in the inhibition of the initiation of 
mRNA translation (173). The phosphorylated form of eIF2 functions as a dominant 
inhibitor of the guanine ex change factor eIF2B, and prevents the recyc1ing of eIF2 
between consecutive rounds of translation initiation (Fig. 7 A) (317). Phosphorylation of 
eIF2a is induced by many physiological conditions inc1uding virus infection, heat shock, 
iron deficiency, amino acid or glucose deprivation, changes in intracellular calcium, and 
the accumulation of unfolded proteins in the endoplasmic reticulum (ER) (60). 
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Figure 7. Regulation of translation. 
(A) eIF2 is a general translational initiation factor composed of three 
subunits Ca, p, and y) that forms two types of complexes: active eIF2-GTP 
and inactive eIF2-GDP. eIF2-GTP binds Met-tRNAi to form a ternary complex 
that is required for binding to the 40S ribosomal subunit and mRNA in order 
to initiate translation. Subsequently, upon joining of the 60S ribosomal 
subunit, GTP from eIF2-GTP is hydrolyzed to GDP. In order to recycle to its 
active form and initiate another round of translation, eIF2-GDP must be 
converted to eIF2-GTP through the catalyzed reaction by eIF2B. The 
recycling of eIF2 is inhibited by phosphorylation on SerSl of its a subunit 
carried out by eIF2a kinases. Phosphorylated-eIF2-GDP has higher affinity 
for eIF2B than eIF2-GDP thereby preventing the GDP-GTP exchange activity 
of eIF2B thus inhibiting protein synthesis. (8) However, several specifie 
mRNAs (GCN4, ATF4, ATF3, CAT-l) contain upstream open reading frames 
CuORF) that help bypass translational inhibition. The mechanism of GCN4 
translation will only be discussed in this figure. Under unstressed conditions 
that result in high eIF2-GTP, translation re-initiation occurs more frequently 
after each uORF. As a result, re-initiation at the GCN4 ORF (blue) becomes 
infrequent. Under stressed conditions that indu ce eIF2a phosphorylation 
and low levels of eIF2-GTP, re-initiation occurs less frequently at the uORFs. 
This increases the probability of the 40S ribosomal subunit to scan longer 
and read-through the uORFs, and subsequently initiate translation on the 
AUG initiation codon of the downstream ORF. 
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Phosphorylation of eIF2a is induced by several kinases including PKR (172), 
PERK (273), GCN2 (27) and HRI (47). Each kinase is activated upon a specifie type of 
stress that generates different biological outcomes in order to cope with that specifie 
stress response (Fig. 8). Each kinase is described below with emphasis on PERK and 
PKR. 
l 
HRI (heme-regulated eIF2a kinase) is expressed predominantly in erythroid cells 
and is regulated by heme, the prosthetic group of hemoglobin (46). HRI contains two 
heme-binding domains located in the N-terminus and the kinase insertion domains (264). 
The N-terminus domain is always stably bound to heme (44). In contrast, heme reversibly 
binds to the kinase insertion domain and inhibits HRI kinase activity (48). Consequently, 
HRI activity is dependent according to intracellular heme concentrations (Fig. 9A). It was 
previously documented that protein synthesis in reticulocyte lysates is dependent upon 
the availability of heme (48). Upon heme deficiency, inhibition of protein synthesis 
correlates with the activation of HRI and eIF2a phosphorylation (47). Small amounts of 
HRI mRNA are also found in non-erythroid tissues but no evidence of HRI protein 
expression has been reported (26). On the other hand, recent studies have implicated HRI 
in response to heat shock, osmotic and oxidative stresses (214). 
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GCN2 was first cloned and identified in yeast (87). GCN2 functions in the 
coordinate regulation of genes involved in amino acid biosynthesis (139). Regulation of 
GCN2 kinase activity is mediated by homologous sequences to histidyl-tRNA 
synthetases (HisRS). During amino acid starvation, uncharged tRNAs accumulate and 
bind to the HisRS-related domain and stimulate GCN2-mediated phosphorylation of 
eIF2a. Phosphorylation of eIF2a leads to increased translational expression of GCN4, a 
transcriptional activator of genes involved in amino acid biosynthesis (Fig. 9B) (140). 
Amino acid starvation has also been reportedto control translation initiation in 
higher eukaryotes. Identification and characterization of GCN2 orthologs have been 
shown in many species from Drosophila, mice and humans (27). AlI GCN2 orthologs 
contain the HisRS-related sequences juxtaposed to the kinase domain. Expression of 
mammalian GCN2 proteins functionalIy complement GCN2 in the gcn2t!. yeast, and are 
able to phosphorylate eIF2a (86). This suggests that the mechanism of phosphorylation 
of eIF2a in response to nutrient deprivation is conserved from yeast to mammals. 
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Figure 8. The eIF2a. kinase family. 
Four eIF2a. kinase farnily rnernbers have been identified to date (BRI, GCN2, 
PERK, and PKR). Although the signaling pathways converge in the 
phosphorylation of eIF2a. and inhibition of protein synthesis, each kinase is 
activated upon specifie conditions. HRI is activated upon herne deficiency, 
PKR is activated in response to virus infection and dsRNA, PERK activity is 
induced upon ER stress, whereas GCN2 kinases are activated during arnino 
acid starvation. 
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Figure 9. Translational control by HRI & GCN2. 
(A) HRI is regulated by heme through the two heme-binding do mains in the 
N-terminus and kinase domain (KD). Herne is constitutively bound to the N-
terminus heme-binding domain (HBD), and HRI is kept inactive by heme 
bound to the HBD in the KD. Upon he me deficiency caused by a depletion of 
intracellular iron, HRI kinase activity is induced thereby inhibiting 
translation of globin mRNAs by phosphorylating eIF2a. 
(8) Amino acid deprivation leads to the accumulation of uncharged tRNAs 
which in turn are recognized by the histidyl-tRNA synthetase-like domain 
(HisRS) of GCN2 thereby inducing its dimerization and activation. GCN2 
subsequently inhibits protein synthesis by phosphorylating eIF2a except for 
the increased translation of GCN4, a transcriptional activator of amino acid 
biosynthesis. GCN4 mRNA bypasses the negative regulation of eIF2a 
phosphorylation due to specifie regulation in the S'UTR containing upstream 
open reading frames (uORF). 
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The most recently identified eIF2a kinase member is the PKR-like endoplasmic 
reticulum kinase/pancreatic eIF2a kinase (pERKlPEK) (298,299). PERK is localized in 
the ER membrane via its signal peptide (SP) within amino acids 1-28. It spans the ER 
membrane due to its transmembrane domain (TM: aa 514-534). The ER-Iuminal portion 
of PERK consists of the N-terminus sensor domain (aa 29-513). This domain is 
homologous to the IRE1 sensor domain (see section 2.2.3.4) and is responsible for 
interaction with ER-resident chaperones (128). The C-terminus effector domain is found 
on the cytosolic side of the ER and consists of the kinase domain (KD: aa 592-1115). Its 
kinase domain is homologous to the PKR KD (see section 2.2.4) except that it possesses 
a larger eIF2a insert region (Fig. 10A) (273). PERK phosphorylates eIF2a in response to 
ER stress in order to shut down protein synthesis of those proteins destined for the 
secretory pathway in order to relieve the load in the ER. This response is known as the 
unfolded protein response (UPR) and is discussed in section 2.2.3.4. 
PERK is a type l transmembrane ER resident eIF2a kinase that is activated under 
ER stress-inducing conditions, such as protein misfolding, protein overload in the ER, 
inhibition of glycosylation, and calcium depletion. PERK contains aluminaI domain 
capable of sensing misfolded proteins, and a cytoplasmic kinase domain. PERK is kept in 
an inactive state as a monomer by the interaction of its luminal domain with an ER 
chaperone termed BiP. Upon induction of ER stress, BiP dissociates from the monomeric 
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PERK protein, and contributes to the proper folding of misfolded proteins. PERK can 
then oligomerize on the ER membrane and become activated by autophosphorylation. 
The activated forms of PERK will ultimately reduce the protein overload in the ER by 
attenuating protein synthesis by phosphorylating eIF2a via its cytoplasmic kinase domain 
(Fig. lOB) (273). 
The inhibition of translation by PERK is a transient response in order for cells to 
recover from ER stress. Late in the ER stress response, the HSP40 co-chaperone p58IPK is 
activated by ATF6 and binds to the KD to inhibit PERK (335,353). However the 
inactivation of PERK is not sufficient to recover from its translational block since 
phosphorylation of eIF2a has already occurred. Several eIF2a phosphatases have been 
identified that appear to target eIF2a during the late stages of ER stress. Nck-l was 
shown to recruit a caIycuIin A sensitive phosphatase onto eIF2a but its regulation upon 
ER stress is still unresolved (178). The other is PPI which is regulated by CreP and 
GADD34. CreP constitutively regulates PPI whereas GADD34 is induced by ATF4 late 
in ER stress where it targets PPI to the ER and induces eIF2a dephosphorylation 
(166,181,219,244,245). Thus, the late activation ofp58IPK and GADD34 during ER stress 
serves as a negative feedback Ioop that restricts protein synthesis inhibition by PERK and 
eIF2a phosphorylation. 
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Figure 10. Translational control by PERK. 
(A) The ER-resident PKR-like protein kinase (PERK) is a serinejthreonine 
kinase that is embedded in the membrane ofthe ER and contains 1115 amino 
acids. The lumenal N-terminus half is composed of the sens or domain 
(homologous to the sens or domain of IRE1) and binds to BiP in the inactive 
state. The sens or domain is flanked by a signal peptide (SP) and a 
transmembrane do main (TM), enabling PERK to localize to the ER 
membrane. The C-terminus consists of the kinase do main that is homologous 
to the PKR kinase domain except that PERK has a larger eIF2 insert region. 
(8) In unstressed cells PERK is kept inactive via the tight binding of the ER-
resident chaperone BiP. Pharmacological and physiological conditions that 
promote proteiil misfolding induce an ER stress response. BiP dissociates 
from PERK to participate in protein folding, and PERK oligomerizes and 
trans-autophosphorylates rendering the kinase active. In turn, PERK induces 
the phosphorylation of eIF2a thus inhibiting translation and alleviating 
accumulation of proteins in the ER. 
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The ER has evolved highly specific signaling pathways tenned the unfolded 
protein response (UPR) to cope with the accumulation of misfolded or unfolded proteins. 
The UPR consists of several adaptive pathways that are activated upon specific sensors 
that help reduce the amount of new proteins translocated into the ER lumen, to increase 
the retro-translocation and degradation of misfolded proteins, and to increase the folding 
capacity in the ER lumen. The UPR orchestrates the transcriptional activation of genes 
mediated by IRE1 and ATF6, and the general translational inhibition and selective 
translation of specific mRNAs mediated by PERK. BiP serves as a common regulator 
between these three sensors in response to ER stress (30,297). 
Under unstressed conditions, BiP binds to IRE1, ATF6 and PERK to prevent their 
signaling. Upon protein overload or misfolded proteins in the ER lumen, BiP is released 
from the sensor domains of the three UPR sensors, and helps in the folding of the luminal 
proteins. This frees IRE 1 and PERK to induce homodimerization and 
autophosphory1ation leading to their activation (30). In contrast, release of ATF6 from 
BiP pennits its transport to the Golgi compartment where it is c1eaved and discharged to 
the cytosol and functions as a transcription factor (Fig. Il) (297). 
Once IRE 1 is activated, it c1eaves XEP 1 mRNA to remove a 26-nuc1eotide intron 
thus generating a translational frame-shift. Spliced XBP 1 mRNA encodes for a 
transcriptional activator for many UPR target genes (Fig. Il). Activated cytosolic ATF6 
is a UPR transducer that can bind to ER stress response element (ERSE) motifs (359) in 
the promoters of UPR responsive genes (361). One of the mRNAs induced by 
66 
proteolysed ATF6 is XBP1 mRNA which is ultimate1y spliced by IREI (360). This 
suggests that IRE 1 and ATF6 are involved in parallel pathways that ultimately converge 
to regulate common targets upon ER stress. 
As described earlier, PERK activation upon ER stress leads to translational 
inhibition in order to relieve the ER lumen from protein overload. Although general 
protein synthesis is inhibited upon ER stress, eIF2a phosphorylation selectively promotes 
translation of the transcription factor ATF4 (Fig. 11) (126). ATF4 induces transcription 
of genes (such as the previously mentioned GADD34) involved in amino acid 
metabolism, oxidation-reduction reactions, and ER stress-induced apoptosis, such as 
CHOP/GADD153 (Fig. Il) (129). 
When cells are unable to cope or adapt to prolonged ER stress, the UPR signaling 
pathways induce an apoptotic response to eliminate susceptible cells. CHOP/GADD153 
is a transcription factor that has been shown to activate ER stress-induced apoptosis by 
repressing the expression of the apoptotic repressor Bc1-2 (Fig. 11) (126). Another 
apoptotic pathway induced by ER stress is the caspase activation cascade mediated by 
caspase-12 (239). Procaspase-12 is an ER membrane-associated effector caspase that is 
activated by c1eavage by caspase-7 that is recruited to the ER after prolonged ER stress 
(267). This in tum initiates the caspase cascade leading to the activation of caspase-9 and 
caspase-3 (Fig. Il) (234). 
Although three different UPR sensors have been characterized, the complexity of 
the UPR signaling pathways suggest that other sensors may be involved or have yet to be 
discovered. Recently, two novel ER stress transducers have been identified in astrocytes 
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or damaged neurons. OASIS (182) and BBF2H7 (183) are both transcription factors that 
are activated during late phase ER stress in a similar matter as ATF6. That is they are 
imbedded in the ER membrane, cleaved and translocated to the nucleus to induce the 
UPR response. OASIS mediates the transcription of target genes with ERSE and cyclic 
AMP-responsive elements (182), whereas BBF2H7 is involved in suppressing ER stress-
induced apoptosis (183). These new findings reveal pivotaI roles for novel ER stress 
transducers in modulating the unfolded protein response in various tissues, and the 
possibility that cell type-specifie UPR signaling also exists in aIl cells. 
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Figure 11. The unfolded protein response pathway. 
The UPR pathway is initiated by conditions that induce ER stress (Le. protein 
misfolding). The misfolded proteins are sensed by BiP and in turn BiP 
dissociates from the three ER-resident sensors of the UPR (ATF6, IREl, and 
PERK). ATF6 translocates to the Golgi apparatus where it is cleaved by 
SlP jS2P peptidases thus generating a nuclear form that acts as a 
transcriptional activator for ER stress-inducible genes such as BiP and CHOP. 
ATF6 also induces XBP-l mRNA that is spliced via the endonuclease activity 
of activated IREL Spliced XBP-l induces transcription of ER chaperone genes 
involved in protein folding or ER-associated degradation response (ERAD). 
In order to relieve the accumulation of proteins in the ER lumen, PERK 
activation inhibits overaU protein synthesis by eIF2a phosphorylation. 
However, selective translation can still occur despite protein synthesis 
inhibition mediated by eIF2a phosphorylation. Such is the case of the 
transcription factor ATF4. Late in the ER stress response, the adapted ceU 
needs to turn back on translation by inducing GADD34 transcription via 
ATF4. Together with the PPl phosphatase, GADD34 promotes eIF2a 
dephosphorylation thus reinstating translation. However, if the cell has not 
adapted to the ER stress response, the apoptotic pathway is induced by 
CHOP. CH OP is a transcriptional repressor of the inhibitor of apoptosis Bcl-2. 
AIso, the ER-resident procaspase-12 is processed by caspase-7 in which the 
activated caspase-l2 initiates the caspase cascade inevitably inducing an 
apoptotic response. 
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The double-stranded (ds)RNA-activated protein kinase, PKR, is an interferon 
(IFN)-inducible serine/threonine and tyrosine kinase that is activated upon virus infection 
(14,172,316). Human PKR is encoded on chromosome 2p21-22 (15,308), whereas 
mouse PKR is located on chromosome 17E2 (15). The human pkr gene consists of 17 
exons while the mouse gene has 16 exons (188). PKR is a 68 kDa protein containing 551 
amino acids in humans and a 65 kDa protein containing 515 amino acids in mice (61). 
The kinase is divided into two distinct domains: the N-terminus regulatory domain and 
the C-terminus kinase do main (Fig. 12) (172). 
The N-terminus regulatory domain consists of the dsRNA-binding domain 
(dsRBD) composed of two tandem copies of a conserved dsRNA-binding motif 
(dsRBMI: aa 11-77 and dsRBMII: aa 101-167) separated by 20 amino acids in between 
them (Fig. 12). As the name implies, this domain binds to dsRNA or replicative 
intermediates produced during virus infection inducing the dimerization ofPKR (61,172). 
The C-terminus kinase domain (KD: aa 228-551) is composed of eleven 
conserved kinase sub-domains (I-XI) (Fig. 12). The sub-domain II contains the ATP-
binding pocket and mutation of Lys296 (K296H or K296R) within this region renders the 
PKR kinase activity inactive (326,327). The K296H mutant functions as a dominant-
negative and prevents PKR activation and eIF2a phosphorylation (326,327). However, 
the mutant protein can still dimerize and bind to dsRNA but is unable to induce any 
kinase activity (346). The sub-domain IV spans the eIF2a-insert region and mediates the 
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substrate recognition function between PKR and eIF2a. Between sub-domains VII and 
VIII, there are two autophosphorylation sites, Thr446 and Thr451, that are essential for 
PKR kinase activity (271). 
& 
PKR is one of the best-characterized interferon (IFN) inducible proteins (284) that 
phosphorylates eIF2a on serine 51 in response to stress signaIs as a result of virus 
infection (14,85,126,342). This phosphorylation of eIF2a does not only inhibit the 
infected host cell translation, but it also restrains viral protein synthesis as a anti-viral 
mechanism (11,198,199,313). Basically, PKR is activated in a 3-step sequential manner: 
dimerization, autophosphorylation and activation followed by substrate recognition (Fig. 
13). 
Upon virus infection, dsRNA accumulates in the infected cell and the dsRBD of 
PKR senses and binds to these viral replicative intermediates. The binding of PKR to 
dsRNA allows PKR to dimerize and induce trans-autophosphorylation on many 
serine/threonine and tyrosine residues. The phosphorylation of Tyrl011162 and Thr258 
influence dsRNA-binding and/or autophosphorylation while Thr446/451 and Tyr293 
phosphorylation renders the kinase active and promotes eIF2a phosphorylation 
(75,88,316,322,323). 
Through this capacity PKR exerts its anti-viral activity on a wide range of DNA 
and RNA viruses, and mediates the biological functions of IFNs (311). In addition to 
translational control, PKR has been implicated in various signaling pathways leading to 
gene transcription by modulating the activities of various transcription factors including 
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NF-ill (189), Stats (278) and the tumor suppressor p53 (72). These transcriptional 
pathways modulated by PKR are summarized below (section 2.2.4.4) as weIl as its role in 
translational regulation (section 2.2.4.3). 
Since PKR regulates translation, it needs to be in close proximity to the 
translational machinery in order to target eIF2a for phosphorylation during VIruS 
infection. It was previously shown that the dsRBD of PKR facilitates its association with 
the 40S ribosomal subunit providing PKR access to its substrate (367). AIso, the 
activation of PKR via ribosome-association can be disrupted by the L18 ribosomal 
protein of the 60S subunit preventing PKR binding to dsRNA and autophosphorylation 
(191). The ribosome localization ofPKR is critical for its local activation in response to 
virus infection. When infected ceIls produce and secrete IFNs to stimulate PKR induction 
of neighboring infected ceIls, there is a minimal or negligible eIF2a phosphorylation 
detected in these ceIls. However, this localized eIF2a phosphorylation is sufficient to 
inhibit viral RNA translation without affecting overaIl translation of the host ceIl. It 
appears that restricting PKR activation towards locations where viral RNA and protein 
synthe sis occur limits the spread and replication of virion production. 
In addition, PKR has been shown to be localized in the nucleus (160). Although 
there have been sorne reports about translation occurring in the nucleus (151-153), the 
role of nuclear PKR remains unclear. However, a recent study suggests that its ro1e may 
be involved in ER stress-induced apoptosis, since activated PKR migrates to the nucleus 
in tunicamycin-treated ceIls and in neurons of Alzheimer's disease patients (248). This 
73 
study supports the notion that PKR aiso regulates gene transcription by modulating 
transcription factors, and will be discussed in the following section. 
One of the PKR mechanisms that direct IFN and dsRNA signaling pathways is 
the modulation of the signal transducers and activators of transcription (Stat). Signaling 
cascades triggered by IFN and other cytokines are modulated by the Stat transcription 
factor proteins (76). PKR physically binds to Statl via its dsRBD but this Interaction is 
not a kinase-substrate function between the two proteins (Fig. 14). The inactive form of 
PKR interrupts the DNA-binding activity of Statl and is independent of its kinase 
function (344). This binding is disrupted upon IFN or dsRNA treatment suggesting that 
both proteins are heid together in an inactive state in untreated cells and that activated 
PKR releases Statl to induce its transcriptional activity. However, controversial evidence 
shows that Statl phosphorylation on Ser727 and transactivation is abolished in PKR-1-
MEFs (266). 
PKR has aiso been shown to associate with Stat3 and is required for its 
phosphorylation and activation in response to PDGF treatment by regulating ERK 
activity (79). Despite these claims, our lab has shown that Statl and Stat3 
phosphorylation and transactivation are impaired by PKR activation via the phosphatase 
activity of TC-PTP (339). 
Sorne early evidence suggested that PKR may regulate NF-KR activation. The 
NF-KB transcription factors regulate gene expression of a number of cellular processes 
mainly involved in the immune and inflammatory responses (134), and apoptosis (94). 
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NF-Kl3 is maintained in the inactive state and sequestered in the cytoplasm by IKB 
proteins. When the IKK complex phosphorylates IKB on Ser32/36 residues, it is targeted 
for ubiquitination and degradation. This in turn frees NF-Kl3 where it translocates to the 
nucleus and induces its transcriptional activity (Fig. 14) (269). 
Cells depleted of PKR activity were unresponsive to NF-KB activation when 
treated with dsRNA but not with TNFa (225). Equally, PKR-1- MEFs displayed impaired 
NF-KB activation in response to the synthetic dsRNA compound poly(rI-rC), and 
consequentially had defects in type 1 IFN production compared to their wild type 
counterparts (190,356). However, when the PKR-1- MEFs were primed with IFNs prior to 
dsRNA treatment, NF-Kl3 activation was restored, suggesting another IFN-inducible 
pathway may also regulate NF-Kl3 activity (356). 
It was be1ieved that PKR was capable of directly phosphorylating IKB to induce 
NF-KB activation upon dsRNA (189). However, once again controversial evidence 
suggested otherwise that PKR appears to have an indirect role regarding NF-KB 
activation (197). It was later confirmed by our group and others that PKR activates the 
IKK complex to induce NF-Kl3 activation upon dsRNA or vesicular stomatitis virus 
(VSV) infection independent of its kinase function (37,111,158,364). Although these 
studies show that the KD of PKR interacts with the IKK complex in response to dsRNA, 
the role of PKR catalytic activity in this process is still debatable today. PKR-1- MEFs 
suggest that PKR kinase activity is indispensable to the full activation ofNF-Kl3 (112). In 
contrast overexpressed catalytically inactive PKR is capable of inducing IKK activation 
(56,158) suggesting that catalytic activity of PKR is not required. These studies support 
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the notion that protein-protein interactions are required for IKK activation and not PKR 
kinase function. 
It appears that experirnental designs and conditions affect the results between 
PKR and NF-KB activation, and that they are difficult to interpret. Nevertheless, sorne 
NF-KB activation can still be triggered in PKR-1- MEFs despite the huge suppression 
(356). Due to these discrepancies, the question rernains aS to whether PKR catalytic 
activity is required for IKK activation. 
Finally, PKR can also rnodulate sorne functions of p53 (Fig. 14). The turnor 
suppressor p53 rnounts a transcriptional response resulting to cell cycle arrest and 
apoptosis upon genotoxic stress (see section 1). PKR has been shown to induce p53-
rnediated apoptosis upon TNFa treatrnent in U937 cells (358). Our lab has established a 
physical interaction between PKR and the C-terminus of p53 resulting in phosphorylation 
on Ser392 (72). Also, p53 activation upon adriarnycin or y-irradiation is irnpaired in cells 
devoid ofPKR (71). Furthermore, PKR-1- MEFs display defective phosphorylation ofp53 
on Ser18 (SerI5 in hurnan p53) as well as an irnpaired ability to induce cell cycle arrest 
and p53-target genes (71). The precise rnechanisrn underlying the PKR-p53 pathway 
rernains unknown, and future studies are needed to justify the connection between the 
two proteins and the turnor suppressor functions of PKR. 
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Figure 12. Structure of PKR. 
Human dsRNA-activated protein kinase (PKR) is a serinejthreonine and 
tyrosine kinase composed of 551 amine acids. The N-terminus comprises the 
regulatory do main termed dsRNA-binding do main (dsRBD) containing two 
dsRNA-binding motifs (dsRBMlj2). This domain binds to dsRNA and 
promotes PKR dimerization. The C-terminus portion is the kinase do main 
(KD) containing 11 conserved sub-domains (I-XI). The ATP-binding site can 
be found in sub-domain II, whereas the eIF2 insert region is within sub-
domain IV. 
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Figure 13. Translational control by PKR. 
Virus infection triggers the production of IFNs and subsequent induction of 
PKR protein levels. When dsRNA is produced during virus replication, the 
dsRNA-binding domain (dsRBD) of PKR binds to these replicative 
intermediates and allows the dimerization of PKR. Dimerization induces the 
catalytic activity of the kinase domain (KD) in which trans-
autophosphorylation of PKR renders the kinase active. Activated PKR can 
now target its well studied substrate eIF2a and induce its phosphorylation 
on SerS1 thus inhibiting protein synthesis. 
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Figure 14. Transcriptional regulation by PKR. 
Inactive PKR monomers are bound to unphosphorylated forms of Statl. Upon 
IFNajp stimulation or dsRNA produced during virus infection, the PKR-Statl 
dimers are disrupted and each protein is activated via separate mechanisms. 
The IFN receptors (lFNARlj2) induce Statl phosphorylation and 
dimerization with other Stats where the dimers migrate to the nucleus to 
induce transcription of genes with interferon-sensitive response elements 
(lSRE). The intracellular dsRNA induces PKR dimerization and activation. 
PKR has been shown to induce IKK activation, although the role of PKR 
kinase activity in this pro cess remains debatable. The activated IKK complex 
phosphorylates IxB that keeps NF-xB in the inactive state. Upon IxB 
phosphorylation, it dissociates from NF-xB and is targeted for degradation. 
In turn, NF-xB translocates to the nucleus to induce gene transcription. 
Furthermore,PKR has been implicated in p53 activation upon DNA damage. 
However the biological significance or mechanism of activation is still 
unknown. 
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Vesicular Stomatitis Virus (VSV) is a member of the Rhabdoviridae family, and 
grouped into the Vesicu/ovirus genus. The genus contains approximately 35 serologically 
distinct viruses, most importantly are the Vesicular Stomatitis Virus Indiana and New 
Jersey strains that are known to cause vesicular disease in horses, cattle, swine, and 
humans. Although the infection is transmitted directly by the transcutaneous or 
transmucosal route, VSV has been isolated from sand-flies, mosquitoes, and grasshoppers 
suggesting that it could be an arbovirus (insect-bome). Natural VSV infections take place 
in two steps: cytolytic infections ofmammalian hosts and transmission by insects through 
non-cytolytic persistent infections (277). 
There is also sorne evidence that VSV could be a plant virus and that animaIs are 
the closing stages of the epidemiologicallink in which the pathogenesis of the disease is 
unclear. VSV infectivity is stable in an alkaline environment, but the virus is sensitive to 
UV irradiation and sunlight. In clinical practice VSV is inactivated easily by detergent-
based disinfectants. VSV is a common laboratory virus, and the prototypical virus to 
study the properties of all Rhabdoviruses and virus evolution (236,277). 
Rhabdoviruses are bullet shaped in structure and the virions are approximately 
45-100 nm in diameter and 100-400 nm long. They are comprised oftwo major structural 
components: the host-derived envelope, which is a lipid bilayer with large peplomers 
83 
(glycoprotein projections of the outer viral envelope), and the ribonuc1eoprotein (RNP) 
core, which contains the genetic material within a helically coiled cylindrical 
nuc1eocapsid. The cylindrical nuc1eocapsid is what gives the virus es their distinctive 
bull et shape (Fig. 15A) (277). 
VSV is a member of the Mononegavirales order meaning the genome is a single 
linear, negative-sense molecule of ssRNA and is about 11-15 kb in size (12,277). The 
RNA genome encodes five major proteins: glycoprotein (G), matrix protein (M), 
nuc1eocapsid protein (N), large protein (L) and phosphoprotein (P) (Fig. 15B). The five 
genes encoded within the genome are in the order of3'-N-P-M-G-L-5' (13,62). The N, P, 
and L proteins encase the viral RNA and are involved in the viral genome transcription 
and replication. The P protein is the major phosphoprotein (49) and the L protein serves 
as the RNA-dependent RNA polymerase containing 5' capping and 3' polyadenylation 
activities (17). Together with the N protein, they serve as the viral transcriptase 
catalyzing the replication ofthe mRNA (33,78). 
The G and M proteins consist of the membrane-associated proteins. The G protein 
is oriented extemally spanning the membrane and thus comprises the major antigenic 
determinant of the virus (65,336). It enables viral entry to the cell by mediating both virus 
attachment to the host cell receptors and fusion of the viral envelope with the endosome 
following endocytosis (65). The M protein is known as the bridging molecule because it 
associates with the inner surface of the viral membrane along with the RNP core. This 
bridge allows the two structures to come together during virion assembly and budding. It 
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is believed to bind the cytoplasmic tail of the G protein enabling the RNP core to cluster 
with the G protein prior to budding (54). Therefore the M protein contributes in the final 
stages of the virallife cycle (Fig. 16) when the virions pinch off from the infected cells 
(159). 
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Figure 15. Vesicular stomatitis virus genome & virus particle structure. 
(A) Vesicular stomatitis virus (VSV) is composed of five viral proteins that 
are assembled into a bullet shaped virus particle that is enveloped in a lipid 
bilayer. Embedded in the membrane are the peplomers (glycoprotein: G) 
involved in cell adherence. Beneath the membrane is the matrix (M) protein. 
The M protein is the main structural protein and is involved in the formation 
of progeny virions and the budding process. Inside the virus is the 
ribonucleoprotein (RNP) core, which contains the ssRNA genome within a 
helically coiled cylindrical nucleocapsid (N). The P (phosphoprotein) and the 
L (large) proteins serve as the viral polymerase . 
. (8) The negative sense, ssRNA genome of VSV consists of five genes that 
encode the five major viral proteins: the nucleocapsid protein (N), the 
phosphoprotein (P), the matrix protein (M), the glycoprotein (G) and the 
large polymerase protein (L). Transcription of viral genes proceeds from the 
3' to S'end of the negative strand genome thus generating positive sense 
transcripts beginning with the N gene. Each protein has its own transcribed 
capped and polyadenylated mRNA. 
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VSV is known to infect a wide range of cell types by means of the G protein 
targeting common cellular receptors that are shared between different cell types (277). 
However, the receptor has not been identified yet and sorne speculations indicate that the 
phosphatidylserines of the cell membrane may contribute to the binding of the G protein 
and viral endocytosis (Fig. 16) (65,66,68) but it remains questionable (287). 
During endocytosis, the pH of the endosome becomes acidic and induces 
membrane fusion thus releasing the viral RNP core into the cytoplasm (Fig. 16) (34,224). 
Since the virus brings its own polymerase (L protein) with it during infection, it binds to 
the 3' -end of the negative strand RNA genome. The viral L polymerase recognizes viral 
nuc1eotide sequences at the 3' -end (141) and initiates the sequential transcription of 5 
individual positive strand mRNAs encoding the 5 individual proteins (38,258,276). The 
VSV mRNAs are capped and polyadenylated, and translated with the cellular ribosomal 
machinery (274,275). 
Through an unknown process, the viral polymerase switches from transcription of 
viral mRNAs to replication of the viral genome possibly via the functions of the P protein 
(63). This switch only occurs after viral transcription and protein synthesis. Virus 
replication is restricted to the cytoplasm of the cell (277). The genome is replicated into a 
full length positive sense RNA which is used as a template to generate more negative 
sense RNA genomes that will be encapsidated (Fig. 16). During the replication process, 
dsRNA or replicative intermediates are produced, and are sensed by the dsRBD of PKR 
as described earlier in order to initiate the anti-viral response. Encapsidation of the RNA 
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genome is mediated by the N protein forming the RNP core along with the P and L 
proteins. The RNP core is then condensed with the help of the M protein present on the 
cell membrane embedded with G proteins. The virions are then formed and bud from the 
plasma membrane releasing the progeny virus es (Fig. 16) (159,277). 
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The importance of PKR in innate immunity against virus infection has been 
established by many groups for sorne time now (2, Il ,230,231). It is believed that PKR is 
induced by IFNs produced during virus infection and its activation is required to inhibit 
virus replication by blocking viral protein synthesis via the phosphorylation of eIF2a 
(230). Two different strains of PKR-1- mice have been generated (2,356), but they are not 
particularly sensitive to virus infection suggesting that perhaps other eIF2a kinases may 
be involved in this redundancy. It was believed that viruses have developed mechanisms 
of inhibiting PKR activity and this would explain why PKR-1- mice are not more 
susceptible to virus es as their wild type counterparts. However, this theory does not 
explain why virus es that do not encode for PKR-inhibitors continue to replicate despite 
the high levels ofPKR activation, as is the case with VSV. 
It was shown that PKR-1- mice were susceptible to VSV infection only during 
intranasal inoculation (11), but it was later determined that this vulnerability is mouse 
strain dependent (93). This underlines the importance that other host factors or redundant 
pathways may contribute to the resistance to VSV infection in PKR-1- mice. This c1aim 
correlates with the fact that Statl-I- mice are also susceptible to VSV infection despite the 
presence of PKR (228). It appears that the role of PKR during VSV infection is to slow 
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down virus replication by inhibiting protein translation. In turn, this buys time for the cell 
to initiate an anti-viral response to hait completely VSV replication by inducing IFN-
target genes. Thus prirning cells with IFNs have been shown to inhibit VSV replication 
(19), and in sorne cases PKR was not required for resistance to VSV infection in IFNy-
treated neurons (51). This would explain the fact that VSV has enabled rnethods to block 
IFN-inducible gene translation by preventing host mRNA export instead of targeting 
PKR function (100,103). 
VSV has also found mechanisms to inhibit host protein synthesis without 
affecting its own translation by compromising other initiation factors involved in cap-
dependent translation (eIF4E, eIF4G, and eIF4A) (67). However, the mechanisrns by 
which VSV inhibits host cell translation have yet to be determined. Taken together, these 
data indicate that depending on the cell type or animal strain, the role of PKR in VSV 
infection appears to be working in synergy with other signaling pathways. 
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Figure 16. VSV replication cycle. 
The attachment of VSV to the host cell is mediated by the glycoprotein (G) 
embedded in its membrane. Adhered viral particles are engulfed by 
endocytosis and enter the cellular endosomal trafficking pathway. The 
endosomes harboring VSV acidify (H+), and the decrease in pH triggers a 
conformational change in the G protein that mediates fusion between the 
viral envelope and the endosomal membrane. The viral RNP core is released 
into the cytoplasm and initiates viral gene transcription. The viral 
polymerase first transcribes the individual mRNAs for each viral gene, which 
are then translated by the host translational machinery. During late stages of 
infection, the viral polymerase switches from transcription to replication and 
synthesizes copies of the negative-sense VSV genome using positive-strand 
intermediates as templates. During this process, dsRNA (replicative 
intermediates) are produced and can initiate the cellular anti-viral 
responses. Finally, the viral proteins and genomic RNA are assembled into 
complete virus particles, and the viral progeny bud from the cell through the 
plasma membrane. 
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The eIF2a kinases, PERK and PKR, have been shown to play important roles in 
regulating protein synthesis upon ER stress and virus infection, respectively, through 
their capacity to phosphorylate eIF2a. Although the regulation of translational control by 
eIF2a kinases has been thoroughly studied, it does not explain the differences between 
the biological outcomes mediated by the different eIF2a kinases. Modulation of different 
signaling pathways by each eIF2a kinase could justify these diverse effects. However, 
little is known about the downstream targets or pathways that may be involved and if 
eIF2a kinases function individually or in synergy to adapt to various stress conditions. 
Since eIF2a kinase activity is induced by various stresses, the aim of this research 
was first to determine if eIF2a-dependent pathways require a functional interaction 
between eIF2a kinases during virus infection, and second to verify if the activation of 
PERK and PKR can modulate other stress sensors, such as p53, through eIF2a-
independent pathways. 
l 
Work with cultured cells in many laboratories has assigned PKR antiviral, anti-
proliferative, and tumor suppressor functions in vitro. However, the anti-proliferative and 
tumor suppressor functions of PKR have not yet been verified in vivo. Specifically, the 
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two distinct PKR knockout mlce that have been generated did not exhibit growth 
abnormalities nor were they tumorigenic. Controversial evidence has been accumulating 
regarding PKR functions due to discrepancies between the signaling properties of PKR in 
the two PKR knockout mice. For example, both types of PKR-1- mice have not displayed 
any significant susceptibility to infections with a variety of virus es with the exception of 
intranasal VSV infection. However, unlike the mice, PKR-1- MEFs are modestly more 
permissive to VSV repli cation indicating that the lack of PKR might be compensated by 
the expression of another eIF2a kinase, whose activity is induced by VSV infection. 
1. To characterize the proteins involved for the signaling differences and 
discrepancies observed between the two PKR knockout MEFs. 
2. To investigate the possibility that other eIF2a kinases may be implicated in 
VSV infection considering the modest susceptibility in PKR knockout micè. 
Stress conditions activate signal transduction pathways leading to the induction of 
genes encoding for proteins with key roles in damage sensing and apoptosis. Most stress 
conditions have implicated the tumor suppressor protein p53 as a key sensor that 
mediates various biological outcomes such as cell growth arrest, and induction of 
apoptosis. Sorne stress conditions perturb specific organelles thereby initiating a specifie 
adaptive response. For example, virus infection, energyor nutrient deprivation, or Ca2+ 
depletion from the lumen of the endoplasmic reticulum (ER) can disrupt proper protein 
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folding in this organelle leading to the accumulation of unfolded proteins. This initiates 
transcriptional and translational signaling pathways in part through the activation of 
eIF2a kinases. If these adaptive mechanisms are not sufficient to alleviate ER stress, cells 
undergo apoptosis. Although a number of cellular stresses induce p53 activation via its 
stabilization and accumulation, it is unclear if a cross-talk exists between eIF2a kinases 
and p53, and if it affects the regulation of p53 at the translational or post-translational 
level. 
1. To determine if the downregulation of p53 upon ER stress is mediated 
through the induction of eIF2a kinase activity. 
2. To investigate if eIF2a phosphorylation-mediated translational control 
regulates p53 upon ER stress. 
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The mouse embryonic fibroblasts (MEFs) from the N-,PKR-1- mlce were III 
129/Sv(ev) X C57BL/6J genetic background (356), whereas the C-PKR-1- mice were in 
129/terSv X BALB/c background (2). The strain-matched 129SvEvPKR+1+ and C-PKR-1-
MEFs were also used, and generated as described (93). The PERK+1+ and PERK-1- MEFs 
were used and generated as described (127). The HTI080 stable celllines expressing 
GyrB-PKR WT or the kinase dead GyrB-PKR K296H proteins were generated as 
described (177). The eIF2a SIS and eIF2a A/A knock-in MEFs were generated as 
described (286). The GSK3p+l+ and GSK3p-l- MEFs were used and generated as 
described (144). The NIH 3T3-puro and NIH 3T3-shPKR cells were a generous gift from 
M. Loignon. 
1. TUHE 
Mouse embryonic fibroblasts (MEFs), NIH3T3 and derived celllines, HTI080 
and derived celllines, HeLa, VERO, and COS-l cells were maintained in Dulbecco's 
Modified Eagle Medium (DMEM, Life Technologies Inc.) supplemented with 10% heat-
inactivated calf serum (CS, Life Technologies Inc.), and antibiotics (Penicillin-
Streptomycin 100 U/ml, ICN Biomedicals Inc.). Huh7 and U20S cells were maintained 
in DMEM supplemented with 10% of heat-inactivated fetal bovine serum (FBS; Life 
Technologies Inc.), and penicillin-streptomycin (100 U/ml) , 0.1 mM of MEM non-
essential amino acids (GIBcoBRL). A549 cells were maintained in F12K medium 
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(Cellgro) supplemented with 10% FBS and penicillin-streptomycin (100 U/ml). HCTl16 
cells were maintained in McCoy's medium (MultiCell) supplemented with 10% FBS and 
penicillin-streptomycin (100 U/ml). 
Transfections were performed using LipofectAMINE Plus reagents (Invitrogen) 
according to manufacturer's instructions. Briefly, 5 x 105 cells were seeded in 6-cm 
plates. The day after, cells were incubated with reagents and 2-5 Jlg of vector DNA or 10 
Jlg/ml ofpoly(rI-rC) dsRNA in serum-free medium at 37°C for 3-5 h. The medium was 
then replenished with 10% serum and cells were incubated for an additional 24 or 48 
hours (unless specified in figure legends) before proteins were extracted. 
For siRNA transfection, 1.25 x 105 HT1080 cells were seeded onto 6-well plates. 
The following day, cells were transfected with 200 pmoles of non-specifie (GL-2) or 
human eIF2a or human PERK siRNA (Dharmacon) using 4 III LipofectAMINE 2000 
(Invitrogen) in medium devoid of serum. Six hours post-transfection, the plates were 
washed with serum-free DMEM and replenished with medium containing 10% serum. 
Cells were incubated at 37°C for an additional 72 hours before being treated \vith 
thapsigargin or coumermycin. 
5 
Cells were treated with: IFNa/p (1000 IV/ml, Cedarlane), IFNy (100 IV/ml, 
Cedarlane), thapsigargin (TG, 1 J...lM, Sigma), tunicamycin (TM, 10 J...lg/ml, Sigma), 
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zV AD-fmk (10 )lM), MG132 (10 )lM, Biomol), 1-Aza-Kenpaullone (1 )lM), SalO03 (75 
)lM, compound 3, salubrinal derivative, generous gift from J. Pelletier), coumermycin 
(100 ng/ml, Sigma), adriamycin (ADR, 1 )lM). 
Cells were infected with vesicular stomatitis virus (VSV, Indiana serotype) with a 
multiplicity of infection (MOI) indicated in figures. Cells were plated onto 6 cm plates, 
and virus was allowed to adhere to cells at room temperature for 1 hour in serum-free 
medium. After 1 hour, medium was replenished with 10 % CS and cells were incubated 
at 37°C for indicated period oftime post-infection before proteins were extracted. 
The VSV plaque assay protocol was previously described (294). Briefly, PERK+1+ 
and PERK-1- MEFs were infected with vesicular stomatitis virus (VSV, MOI 1 or 100). 
One hour post-infection, the non-adherent virus was removed and plates were washed 
twice with serum-free DMEM and replenished with complete medium. At different hours 
post-infection, medium was collected and was seriaI diluted with serum-free DMEM then 
used to infect VERO cells (100% confluence). One hour post-infection, medium from the 
VERO cells was removed and replaced with complete medium containing 0.5% methyl 
cellulose (Sigma-Aldrich) for 24-36 hours. VERO cells were fixed in 4% formaldehyde 
and stained with crystal violet. Plaques were counted and titers calculated as plaque 
forming units (pfu)/ml. Triplicate experiments were performed, and the averages of the 
viral titers were calculated. 
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One day before transfection, 0.8 x 106 HeLa or Huh7 cells were seeded in 6-cm 
plates. Cells were infected with recombinant vaccinia virus containing the bacterial T7 
RNA polymerase gene (106) for an hour followed by transfection with LipofectAMINE 
Plus reagents (lnvitrogen) and 2).tg ofDNA containing the gene ofinterest in expression 
vector under the control of T7 promoter. Cells were incubated in serum-free medium at 
37°C for 6 hours followed by the addition of complete medium and incubation for an 
additional 18 hours before protein extraction. 
The plasmids used were previously described: GFP-p53 WT cDNA in the 
pEGFPIN1 vector (40), pcDNA3 plasmids containing wild type PERK or ml:ltant PERK 
K618A (128), and wild type PKR or dominant-negative P~6 (91). Plasmids 
containing BiP/Grp78, XBP-1 or CHOP/GADD153 were generous gifts from D. Ron. 
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Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and 
proteins wete extracted in ice-coldlysis buffer containing 10 mM Tris-HCl, pH 7.5, 50 
mM KCl, 2 mM MgClz, 1 % Triton X-100, 3 ).tg/ml aprotinin, 1 ).tg/ml pepstatin, 1 ).tg/ml 
100 
leupeptin, 1 mM dithiothreitol, 0.1 mM Na3 V04, and 1 mM phenylmethylsulfonyl 
fluoride. Extracts were kept on ice for 15 min, centrifuged at 10,000 x g for 15 min (4 
OC), and supematants were stored at -80 oC. Proteinswere quantified by Bradford assay 
(BioRad). 
Protein extracts were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) as described (283). Proteins were then electroblotted onto 
PVDF membranes (Immobilon P, Millipore). 
PERK+1+ and PERK-1- MEFs were infected with VSV or treated with thapsigargin 
before being lysed with 8 M urea, 4% (w/v) CHAPS, 65 mM DTT, 0.5% (v/v) IPG buffer 
pH 4-7 or pH 6-11 (Bio-Rad). Isoelectric focusing (IEF) step was performed using the 
Ettan IPGphor Isoelectric Focusing unit (Amersham) and 7 cm strips pH 4-7 or pH 6-11 
(Bio-Rad). The strips were passively rehydrated with 125 III of rehydration buffer 
containing 80 Ilg of the protein extracts, 8 M urea, 2% (w/v) CHAPS, 10 mM DTT, 0.5% 
(v/v) IPG buffer pH 4-7 or PI:I 6-11, and trace amount ofbromophenol blue for 10 hours. 
IEF was performed at 150 V for 40 minutes, 500 V for 40 minutes, 1000 V for 40 
minutes, and 5000 V for 2.5 hours. The strips were then equilibrated for 12 minutes in 50 
mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 1% (w/v) DTT, and trace 
amount of bromophenol blue. The strips were then incubated for 5 minutes in 50 mM 
Tris-HCl pH 8.8, 6 M ure a, 30% glycerol, 2% SDS, 2.5% (w/v) iodoacetamide, and trace 
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amount of bromophenol blue. The equilibrated strips were then subjected to second 
dimension with SDS-l O%P AGE followed by immunoblot analysis. 
Following SDS-P AGE and protein transfer onto PVDF membranes, the 
membranes were blocked in phosphate buffered saline with 0.5% Triton-X100 (PBST) 
containing 5% non-fat milk for one hour at room temperature. Primary antibodies 
(1: 1 000 dilution) were all prepared in PBST containing 5% BSA and incubated ovemight 
at 4°C. The following day, membranes were washed 6 times with 5 minute incubation 
periods with PBST at room temperature. Then the corresponding secondary antibody was 
incubated for one hour at room temperature. AlI secondary antibodies (1: 1000 dilution) 
were prepared in PBST containing 5% non-fat milk. The membranes were then washed 6 
times for 5 minutes with PBST and proteins were visualized by enhanced 
chemiluminescence (ECL). Quantification ofbands was performed by densitometry using 
the NIH Image 1.54 software. 
The primary antibodies used were as follows: goat polyclonal antibody to PERK 
(T-19, Santa Cruz), rabbit polyclonal antibody to phosphothreonine 980 of PERK (Cell 
Signaling), rabbit polyclonal antibody to PERK (this antibody detects a shift in the 
migration of PERK when activated, generous gift from D. Ron) , rabbit polyc1onal 
antibody to PERK (Cell Signaling), rabbit polyc1onal antibody to phosphoserine 51 of 
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eIF2a (1:5000 dilution, BioSouree), mouse monoclonal antibody to mouse eIF2a, rabbit 
polyclonal anti-human eIF2a (se-11386, Santa Cruz, CA), rabbit antiserum to TrpE-yeast 
eIF2a fusion protein (CM-217), rabbit polyclonal antibody to Caspase-12 (Cell 
Signaling), mouse monoclonal antibody to mye epitope (9E10, Santa Cruz), rabbit 
polyclonal antibody to phospho-JNK-1 (Cell Signaling), rabbit polyclonal antibody to 
JNK-1 (Cell Signaling), rabbit polyclonal antibody to phospho-p38 MAPK (Cell 
Signaling), rabbit polyclonal antibody to p38 MAPK (Cell Signaling), mouse monoclonal 
antibody to PKR (B-10, se-6282, Santa Cruz), rabbit polyclonal antibody to PKR (D-20, 
se-708, Santa Cruz), rab bit polyclonal antibody to phosphothreonine 446 of PKR (UBI), 
rabbit antiserum to residues 101-112 within the N-terminus of mouse PKR (1), rabbit 
antiserum to human PKR (first 80 amino aeids of hPKR), rabbit polyclonal antibody to 
VSV (1 :5000 dilution, manufaetured by Dr. Earl Brown), rabbit polyclonal antibody to 
P ARP (Cell Signaling), mouse monoclonal antibody to Actin (1 :5000 dilution, Clone C4, 
ICN Biomedicals Inc.), rabbit polyclonal anti-histidine antibodies (sc-803, Santa Cruz), 
rabbit antiserum to phosphoserine 32 of IK13a (9241S, New England Biolabs), rabbit 
antiserum to IKBa (06-494, Upstate Biotechnology Inc.), rabbit polyclonal antibody to 
mouse p53 (FL-393, Santa Cruz), mouse monoclonal antibody to human p53 (DO-l, Ab-
6, Oncogene Science), a rabbit polyclonal antibody to mouse p53 (CM-5, Novocastra), 
rabbit polyclonal antibody to GSK3p (Cell Signaling), rabbit polyclonal antibody to 
phosphoserine 641/645 of glycogen synthase (Upstate), mouse monoclonal antibody to 
glycogen synthase (Cell Signaling), rabbit polyclonal antibody to PUMA (3041, ProSci 
Inc.), rabbit polyclonal antibody to NOXA (2437, ProSei Ine.). 
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Anti-mouse IgG-HRP or anti-goat IgG-HRP or anti-rabbit IgG-HRP conjugated 
antibodies were used as secondary antibodies (1: 1000 dilution). Proteins were visualized 
by enhanced chemiluminescence (ECL) according to manufacturer's specification 
(Amersham Life Science Inc., Cleveland, OH). 
5 
1 
Equal amounts of protein extracts were incubated with 2 /-lg of the specified 
antibody for 2 hours in 4°C with rotatiôn. Proteins were then immunoprecipitated using 
50 /-lI of a 50% suspension of anti-mouse IgG (whole molecule) agarose beads (Sigma) or 
protein A-agarose beads (Pharmacia). The samples were then rotated for additional 2 
hours at 4°C. The immunoprecipitates were washed three times in the lysis buffer, and 
subjected to SDS-PAGE and immunoblot analysis. 
Equal amount of protein extracts were used for a pulldown with poly(rI-rC) 
dsRNA coupled to agarose beads (Type 6, Amersham Pharmacia Biotech). The samples 
were rotated for 2 hours at 4°C before being washed 3 times with lysis buffer. The 
dsRNA-bound proteins were subjected to SDS-PAGE followed by immunoblot analysis. 
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Whole cell extracts (200-500 ~g of protein) were used for a pulldown with 
poly(rI-rC) dsRNA coupled to agarose beads (Type 6, Amersham Biosciences) or for an 
immunoprecipitation with the anti-mPKR antibody (D-20). The bound proteins were 
equilibrated in kinase buffer (10 mM Tris-HCI pH 7.7, 50 mM KCI, 2 mM MgClz; 3 
~g/ml aprotinin, 1 ~g/ml pepstatin, 1 ~g/mlleupeptin, 1 mM DTT, and 1 mM PMSF) and 
incubated in the presence of 1 ~Ci of [y-32p]ATP. The reactions were incubated at 30°C 
for 30 min and subjected to SDS-10%PAGE followed by either immunoblot analysis or 
autoradiography. 
For measurmg GSK3 activity, 1 00 ~g whole cell extracts were used for 
immunoprecipitation with anti-GSK3p antibody (Cell Signaling) and protein A-agarose 
beads (Pharmacia). Bound proteins (15 ~l) was mixed with 15 ~l of kinase buffer (50 
mM HEPES (pH 7.2),0.1 mM EDTA, 0.1 mM DTT, 1 ~Ci [l2p]ATP, 10 mM MgClz, 
and 5 mg/ml synthetic phospho-CREB substrate peptide (KRREILSRRP[pS]YR) with or 
without 1-Aza-kenpaullone (1 ~M). After 30 min of incubation at 30°C, 1 0 ~l of TCA 
was added and the reaction mixtures were centrifuged, and 20 ~l of the supematant was 
spotted onto Whatman PlO phosphocellulose paper. Filters were washed in three changes 
0[0.85% phosphoric acid, dried and subjected to liquid scintillation counting. 
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Protein extracts were immunoprecipitated with rabbit polyclonal antibody to 
mouse PKR (D-20, Santa Cruz) and protein A-agarose beads (Pharmacia). The 
immunoprecipitates were equilibrated in 1 X PKR kinase buffer containing 10 mM Tris-
HCI pH 7.7, 50 mM KCI, 2 mM MgClz, 3 /-lg/ml aprotinin, 1 /-lg/ml pepstatin, 1 /-lg/ml 
leupeptin, 1 mM DTT, and 1 mM PMSF. Activator reovirus dsRNA was then added to 
the final concentration of 0.1 /-lg/ml in the presence of 1 /-lg ofbacteria purified histidine-
tagged eIF2a (368) and 1 /-lM ATP. After incubation at 30°C for 30 min, the reactions 
were subjected to SDS-PAGE and immunoblotting with rabbit antiserum to 
phosphoserine 51 of eIF2a followed by immunoblotting with rabbit polyclonal anti-
histidine antibodies. 
GFP-positive and live cells were scored and classified into two groups; the first 
group with fluorescence predominantly in the nucleus and the second with fluorescence 
in both nucleus and cytoplasm. Total green fluorescence in the nucleus and whole cell 
were quantified with AxioVision 4.5 software from 100 randomly se1ected GFP-positive 
and live cells. 
For immunofluorescence, cells were stained with a 1 :200 dilution for mouse 
monoclonal antibody to p53 (DO-l, Oncogene Science) or a 1:100 dilution for rabbit 
polyclonal antibody to GSK3p (Cell signaling). Cells were incubated with primary 
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antibodies for 16 h at 4°C, washed with PBS, and incubated for 1 h with Alexa Fluro-
488-conjugated secondary antibody or Alexa Fluro-546-conjugated secondary antibody 
(Molecular Probes). The nucleus was visualized after staining with 0.05 llg/mL of 4,6-
diamidino-2-phenylindole (DAPI; Sigma). Images were captured on a Zeiss microscope 
using equal exposure times. Nuclear/cytoplasmic ratios were determined by calculating 
total pixel intensity in a circle of 4 Ilm in diameter in the nucleus and the cytoplasm using 
Axio Vision 4.5 software. The background was determined by calculating pixel intensity 
in a 4 Ilm diameter cell-free area. This area was then subtracted from the nuc1ear and 
cytoplasmic measurements for each cell within the microscopy field. 
1 
The yeast strain used was J110 (Mata ura3-52 le'U2-3, 2-112 trpl-1163 
gcn211<LEU2>@leu2) (206). 
Wild type mouse PKR (mPKR) and human PKR (hPKR) were inserted in p YES3/CT 
vector (Invitrogen) whereas the exon-skipped form ofmPKR (ES-mPKR; aa 136 to 518) 
was subc10ned into p YES2 vector (Invitrogen). 
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JIIO yeast cens were transformed with DNA us mg the LiAc method (3). 
Transformed strains were grown in SGAL liquid medium ovemight at 30°C. 
Yeast protein extracts were prepared as described (3). Immunoblot analysis was 
performed as described above. 
1 
T502 Forward 5' -CAGCACCTGGAAGTTTTTCC-3' 
mPKR'lmQ2 R~~~~~ji7$Jll;~·i(;i;~,;l'j~~TT~~~~11.GGg,ç;,wJ~'lF:GC~~{ 
T503 Forward 5' -TTCAGGTGTCACCAAACAGG-3' 
~~~_,~,_,~i!m3~} .~;;,i~y~j}~!1~';(5'-G!!,~,~9CTAGt 
58 35 
58 35 
7 
Exon-skipped mPKR cDNA from N-PKR-1- cens was c10ned as described (356) 
and subc10ned into BamHI/XbaI sites of p YES2 expression vector (lnvitrogen). Table l 
summarizes an the primers used for RT -PCR analysis of RNA from C-PKR-1- cens. The 
primers were designed according to the mouse PKR sequence [accession number: 
108 
M65029; locus: MUSSTKINA (154)]. Total RNA isolation was established usmg 
TRIzoL (GIBcoBRL) according to the protocol provided by the manufacturer. One ~g of 
RNA was used for reverse transcription (RT) with the Moloney Murine Leukemia Virus 
(M-MLV) reverse transcriptase (GIBcoBRL) using the 0Iigo-(dT)18 primer (RT was 
performed as described by manufacturer). 
The single-stranded cDNA was amplified by PCR using the T502/T302 or 
T503/T303 set ofprimers (see Table 1) and Taq DNA polymerase (cat.#ll46 165, Roche 
Diagnostics) with 35 PCR cycles to generate the final product: 1 minute at 94°C for the 
denaturing step, 1.5 minutes at 58°C for the annealing step, 2 minutes at 72°C for the 
elongation step. PCR products were visualized by ethidium bromide staining under a UV 
light source. The PCR products generated by the T503/T303 primer set were subcloned 
into the pCR2.1 vector provided by the TA cloning kit (K2000-0l, Invitrogen) and 
subjected to DNA sequencing. 
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Normalized cDNA from 12 different mouse tissues (mouse MTC Panel I, K1423-
1, Clontech) were subjected to 35 cycles of PCR using the T502/T302 set of primers 
(Table1) with 1 minute at 94°C for the denaturing step, 1.5 minutes at 58°C for the 
annealing step, 2 minutes at 72°C for the elongation step. PCR products were separated in 
agarose gels and subjected to Southem blot analysis using as a probe the entire wild type 
mPKR cDNA labeled with e2P-a]dCTP, as previously described (302). 
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Approximately 2 X 107 cells (two 15 cm plates/gradient) were used for each 
sucrose gradient. Prior to harvest, 1 00 ~glml of cyc10heximide was added to the medium 
and then removed immediately. Plates were then washed 3 times with 10 ml ice cold 1 X 
PBS containing 100 ~g/ml cyc1oheximide, and the plates were placed on ice. The cells 
were lysed directly on plates with 500 ~l ofpolysome lysis buffer (15 mM Tris-HCl, pH 
8.0,5 mM MgClz, 0.3 M NaCI, 0.5 mM DTT, 100 ~glml cyc1oheximide, and 1 % Triton 
X-100). Extracts were transferred into a 1.5 ml Eppendorftubes, and placed on ice for 10 
minutes. Tubes were centrifuged at 13 000 X g for 10 minutes. Supematants were 
recovered and layered onto 10 ml 10-55% sucrose gradients (10-55% sucrose, 20 mM 
Tris-HCl, pH 8.0, 140 mM KCI, 5 mM MgClz, 0.5 mM DTT, and 100 ~glml 
cycloheximide). The gradients were prepared with the ISCO Model160 Gradient Former. 
The lysate was sedimented at 40,000 rpm for 2h35m in a SW40Ti rotor at 4°C. 
The gradients were fractionated into 20 fractions of 500 ~l using the ISCO 
Density Gradient Fractionation System-Foxy Jr. Fraction Collector while measuring the 
absorbance at 254 nm. Samples were collected into 1.5 ml Eppendorf tubes and stored at 
-80°C. 
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The RNA was isolated from each fraction (500 ~l) using equal amount ofvolume 
ofTRIzoL (GIBcoBRL). Fractions were centrifuged for 15 minutes at 13 000 X g after a 
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volume of 100 !lI of chloroform was added in order to separate aqueous phase from the 
organic phase. The aqueous (supematant) phase was transferred to a new tube containing 
500 !lI of isopropanol and RNA was precipitated ovemight at -20°C. The following day, 
tubes were centrifuged at 13 000 X g for 30 minutes. RNA pellet was washed with 400 !lI 
of 75% ethanol (-20°C) and air-dried for 5-10 minutes before being dissolved in 10 !lI 
dH20. Samples were stored at -80°C. 
p53 Forward 5'-AACCTACCAGGGCAGCTACG-3' 58.5 28 .i;~.~~irse 
ATF4 Forward 5'-CTGGCTGTGGATGGGTTGGT-3' 58 23 
GAPDH Forward 60 23 
A volume of3 !lL of the extracted RNA (from each fraction) was used for reverse 
transcription using the SuperScript II RNase H- Reverse Transcriptase (200D/!lL, 18064-
014, Invitrogen) and 100 !lM oligo-dT primer (dT2oVN) according to the manufacturer's 
instructions. Once reaction was completed, the final volume of the 20 !lI reaction was 
adjusted to 100 !lI with dH20, and 2 !lI of the diluted cDNA was used for polymerase 
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chain reaction. The TaqPlus Precision Polymerase (1000 U, 600212, Stratagene) was 
used for PCR according to the manufacturer's specifications. Table 2 summarizes the 
primers used for PCR, including the number of cycles and corresponding annealing 
temperature for each set of primers. PCR pro gram: (94°C, 1 min; annealing temperature, 
1 min; 72°C, 1 min) X number of cycles. 
Apoptotic assays were carried out by surface staining with the Annexin-V FITC 
apoptosis kit (BioSource) following the manufacturer' s instructions. The stained cells 
were analyzed by flow cytometry using F ACScan (Becton Dickinson), and data was 
analyzed using the WinMDI 2.8 software (Scripp Institute). Samples were gated on a dot-
plot showing forward scatter and side scatter in order to exclude cell debris not within 
normal cell size. Gated cells were plotted on a dot-plot showing Annexin-V staining 
(FLI-H) and Propidium Iodide (PI) staining (FL2-H). 
112 

OF IN 
1 
The striking signaling differences between the two types of PKR-1- cells prompted 
us to investigate the possible expression of truncated PKR proteins as a result from 
incomplete disruption of the pkr gene. Specifically, Yang et al. (356) initially 
hypothesized that the N-PKR-1- mice might express a truncated PKR, which is the product 
of translation of a P KR rnRNA devoid of exons 2 and 3. Translation of this exon-skipped 
rnRNA could initiate from an AUG that corresponds to methionine 136 producing a 382 
amino acid (aa) C-terminal fragment of mPKR (356). In fact, the 42-44 kDa exon-
skipped mouse PKR (ES-mPKR) protein was detected in reticulocyte lysates 
programmed to translate the ES-mPKR rnRNA from N-PKR-1- cells (356). However, 
Yang et al. were not able to detect ES-mPKR expression in extracts from N-PKR-1- cells 
due to the unavailability of antibodies against the C-terminus part ofmPKR (356). 
To test whether N-PKR-1- cells express the PKR fragment produced from the 
translation of exon-skipped mouse PKR rnRNA (Fig. 17 A) (356), we performed western 
blot analysis with protein extracts from strain"matched PKR+1+ and N-PKR-1- MEFs (Fig. 
17B). To induce PKR protein expression, MEFs were treated with mouse IFNa/p. 
Immunoblot analysis with an anti-PKR monoclonal antibody (mAb) specific for an 
epitope within the C-terminus half of the kinase (clone B-10, top panel) detected the 
expression of full-Iength PKR in PKR+1+ cells (lanes 1 and 2) and the presence of a 45 
kDa protein in isogenic N-PKR-1- MEFs (lane 3), which was highly induced by IFN 
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treatment (lane 4). To further substantiate this finding, we performed a western blot 
analysis with protein extracts from isogenic PKR+1+ and N-PKR-1- MEFs using a rabbit 
polyclonal anti-PKR Ab (clone D-20) specifie for an epitope at the very C-terminus end 
of the kinase (Fig. lB, bottom panel). Similarly, we observed the presence of the 45 kDa 
protein in N-PKR-1- cens (lane 3), which was significantly induced after IFN treatment 
(lane 4). Note that this protein was undetectable in protein extracts from isogenic PKR+1+ 
cells (lanes land 2). To confirm that the 45 kDa protein is specifically expressed in N-
PKR-1- cells, we performed an immunoprecipitation with the rabbit polyclonal anti-mouse 
PKR Ab (clone D-20) followed by immunoblotting with the monoclonal anti-mouse PKR 
Ab (clone B-lO; Fig. l7C). This assay demonstrated the expression of the 45 kDa exon-
skipped mPKR (ES-mPKR) protein in the N-PKR-1- cells. 
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Figure 17. Immunodetection of exon-skipped mouse PKR in N-PKR-1- MEFs. 
(A) Schematic representation of ES-mPKR. ES-mPKR is translated from an 
alternative start site at position 553 within exon 5 of the PKR mRNA (Met 
136). The primary initiator AUG within exon 2 was disrupted by the 
neomycin resistance gene (neor) to generate the N-PKR-/- mouse. ES-mPKR is 
a 382 aa, 45 kDa protein, which contains part of the dsRNA binding-motif 2 
(dsRBM2), and an intact kinase do main (KD). 
(8) ES-mPKR is recognized by two different PKR antibodies. Protein 
extracts from isogenic (Le. genetic background 129Sv(ev) x C57BL/6J) 
PKR+/+ and N-PKR-/- MEFs before (lanes 1 and 3) or after stimulation with 
mIFNa/~ (1000 IU/ml for 18 hours; lanes 2 and 4) were subjected to 
immunoblot analysis with a anti-mPKR mAb (B-I0; top panel) or with a 
rabbit polyclonal anti-mPKR antibody (D-20; bottom panel) both specifie for 
the C-terminus domain of mPKR. The positions of mPKR and ES-mPKR 
protein are indicated. 
(C) Immunoprecipitation of ES-mPKR from N-PKR-/- MEFs. Prote in extracts 
(500 /lg) of PKR+/+ and N-PKR-/- MEFs before (lanes 1 and 3) and after 
stimulation with mIFNa/~ (1000 IU/ml, 18 ho urs; lanes 2 and 4) were 
subjected to immunoprecipitation with 2 /lg of the rabbit polyclonal anti-
mPKR Ab (D-20). Immunoprecipitates were then subjected to SDS-I00/0PAGE 
and immunoblotted with the anti-mPKR mAb (B-I0, Santa Cruz). The 
positions of mPKR and ES-mPKR proteins are indicated. 
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Since ES-mPKR possesses an intact kinase domain, we examined whether ES-
mPKR retains the catalytic activity of PKR. To this end, protein extracts from isogenic 
PKR+1+ and N-PKR-1- cells were subjected to immunoprecipitation with the rabbit 
polyc1onal anti-mouse PKR antibody (clone D-20) followed by in vitro kinase assay in 
the presence of recombinant histidine-tagged eIF2a, dsRNA and ATP (Fig. 18A). 
Phosphorylation of eIF2a was then detected by immunoblot analysis using a 
phosphoserine 51 specific anti-eIF2a antibody (top panel). The leve1s of recombinant 
eIF2a in the kinase reactions were measured by immunoblot analysis with anti-histidine 
antibodies (bottom panel). These assays showed that eIF2a is phosphorylated on serine 
51 in N-PKR+1+ cells (lane 1), and this phosphorylation was more highly induced after 
IFN treatment (lane 2). On the other hand, eIF2a phosphorylation in the PKR 
immunoprecipitates from N-PKR-1- MEFs (lane 3) was lower than in PKR+1+ MEFs (lane 
1) and detectable only after IFN treatment (lane 4). These differences most likely 
reflected the different levels of expression of full-Iength mPKR and ES-mPKR in PKR+1+ 
and N-PKR-1- cells, respective1y (Fig. 17B). 
We tested the ability of ES-mPKR to induce the phosphorylation of eIF2a in vivo. 
For this, we used the human hepatocarcinoma Huh7 cells, which exhibit 80-90% 
transfection efficiency as judged by the expression of the green fluorescence protein 
(GFP, data not shown). That is, WT-mPKR and ES-mPKR were transiently expressed in 
Huh7 cells using the vaccinia/T7 virus system (Fig. 18B). Protein extracts were subjected 
to immunoblot analysis for mPKR (top panel), eIF2a serine 51 phosphorylation (middle 
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panel), or total eIF2a levels (bottom panel). We found that expression of both WT-
mPKR and ES-mPKR was able to induce the phosphorylation of endogenous eIF2a 
(lanes 2 and 3) demonstrating that ES-mPKR indeed acts as an eIF2a kinase in vivo. In 
these experiments, we noticed that ES-mPKR migrated higher than the 45 kDa protein 
marker (Fig. 18B, lane 3; Fig. 19A, lane 3) probably due to its phosphorylation caused by 
overexpresslOn. 
no 
We also examined whether ES-mPKR retains its capacity to bind dsRNA and 
autophosphorylate. To this end, we used HeLa cells to express transiently wild type (WT) 
mPKR or ES-mPKR using the recombinant vaccinia/T7 virus method. In this method, 
transfected genes under the control of bacteriophage T7 promoter are efficiently 
transcribed in the cytoplasm by the T7 RNA polymerase delivered into the cells by 
infection with recombinant vaccinia virus es (106). This method is suitable for expressing 
PKR and studying the translational functions of the kinase (206). 
First, we tested the dsRNA-binding capacity of ES-mPKR. Protein extracts from 
HeLa cens expressing WT -mPKR and ES-mPKR were incubated with poly(rI-rC)-
agarose beads, and proteins bound to dsRNA were detected by immunoblotting (Fig. 
19A). We found that WT-mPKR was capable of binding to dsRNA (lane 5) unlike ES-
mPKR (lane 6). 
When the dsRNA-bound proteins were subjected to in vitro autophosphorylation 
assay in the presence of e2p-y]ATP (Fig. 19B), we found that WT-mPKR was highly 
autophosphorylated (lane 2) whereas no kinase activity was detected for ES-mPKR (lane 
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3). The high MW band (~110 kDa) phosphoprotein was non-specifie. These data 
suggested that ES-mPKR lacks the ability to bind dsRNA and conceivably the capacity to 
autophosphorylate in the presence of dsRNA. 
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Figure 18. Functional analysis of the kinase activity of ES-mPKR. 
(A) ES-mPKR exhibits eIF2a kinase activity in vitro. Protein extracts (500 
/lg) of PKR+/+ and N-PKR-/- MEFs before (lanes 1 and 3) and after stimulation 
with mIFNa/~ (1000 lU/ml, 18 hours; lanes 2 and 4) were subjected to 
immunoprecipitation with 2 /lg of the rabbit polyclonal anti-mPKR Ab (D-20, 
Santa Cruz). Immunoprecipitates were incubated with 1 /lg of recombinant 
histidine-tagged eIF2a in the presence of 0.1 /lg/ml activator reovirus dsRNA 
and 1 /lM ATP. After incubation at 30QC for 30 min, the reactions were 
subjected to SDS-12%PAGE and immunoblot analysis using a rabbit 
polyclonal anti-phosphoserine 51 eIF2a specifie Ab (top panel) foUowed by 
immunoblot analysis with anti-histidine tag Ab (bottom panel). 
(8) ES-mPKR exhibits eIF2a kinase activity in vivo. Huh7 ceUs were 
infected with vaccinia virus/T7, and transfected with either pYES2 vector 
DNA (mock; lane 1), WT-mPKR in pYES3/CT vector (lane 2), ES-mPKR in 
pYES2 vector (lane 3). Ten /lg of protein extracts were subjected to a SDS-
12%PAGE foUowed by immunoblot analysis with either rabbit polyclonal 
anti-mPKR Ab (D-20; top panel), rabbit polyclonal anti-phosphoserine 51 
eIF2a Ab (second panel) or rab bit polyclonal anti-human eIF2a Ab (bottom 
panel). 
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Figure 19. Functional analysis orthe dsRNA-binding activity of ES-mPKR. 
(A, B) ES-mPKR does not bind dsRNA. HeLa ceUs were infected with 
recombinant vaccinia /T7 virus, and transfected with either pYES2 vector 
DNA alone (mock; lane 1), WT-mPKR in pYES3/CT vector (lane 2), or ES-
mPKR in pYES2 vector (lane 3). Whole ceU extracts (WCE) containing 10 J..lg 
of protein used to detect the expression of PKR proteins by immunoblotting 
with the rab bit polyclonal anti-mPKR Ab (D-20) (B, lanes 1-3). For the dsRNA 
pull-down assays, 200 J..lg of protein extracts were incubated with poly(rI-
rC)-agarose beads, and the dsRNA-bound proteins were subjected to 
immunoblotting with rab bit polyclonal anti-mPKR Ab (D-20; A, lanes 4-6) or 
kinase assay in the presence of [3ZP-y]ATP (B, lanes 1-3). 
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It has been demonstrated that hPKR substitutes the function for GCN2 (86), the 
only eIF2a kinase in Saccharomyces cerevisiae (87). Since expression of PKR in yeast 
induces endogenous eIF2a phosphorylation (86), we examined whether expression of 
ES-mPKR in the yeast strain nl0, which lacks GCN2 (gcn2L1) (272), was also capable of 
inducing eIF2a phosphorylation in vivo (Fig. 20). 
To do so, ES-mPKR cDNA from N-PKR-1- MEFs was subc10ned into pYES2 
expression vector that allows expression under the galactose-inducible promoter (206). 
nlO cells were transformed with pYES2 vector DNA (mock, lane 1), pYES3/CT mPKR 
cDNA (lane 2), pYES2 ES-mPKR cDNA (lane 3) or pYES3/CT hPKR DNA (lane 4). 
The expression of the PKR forms was induced after growth of yeast cells in galactose-
rich medium. Yeast protein extracts were subjected to immunoblot analysis with 
antibodies against mPKR (first and second from the top panels), hPKR (third from the 
top panel), phosphoserine 51 of eIF2a (fourth from the top panel), and endogenous 
eIF2a (bottom panel). 
We found that the two different anti-mPKR antibodies (B-lO, top panel; D-20, 
second from the top panel) recognized mPKR and ES-mPKR in lanes 2 and 3 
respectively, but not hPKR (lane 4, third panel). We noticed that the D-20 Ab recognized 
full-Iength mPKR better than the B-l ° mAb (lane 2) for reasons that are not immediately 
c1ear. We also noticed a couple of slower migrating bandes) with the anti-mPKR 
antibodies in lane 3, which may represent phosphorylated forms of ES-mPKR. More 
importantly, however, we observed that phosphorylation of endogenous eIF2a was 
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induced in cells expressing ES-mPKR (fourth from the top panel, lane 3) and that eIF2a 
phosphorylation levels were proportional to the amounts of mPKR and ES-mPKR 
expressed in yeast cells. These findings clearly demonstrate that ES-mPKR is 
catalytically active in yeast cell in vivo. 
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Figure 20. ES-mPKR exhibits eIF2a. kinase activity in yeast. 
The yeast strain }110 was transformed with pYES2 vector DNA (mock; lane 
1), WT-mPKR in pYES3jCT vector (lane 2), ES-mPKR in pYES2 vector (lane 
3) or WT-hPKR in pYES3jCT vector (lane 4). Fifty flg ofprotein extracts from 
galactose-induced cells were subjected to a SDS-12%PAGE followed by 
immun ob lot analysis with either an anti-mPKR mAb (B-I0; top panel), a 
rabbit polyclonal anti-mPKR Ab (D-20; second panel), a rab bit polyclonal 
anti-hPKR Ab (third panel), a rabbit polyclonal anti-phosphoserine 51 eIF2a. 
Ab (fourth panel) or a rabbit polyclonal anti-yeast eIF2a. Ab (bottom panel). 
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The above findings prompted us to perfonn similar experiments with MEFs from 
the C-PKR-1- mouse (2). We perfonned immunoblot analysis of protein extracts from 
untreated and IFNa/p-treated cells with either the anti-PKR B-lO mAb (Fig. 2IA, top 
panel) or a rabbit polyc1onal anti-PKR Ab specifie for the dsRBMI within the N-
tenninus domain of mouse PKR (Fig. 2IA, middle panel) (1). Both antibodies detected 
the expression of a ~40 kDa protein in C-PKR-1- MEFs, which was more highly induced 
after IFN treatment (lane 4). This PKR-like protein, herein designated as mPKR*, was 
also detected by immunoprecipitation and immunoblotting with the anti-mPKR BIO mAb 
(Fig. 2IB, lanes 5 to 8). The molecular size ofmPKR* was better assessed by comparing 
its migration on SDS-PAGE to that of the 38 kDa eIF2a phosphoprotein (Fig. 21 C) by 
immunoblotting of the same membrane with anti-mPKR B-I0 mAb (lane 1) or anti-
phosphoserine 51 of eIF2a (lane 2). This experiment showed that the size of mPKR * is 
higher than 38 kDa. In addition, since ES-mPKR is not recognized by the anti-N-
tenninus mPKR Ab (data not shown), we conc1ude that mPKR * and ES-mPKR proteins 
are different (see also below). 
Next, we examined the functionality ofmPKR*. In this, we perfonned dsRNA-
binding' assays with protein extracts from isogenic PKR+1+ and C-PKR-1- cells (2) or 
isogenic PKR+1+ and N-PKR-1- cells (356) using poly(rI-rC) coupled to agarose beads. The 
identity of the pulled-down dsRNA-bound proteins was revealed by immunoblot analysis 
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usmg the anti-PKR B-10 mAb (Fig. 22A). We found that full-Iength mPKR was 
efficiently bound to dsRNA as expected (lanes 1,2,5 and 6). Interestingly, mPKR* in C-
PKR-1- cells was also bound to dsRNA efficiently (lanes 3 and 4). However, mPKR * was 
not present in N-PKR-1- cells (lanes 7 and 8). In these assays, we noticed the presence of a 
protein of 65 kDa in both N-PKR-1- and C-PKR-1- cells that was recognized by the anti-
PKR B-10 mAb. This 65 kDa protein was not fulllength mPKR in C-PKR-1- or N-PKR-1-
cell extracts that were contaminated with PKR+1+ cell extracts since its expression was not 
induced after IFN treatment (lanes 4 and 8). Most likely, the 65 kDa protein represents an 
unknown dsRNA-binding protein, which is recognized by the anti-mPKR B-10 mAb (see 
also below) .. 
Then, we tested whether mPKR * possesses kinase activity. To do so, protein 
extracts from isogenic PKR+1+ and C-PKR-1- MEFs were incubated with poly(rI-rC) 
dsRNA-agarose beads (Fig. 22B), and phosphorylation of dsRNA-bound proteins on the 
pulled down beads was tested in the presence of e2p-y]ATP. The 65 kDa dsRNA-bound 
phosphoprotein in PKR+1+ extracts (lane 1), whose phosphorylation was more highly 
induced after treatment with IFN (lane 2) was mPKR. Contrary to PKR +1+ extracts, C-
PKR-1- protein extracts were free of kinase activity (lanes 3, 4) demonstrating that 
mPKR * is catalytically inactive. Note that the 65 kDa protein recognized by the anti-PKR 
B-10 mAb in C-PKR-1- cells (Fig. 22A, lanes 3 and 4) was not phosphorylated in these 
assays (Fig. 22B, lanes 3 and 4) and therefore, it is unlikely to be a PKR-related protein. 
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Figure 21. Immunodetection of a 40 kDa PKR-like protein in C-PKR-1-
MEFs. 
(A) A PKR-like protein (mPKR*) is recognized by two different PKR 
antibodies. Protein extracts from isogenic PKR+/+ and C-PKR-/- MEFs (Le. 
genetie background 129/terSv X BALB/c) before (lanes 1 and 3) or after 
stimulation with mIFNa/p (1000 lU/ml for 18 hours; lanes 2 and 4) were' 
subjected to immunoblot analysis with anti-mPKR mAb (B-I0; top panel), 
rabbit polyclonal anti-mPKR Ab specifie for the N-terminus domain of the 
kinase (middle panel) or anti-actin antibody mAb (bottom panel). The PKR-
like protein is indicated as mPKR* (lanes 3 and 4). 
(8) Immunoprecipitation of mPKR*. Protein extracts from PKR+/+ and C-
PKR/- MEFs stimulated with mIFNa/p (1000 lU/ml, 18 ho urs) were 
subjected to immunoprecipitation with 11lg of anti-mPKR B-I0 mAb. 
Immunoprecipitates were then subjected to SDS-12%PAGE and 
immunoblotted with anti-mPKR B-I0 mAb. Lanes 1 to 4 are 50 Ilg of whole 
protein extracts (WPE) from PKR+/+ and C-PKR/- MEFs before (lanes 1 and 3) 
or after mIFNa/p stimulation (lanes 2 and 4). 
(C) mPKR* is a 40 kDa protein. Protein extracts from C-PKR/- MEFs after 
stimulation with mIFNa/p (1000 lU/ml, 18 hours; lanes 1) was 
immunoblotted with anti-mPKR B-I0 mAb. The same blot was stripped and 
re-probed with rabbit polyclonal anti-phosphoserine51-eIF2a Ab (lanes 2), 
which recognizes the 38 kDa eIF2a phosphoprotein. 
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Figure 22. Functional analysis of mPKR *. 
(A) mPKR* is a dsRNA-binding protein. Isogenic (Le. genetic background 
129/terSv X BALB/c) PKR+/+ (lanes 1 and 2), C-PKR-/- MEFs (lanes 3 and 4), 
and isogenic (Le. genetic background 129Sv(ev) x C57BL/6J) PKR+/+ (lanes 5 
and 6) and N-PKR-/- MEFs (lanes 7 and 8) were left untreated (lanes 1, 3, 5 
and 7) or treated with mIFNa/p (1000 lU/ml, 18 hours; lanes 2,4,6 and 8). 
Protein extracts (200 Ilg) were used for the pull-down assays with poly(rI-
rC) coupled to agarose beads. The bound proteins were subjected to a SDS-
12%PAGE followed by immunoblot analysis with the anti-mPKR B-l0 mAb. 
The positions of full-Iength mPKR and mPKR* proteins are indicated. The 
band of 65 kDa that was pulled down by dsRNA in both PKR-/- MEFs is not 
mPKR (see Results). 
(B) mPKR* is catalytically inactive. Protein extracts (200 Ilg) from PKR+/+ 
and C-PKR-/- MEFs before (lanes 1 and 3) and after stimulation with 
mIFNa/p (1000 lU/ml, 18 hours; lanes 2 and 4) were used for a pull-down 
with poly(rI-rC) coupled to agarose beads. The dsRNA-bound proteins were 
subjected to an autophosphorylation assay with [32P-y]ATP. Proteins were 
fractionated by SDS-12%PAGE and radioactive bands were visualized by 
autoradiography. 
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Next, we sought to explain the presence of mPKR* in C-PKR-1- cells. We 
speculated that mPKR * might be a product of alternative splicing based on our previous 
findings that spliced forms of PKR are expressed in human cells (206). To test this 
hypothesis, RNA from PKR+1+ and C-PKR-1- MEFs was subjected to RT-PCR analysis 
using two sets of primers, one that amplifies the region of mpkr cDNA between exons 5 
and 14 (Fig. 23A), and the other the region between exons 7 and 13 (Fig. 23B). We 
found that full length PKR was not amplified in RNA samples from C-PKR-1- cells 
providing further evidence that the 65 kDa protein recognized by the anti-PKR B-10 
mAb in C-PKR-1- cells (Fig. 22A) was not a contamination with PKR+1+ cells. Instead, we 
obseryed the presence of two smaller amplified bands (herein designated as SF l-mP KR 
and SF2-mPKR), which were subsequently identified as spliced forms (SF) of the pkr 
gene. 
Sequencing of the c10ned PCR products using the primers indicated in Table 1 
demonstrated that SFl-mPKR is a product of alternative splicing that occurs between 
exons Il and 13 (Fig. 24, middle panel), whereas SF2-mPKR is made by alternative 
splicing between exons 10 and 13 (Fig. 24, bottom panel). Thus, both SF-mPKR products 
bypass exon 12, which contains the neomycin resistance gene used for the generation of 
the C-PKR-1- mouse (2). Analysis of the sequencing data also showed that the alternative 
splicing mechanisms generated non-sense mutations for both alternatively spliced 
products with a stop codon a few nuc1eotides downstream of the splicing site. Thus, SFl-
mPKR consists of 323 residues with a predicted molecular size of 40 kDa, whereas SF2-
mPKR generates a protein of283 residues with a molecular size of35 kDa (Fig. 24). 
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However, the immunoblot analysis in Fig. 2IC c1early identified mPKR* as a 40 
kDa protein suggesting that mPKR* is identical to SFl-mPKR product. Detection of 
SF2-mPKR protein in C-PKR-1- cells was not possible. 
The lack of any detectable leve1s of SF-mPKR proteins in PKR+1+ cells prompted 
us to examine whether these PKR forms are expressed in normal mouse tissue at low 
levels and whether their expression is tissue specifie. To this end, we performed PCR 
analysis of normalized single-stranded cDNA prepared from 12 different normal mouse 
tissues using the T502/T302 set of primers. To increase the sensitivity of the screening, 
the PCR products were detected by Southem blotting (Fig. 25). These experiments 
showed that expression of full-length mP KR did not significantly vary between the mouse 
tissues whereas SF1-mPKR was expressed at very low levels in brain, spleen, lung, 
kidney and testis (Fig. 25). Interestingly, SF1-mPKR was also detected in tissues from 7-, 
11- and 17-day mouse embryo but not in tissue from 15-day mouse embryo indicating 
that its expression could be under developmental control. Detection of SF2-mPKR 
mRNA in these assays was not possible suggesting that its expression is probably unique 
for C-PKR-1- MEFs. 
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Figure 23. Cloning and sequencing of two alternatively spliced forms (SF) of 
mPKR in C-PKR-1- MEFs. 
(A, B) RT-PCR analysÉs of C-PKR-/- MEFs. Exponentially grown PKR+/+ and C-
PKR-/- MEFs both with genetic background 129/terSv X BALB/c were treated 
with 1000 lU/ml of mIFNa/~ for 18 hours. Reverse transcription (RT) was 
performed using 1 ~g of total RNA, oligo-dT 18 primer, and Moloney murine 
leukemia virus (M-MLV) reverse transcriptase followed by PCR with either 
the T503/T303 set of primers (A) or with the T502/T302 set of primers (B). 
Amplified DNA was subjected to 1.5% agarose electrophoresis and bands 
were visualized by EtBr staining. Lane 1, Marker DNA (<l>X174 DNA digested. 
with Hae III). Lane 4, negative control (dHzO). Lane 5, mpkr gene in 
pcDNA3.1/zeo. 
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Figure 24. DNA sequence and schematic representation of SF-mPKR. 
The DNA sequence around the junctions between exonl0jexonll, exon 
Iljexon 12, exon 12jexon 13 ofwild type mPKR, exon 10jexon Il and exon 
Iljexon 13 of SF1-mPKR, and exon 10jexon 13 of SF2-mPKR are shown (top 
panels). The predicted structures and molecular sizes of SFl-mPKR and SF2-
mPKR (middle and bottom panels) are shown and compared to full-Iength 
mPKR (top panel). 
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Figure 25. Tissue distribution of SF1-mPKR rnRNA. 
Normalized cDNAs from mouse multiple tissue panel (mouse MTC Panel 1; 
K1423-1; Clontech) was used as templates for PCR amplification with 
TS02/T302 set of primers. The PCR products were subjected to a 1.5% 
agarose gel electrophoresis followed by a Southern blot analysis using 3Zp_ 
labeled full-Iength mPKR cDNA as a probe. The radioactive bands were 
visualized by autoradiography. The top panel corresponds to a long film 
exposure of the membrane (24 hours), whereas a shorter film exposure (8 
ho urs) is shown in the bottom panel. 
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The partial inactivation of PKR in both PKR-1- mice may account, at least in part, 
for the signaling differences between the two PKR-1- cell types. For example, previous 
work with N-PKR-1- cells showed an impaired IKBa phosphorylation and NF-KB 
activation in response to dsRNA treatment (56,356,364). Contrary to this, NF-KB 
activation by dsRNA is normal in C-PKR-1- cells compared to isogenic PKR+1+ cells 
(157). We further confirmed this finding by assessing IKBa phosphorylation levels in 
PKR+1+ and C-PKR-1- cells in response to dsRNA (Fig. 26A). We found that IKBa 
phosphorylation in vivo was induced at equalleve1s in both PKR+1+ and C-PKR-1- cells 
(Fig. 26A, top panel). This finding demonstrates that the catalytic activity of mPKR plays 
no role in dsRNA-mediated signaling to NF-KB-dependent transcription. This is in 
agreement with recent findings from us and others showing that the catalytic activity of 
hPKR is dispensable for NF-KB-mediated gene transcription (37,158). 
We also examined the eIF2a phosphorylation levels in virus infected C-PKR-1-
MEFs. To this end, cells derived from isogenic PKR+1+ and C-PKR-1- mice bred onto 
l29SvEv background (93) were infected with vesicular stomatitis virus (VSV) (Fig. 
26B). Immunoblot analysis with anti-eIF2a phosphoserine 51 antibodies (Fig. 26B, top 
panel) followed by immunoblotting with anti-mouse eIF2a mAb (bottom panels) showed 
no significant differences in eIF2a phosphorylation between PKR+1+ and C-PKR-1- cells. 
These data show the redundancy of PKR in eIF2a phosphorylation in response to VSV 
infection. 
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Figure 26. Signaling properties of C-PKR-1- MEFs. 
(A) Induction of IKlJa phosphorylation by dsRNA in vivo in C-PKR-/- MEFs. 
Exponentially grown PKR+/+ and C-PKR-/- MEFs of 129/terSv X BALB/c 
genetic background were untreated (lanes 1 and 6) or treated with 0.1 
mg/mL poly(rI-rC) for the indicated time (lanes 2-5 and 7-10). Protein 
extracts (50 Ilg) were subjected to SDS-l0%PAGE, transferred onto 
Immobilon P membrane . (Millipore). Phosphorylation of IKBa was detected 
. after immun ob lot analysis with rabbit polyclonal anti-phosphoserine 32 
IKBa Ab (top panel) and normalized to IKBa protein levels by 
immunoblotting with a rabbit polyclonal to anti-IKBa Ab (bottom panel). The 
ratio of phosphorylated to total IKBa for each lane is indicated. 
(B) Phosphorylation of elF2a in virus infected C-PKR-/- MEFs. PKR+/+ and 
C-PKR-/- MEFs from mice bred onto 129SvEv genetic background were 
infected with vesicular stomatitis virus (VSV, MOI 10) for the indicated time. 
Protein extracts (50 Ilg) were subjected onto SDS-12%PAGE, transferred 
onto Immobilon P membrane (Millipore) and immunoblotted with a rabbit 
polyclonal anti-phosphoserine 51 eIF2a Ab (top panels) followed by 
immunoblotting with an anti-eIF2a mAb (bottom panels). The ratio of 
phosphorylated to total eIF2a protein is indicated below each lane. 
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The redundancy of PKR in eIF2a phosphorylation in response to VSV infection 
(Fig. 26B), and the recent finding implicating PERK in Hepatitis C virus (HCV) 
replication (256) prompted us to examine whether PERK plays a role in VSV replication. 
To do so, we first assessed the susceptibility of PERK+1+ and PERK-1- MEFs to VSV-
mediated apoptosis. That is, we tested the viability of non-infected or VSV infected (MOI 
1) MEFs at different hours-po st-infection (h.p.i.) (Fig. 27 A). We noticed that a higher 
number of PERK-1- than PERK+1+ MEFs were susceptible to cytopathic effects of VSV 
(Fig 27 A). Pre-treatment with IFNa/p complete1y protected both PERK+1+ and PERK-1-
MEFs against VSV infection (Fig. 27B). To establish whether PERK-1- MEFs were 
indeed undergoing apoptosis, PERK+1+ and PERK-1- MEFs infected with VSV were 
analyzed for staining with Annexin-V, an indicator of early apoptosis (Fig. 28). We 
found that at 24 h.p.i almost 30% of PERK-1- MEFs were apoptotic compared to 10% of 
PERK+1+ MEFs whereas at 36 h.p.i, the population of apoptotic PERK-1- MEFs reached 
60% compared to 20% of the PERK+1+ MEFs (Fig. 28). 
We also examined whether the increased susceptibility of PERK-1- MEFs to VSV 
infection is affected by treatment with either IFNa/p (Fig. 28, middle rows) or IFNy (Fig. 
28, bottom rows). Pre-treatment with either type of IFNs eliminated the apoptotic effects 
of VSV infection in both PERK+1+ and PERK-1- MEFs indicating that IFN-signaling 
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remains intact in PERK-1- MEFs, and expression of one or more IFN-induced genes can 
compensate for the loss of PERK in these cells. 
We then performed viral plaque assays in order to determine if the susceptibility 
of PERK-1- MEFS to VSV infection was due to a higher virus production. We determined 
that VSV production increased exponentially in PERK-1- MEFs (MOI 1, Fig. 29A, left 
panel) with a 3 log higher titer than PERK+1+ MEFs at 12 h.p.i., and 4 log and 8 log 
higher at 24 and 36 h.p.i., respectively. Immunoblot analysis with an anti-VSV antibody 
revealed that VSV protein production was only detectable in PERK-1- MEFs infected with 
MOI 1 (Fig. 29A, right panel). Despite the fact that the VSV titer increased in PERK+1+ 
infected at MOI 100 (Fig. 29B, left panel), it remains relative1y lower than in PERK-1-
MEFs (2-fold lower at 4 h.p.i.) throughout the growth curve and viral production reached 
a plateau after 8 h.p.i. The right panel of Fig. 29B c1early shows that VSV replication was 
significantly higher in infected PERK-1- MEFs due to robust viral protein production. 
These results explain that the susceptibility ofPERK-1- MEFs to VSV-mediated apoptosis 
is due to higher viral protein production and release of progeny virions. 
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Figure 27. Increased susceptibility of PERK-J- MEFs to VSV infection. 
PERK+/+ and PERK/- MEFs were untreated (A) or treated (B) with mouse 
IFNa/p (1000 lU/ml) for 18 hours in the absence (A & B, left panels) or 
presence (A & B, right panels) of VSV infection at a MOI of 1. CeUs were 
photographed at 100x magnification at indicated hours after infection. 
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Figure 28. A higher induction of VSV -mediated apoptosis in PERK-1- MEFs. 
PERK+/+ (A) and PERK-/- MEFs (8) were untreated or treated with either 
mouse IFNa/~ (1000 lU/ml) or IFNy (100 lU/ml) for 20 h followed by 
infection with VSV at MOI of 1. Cells were harvested at 24 or 36 hours post 
infection (h.p.i.) and subjected to Annexin-V /PI staining (BioSource) 
according to manufacturer's specifications. Cells were then subjected to flow 
cytometry analysis using FACScan (Becton Dickinson), and data was 
analyzed using WinMDI version 2.8 software (Scripp Institute). Cells were 
gated on a dot-plot showing forward and 'side scatter in order to excIude 
debris not within the normal size. Gated cells were plotted on a dot-plot 
showing annexin-V staining (FL1-H) and propidium iodide (PI) straining 
(FL2-H). The numbers represent the percentage of gated cells counted for 
their corresponding quadrant. These are data of one out of three 
reproducible experiments. 
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Figure 29. A higher induction of VSV replication in PERK-!- MEFs. 
(A, B) PERK+/+ and PERK-/- MEFs were left uninfected or infected with VSV 
MOI 1 (A) or VSV MOI 100 (B), and protein extracts were subjected to 
immunoblot analysis with an anti-VSV antibody (right panels) or viral titers 
were measured by harvesting medium at indicated hours post-infection 
followed by plaque assay analysis (left panels). The triangle (Â.) represents 
viral titers from PERK+/+ MEFs, and the square (.) represents viral titers 
from PERK/- MEFs. 
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To further characterize the PERK-1- MEFs, we next assessed the eIF2a 
phosphorylation levels in response to VSV infection with different multiplicity of 
infections (MOI 1, 10 and 50). We reasoned that VSV replication might activate 
intracellular pathways leading to PERK-mediated eIF2a phosphorylation. VSV infection 
induced eIF2a phosphorylation leve1s in both types of MEFs, however eIF2a 
phosphorylation was induced at higher levels in PERK+1+ than PERK-1- MEFs (Fig. 30A, 
B and C, top panels). To further verify this observation, we measured the eIF2a 
phosphorylation levels in VSV-infected MEFs using 2D gel electrophoresis (Fig. 30D). 
We noticed that phosphorylation of eIF2a was increased in PERK+1+ than in PERK-1-
MEFs after infection with VSV or treatment with ER stress inducer thapsigargin 
(compare top panels with middle or bottom panels). These data suggested that the higher 
levels of eIF2a phosphorylation are capable of limiting VSV replication in PERK+1+ 
MEFs as opposed to PERK-1- MEFs, in which eIF2a phosphorylation was diminished. 
Next, we performed immunoblot amilysis with a phosphospecific antibody against 
the Thr980-phosphorylation site of PERK, a site that serves as a marker for activation, 
using VSV -infected HeLa cells to detect endogenous PERK phosphorylation (Fig. 31A). 
PERK phosphorylation was induced as early as 2 h.p.i. Thapsigargin (TG) treatment for 1 
hour was used as a positive control. A shift in PERK migration was observed in TG-
treated cells as opposed to VSV infected cells, indicating that TG induces a higher 
phosphorylation pattern of PERK than VSV infection. 
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To further substantiate the above findings, we performed transient transfections of 
plasmids that express either wild type mouse PERK (WT) or the kinase inactive mouse 
PERK bearing the K618A mutation in COS-l cells (Fig. 31B). We reasoned that if PERK 
is activated by VSV infection, then eIF2a phosphorylation should be induced in cells 
transfected with the wild type kinase as opposed to cells expressing the catalytically 
inactive kinase. The expression of both proteins was detected by immunoblotting with 
either an anti-Myc tag antibody (second panel) or with an anti-PERK antibody (third 
panel). In the absence ofVSV infection, we noticed that WT-PERK migrated slower than 
the PERK K618A due to the autophosphorylation of the active kinase (Fig. 31B, lanes 2 
and 3, second and third panels) (128). 
On the other hand, in cells infected with VSV we noticed a slight shift in the 
mobility of WT-PERK after immunoblotting with both antibodies (second and third 
panels, compare lane 2 and 5) indicating PERK activation during virus replication. 
Activation of PERK became more evident after immunoblotting with the 
phosphothreonine 980 antibody (top panel). We detected an induction in PERK 
phosphorylation upon VSV infection (lane 5, top panel) and in cells treated with 
thapsigargin (lane 8, top panel) when compared to uninfected or untreated cells (lane 2, 
top panel). As expected, this phosphospecific antibody was unable to detect the PERK 
K618A mutant since the latter mutation renders the kinase inactive (lanes 3, 6, 9, top 
panel). 
The induction of phosphorylation and activation of PERK upon VSV infection 
correlated with the eIF2a phosphorylation pattern we observed (fourth panel). We 
noticed that VSV infection induced eIF2a phosphorylation is cells transfected with WT-
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PERK compared to cens transfected with PERK-K618A mutant (compare lanes 5 and 6). 
In addition, eIF2a phosphorylation was significantly increased in VSV infected cens than 
in uninfected cens expressing WT-PERK (compare lane 2 and 5). Activation of WT-
PERK and induction of eIF2a phosphorylation in transiently transfected COS-l cens was 
also observed after treatment with thapsigargin, which served as a positive control in 
these assays (lanes 7-9). Based on these results, we conc1uded that VSV-infection results 
in the induction of PERK activity and eIF2a phosphorylation. 
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Figure 30. Enhanced VSV replication in PERK-!- MEFs as a result of 
impaired eIF2a. phosphorylation. 
PERK+/+ and PERK-/- MEFs were infected (lanes 2-4 and 6-8) or not (lanes 1 
and 5) with VSV at MOI of 1 (A), 10 (B) or 50 (C). Proteins extracts were 
harvested at indicated hours post-infection (h.p.i.) and subjected to 
immunoblot analysis using the rabbit polyclonal anti-phosphoserine 51-
eIF2a. antibody (top panels) or with the eIF2a. antibody (lower panels). The 
ratio of phosphorylated to total eIF2a. protein for each lane is indicated. 
(D) PERK+/+ and PERK/- MEFs were either treated with 1 ~M of thapsigargin 
for 2 hours (bottom panels), infected ( middle panels) or uninfected (top 
panels) with VSV at MOI of 10 and harvested at 12 hours post infection. 
Protein extracts were subjected to 2D electrophoresis and immun ob lot 
analysis with a rabbit polyclonal anti-phosphoserine51-eIF2a. antibody. 
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Figure 31. VSV induces PERK-mediated eIF2a. phosphorylation. 
(A) Protein extracts from HeLa cells infected with VSV (MOI 100) were 
coUeeted at different hours post infection (h.p.i.), and subjected to 
immunoblot analysis with a rab bit polyclonal phosphothreonine 980 PERK 
antibody (top panel) or a rabbit polyclonal anti-PERK antibody (H-300; 
bottom panel). 
(8) COS-l eells were transfeeted with either mye-tagged wild-type (WT) 
mouse PERK or the K618A eatalytie mutant of mouse PERK (5 Ilg of plasmid 
DNA) followed by VSV infection or thapsigargin treatment. Protein extracts 
were subjeeted to immunoblot analysis with a rabbit polyclonal 
phosphothreonine 980 PERK antibody (top panel), a mouse monoclonal myc-
tag antibody (second panel), a goat polyclonal anti-PERK antibody (third 
panel), a rabbit polyclonal phosphoserine 51 eIF2a. antibody (fourth panel) 
or with a mouse monoclonal eIF2a. antibody (fifth panel). A non-specifie 
(N.S.) band was used to determine the amount of protein loaded (bottom 
panel). 
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In order to elucidate the mechanisms of VSV-mediated apoptosis, we measured 
caspase-12 activation in PERK+1+ and PERK-1- MEFs in response to infection. Caspase-
12 is an ER-membrane associated cysteine protease activated by ER stress (239). This 
protease is also induced in cells infected with the respiratory syncytial virus (RSV) (32) 
or bovine viral diarrhoea virus (BVDV) (165). Immunoblot analysis with an antibody that 
recognizes the inactive and active (i.e. c1eaved) forms of caspase-12 demonstrated a 
higher activity of the protease in PERK-1- than in PERK+1+ MEFs (Fig. 32A, compare lane 
2 with 5, and lane 3 with 6). Thus, it appears that caspase-12 activation can account, at 
least in part, for the higher induction ofVSV-mediated apoptosis in PERK-1-MEFs. 
It was previously shown that broad-spectrum caspase inhibitors effectively 
prevented the activation of programmed cell death pathways in VSV -infected cells (84). 
In order to get a better understanding on VSV -mediated apoptosis, we treated PERK+1+ 
and PERK-1- MEFs with a general caspase inhibitor (zV AD-fmk) prior to VSV infection. 
We noticed that caspase inhibitors protected PERK+1+ from VSV infection (Fig. 32B, 
compare row 1 column 4 with row 1 column 2). However, the cell rounding phenotype 
associated with VSV infection was not prevented in PERK-1- MEFs treated with caspase 
inhibitors (Fig. 32B, compare row 2 column 4 with row 2 column 2) indicating their 
inability to be rescued from VSV -mediated apoptosis. 
This was further verified by immunoblot analysis of the poly(ADP ribose) 
polymerase (P ARP), a common marker of apoptosis, where its c1eavage is induced in 
VSV infected cells (Fig. 32C) (143). VSV-infected PERK-1- MEFs had a higher PARP 
c1eavage capacity than PERK+1+ cells (Fig. 32C, compare lane 6 with lane 2). When cells 
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were treated with caspase inhibitors pnor to VSV infection, P ARP c1eavage was 
abolished in PERK+1+ cells indicating apoptotic rescue (Fig. 32C, lane 4), whereas such 
inhibitors were unable to prevent P ARP c1eavage in PERK-1- MEFs (lane 8). This 
suggested that caspases play a critical role in VSV -mediated apoptosis in the presence of 
PERK. Conversely, in the absence of PERK, inactivation of caspases is not sufficient to 
abolish apoptosis suggesting that the lack of PERK can induce caspase-independent 
apoptotic pathways. 
ER-mediated apoptosis also proceeds through the activation of c-Jun NHz-
terminal kinase (JNK) (252). On the other hand, virus infection results in the activation of 
JNK-l and p38 mitogen activated protein kinase (p38 MAPK), both ofwhich have been 
implicated in virus-mediated apoptosis (56,156). Taken together, we sought to determine 
the expression and activity of these pro-apoptotic proteins in VSV -infected PERK+1+ and 
PERK-1- MEFs. Immunoblot analysis with phosphospecific antibodies to either JNK-l or 
p38 MAPK showed equallevels of expression and activation of these kinases in both 
types of MEFs (Fig. 33). This indicated that the higher induction of VSV -mediated 
apoptosis in PERK-1- MEFs is independent of JNK -1 and p38 MAPK activation. 
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Figure 32. VSV -induced apoptosis of PERK-J- MEFs proceeds through 
caspase-12 activation. 
(A) Protein extracts from PERK+/+ and PERK-/- MEFs infected with VSV (MOI 
1) were collected at different hours post infection (h.p.i.) and subjected to 
immunoblot analysis with a rabbit polyclonal antibody against caspase-12. 
The upper band represents the inactive protease (procaspase-12) whereas 
the lower band represents the cleaved and active enzyme (caspase-12). 
(B, C) PERK+/+ and PERK/- MEFs were treated with or without caspase 
inhibitors (zVAD-fmk; 10 !lM) 2h before infection with VSV (MOI 2) for 24 
hours. Cells were photographed at 100x magnification (B) or protein extracts 
were subjected to immunoblot analysis with a rabbit polyclonal antibody 
against PARP (C). The upper band represents the fulliength 116 kDa PARP 
protein and the lower band represents the cleaved 89 kDa PARP. 
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Figure 33. VSV-mediated apoptosis is independent of the JNKlp38 MAPK 
pathway. 
Protein extracts from PERK+/+ and PERK-/- MEFs infected with VSV (MOI 1) 
were coUected at different hours post infection (h.p.i.) and were used for 
immun ob lot analysis with a rabbit polyclonal anti-phospho JNK-1 antibody 
(top panel), a rabbit polyclonal anti-JNK-1 antibody (second panel), a rabbit 
polyclonal anti-phospho p38 MAPK antibody (third panel), a rab bit 
polyclonal anti-p38 MAPK antibody (fourth panel). The protein load was 
normalized to Actin after immunoblotting with an anti-Actin monoclonal 
antibody (bottom panel). 
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Given the demonstrated role for PKR in halting VSV replication (11,93,313), we 
wished to examine whether induction of VSV replication and apoptosis in PERK-1- MEFs 
was due to defective activation of PKR. When protein extracts from VSV-infected cells 
were subjected to pull down with poly(rI-rC)-agarose (Fig. 34A) or immunoprecipitation 
with PKR antibodies (Fig. 34B) followed by kinase autophosphorylation, we found that 
PKR kinase activity was severely diminished in PERK-1- MEFs as opposed to their wild 
type counterparts after virus infection (Fig. 34A and B). This indicated that the higher 
replication and apoptotic capacity ofVSV in PERK-1- MEFs is caused, at least in part, due 
to defective PKR activation. We further verified this finding by assessing the activation 
of PKR in vivo by 2D gel electrophoresis and immunoblot analysis (Fig. 34C). We 
observed an increase in PKR protein towards the acidic side (pH 6; bottom left panel, 
arrow) in VSV-infected PERK+1+ MEFs as opposed to the VSV-infected PERK-1- MEFs 
(bottom right panel). This acidic fraction of PKR was present only in PERK+1+ cells 
indicating an induction of PKR activity in cells containing PERK as opposed to cells 
lacking it. 
This finding prompted us to examine whether PKR activity is induced by ER 
stress and, if so, whether its activation is mediated by PERK. To do so, we treated 
PERK+1+ and PERK-1- MEFs with tunicamycin, an inhibitor of protein glycosylation and 
an ER stress inducer, followed by autophosphorylation of immunoprecipitated PKR (Fig. 
35Ar We noticed that PKR kinase activity was induced in PERK+1+ MEFs upon 
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tunicamycin treatment (lanes 1-4) as opposed to PERK-1- MEFs, which failed to activate 
PKR (lanes 5-8). Interestingly, PKR autophosphorylation was significantly diminished 
after 4h of tunicamycin treatment (lane 8) indicating that prolonged ER stress may lead to 
the inactivation of PKR. This data provided evidence for a cross-talk between the two 
eIF2a kinases with PKR functioning downstream of PERK in response to ER stress or 
VSV infection. 
These data suggested that PERK lS capable of modulating PKR 
autophosphorylation and its full scale activation. To further substantiate this, we co-
transfected COS-1 cells with PERK or PKR in the presence or absence of a dominant 
negative PKR mutant (P:KRA6) (91) (Fig. 35B). PERK and PKR were able to induce 
eIF2a phosphorylation upon VSV infection (third panel, compare lanes 9 and 13 to lanes 
2 and 6, respectively), whereas PKR~6 showed no kinase activity (third panel, compare 
lane 3 with lane 10). AIso, PKR~6 was able to prevent PKR-mediated eIF2a 
phosphorylation before and after VSV infection (third panel, compare lane 7 with lane 
14). To this extent, P:KRA6 was capable of inhibiting PERK-mediated eIF2a 
phosphorylation (third panel, compare lane 4 with lane Il, and lane 5 with lane 12). AIso, 
PKR~6 did not affect PERK phosphorylation on Thr980 (top panel). These data further 
substantiate the notion that eIF2a phosphorylation is mediated by both PERK and PKR 
upon VSV infection, and that a cross-talk between both kinases is necessary to inhibit 
viral replication. 
168 
Figure 34. PKR activation is impaired in VSV infected PERK-!- MEFs. 
Protein extracts from VSV infected (MOI 10) PERK+/+ and PERK/- MEFs were 
pulled down with either (A) poly(rI-rC)-agarose beads (Amersham-
Pharmacia) or (B) immunoprecipitated with a rabbit polyclonal anti-mPKR 
antibody (D-20), and subjected to in vitro phosphorylation in the presence of 
[32P]-yATP. Half of the dsRNA-bound PKR was subjected to SDS-l0%PAGE 
and autoradiography (top panel) whereas the other half to immunoblot 
analysis with an antibody against mouse PKR (bottom panel, B-l0). 
(C) PERK+/+ and PERK-/- MEFs were either infected (bottom panels) or 
uninfected (top panels) with VSV at MOI of 10 and harvested at 12 hours post 
infection. Protein extracts were subjected to 2D electrophoresis and 
immun ob lot analysis with a rab bit polyclonal anti-mPKR antibody (D-20). 
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Figure 35. PERK functions upstream to PKR upon ER stress and VSV 
infection. 
(A) PERK+/+ and PERK-/- MEFs were either treated or not with 10 Ilg/ml of 
tunicamycin for indicated period of time. Protein extracts were subjected to a 
similar kinase assay as in Fig. 34. 
(8) COS-1 ceUs were mock transfected (lanes 1 and 8) or transfected with 
either WT PERK (5 Ilg of plasmid DNA, lanes 2, 4, 5, 9, Il and 12) or WT PKR 
with (5 Ilg of plasmid DNA, lanes 6, 7, 13 and 14) or without PKR~6 (2 Ilg of 
plasmid DNA, lane 4 and Il or 5 Ilg of plasmid DNA, lanes 3, 5, 7, 10, 12 and 
14) followed by VSV infection. Protein extracts were subjected to 
immun ob lot analysis with either with a rabbit polyelonal phosphothreonine 
980 PERK antibody (top panel), a mouse monoelo,nal myc-tag antibody 
(second panel), a rabbit polyelonal phosphoserine 51 eIF2a antibody (third 
panel) or with a mouse monoelonal eIF2a antibody (bottom panel). 
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One of the mechanisms proposed to activate PKR during virus infection is the 
dimerization of the kinase upon dsRNA binding (172). Since dsRNA is generated 
throughout the life cycle ofVSV (338), we wanted to investigate if PERK was capable of 
modulating PKR activation in cells transfected with dsRNA (Fig. 36). We noticed that 
the induction of eIF2a phosphorylation was impaired in PERK-1- MEFs upon dsRNA 
treatment as opposed to PERK+1+ cells (Fig. 36A, compare lane 4 with lane2). The same 
was observed regarding PKR activation (Fig. 36B). We performed a PKR 
immunoprecipitation followed by an in vitro kinase assay thus revealing that PERK-1-
MEFs were incapable of fully activating PKR (Fig. 36B, top panel). To the same extent, 
phosphorylation of PKR on Thr446 was impaired in the PERK-1- cells (Fig. 36B, middle 
panel). These results suggested that the efficient activation of PKR by dsRNA required 
PERK. 
Hot stress 
PERK plays an essential role in the ynfolded J2rotein response (UPR) (273), and 
as such, its activation in VSV infection initially indicated an ability of the virus to elicit 
the UPR. This was consistent with the notion that viruses that use the ER as an integral 
part of their replication strategy are likely able to induce an ER stress response (5). In 
fact, previous studies showed that the VSV glycoprotein (G) oligomerizes in the ER prior 
to its transport to the cell surface (363). Misfolded and unassembled VSV-G is retained in 
the ER (77) whereas the interactions of the viral protein with two chaperones, BiP and 
calnexin, are essential for efficient folding and for retention of partially folded G protein 
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forms in the ER (124). Thus, an overload of VSV-G in the ER during virus replication 
might have been one of the mechanisms eliciting an ER stress response in infected cells. 
Contrary to this, we found that expression ofvarious ER stress markers inc1uding CHOP, 
BiP, or XBP-1 was not induced in infected cells nor was their expression impaired in 
PERK-1- MEFs (Fig. 37). As such, we conc1uded that VSV utilizes a novel pathway to 
activate PERK. Although this pathway is not currently known, we hypothesize that virus 
infection might induce protein phosphorylation cascades leading to the activation of 
PERK in the ER. 
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Figure 36. PKR activation is impaired in dsRNA treated PERK-1- MEFs. 
(A) PERK+/+ and PERK-/- MEFs were transfected with dsRNA (10 /-lg/ml, lanes 
2 and 4) or mock transfected (lanes 1 and 3) or treated with thapsigargin (1 
/-lM, 2h; lanes S, 6). Proteins extracts were harvested at indicated hours and 
subjected to immun ob lot analysis using the serine 51 phosphospecific eIF2a 
antibody (top panel) or with the eIF2a antibody (lower panel). 
(8) Protein extracts from dsRNA transfected PERK+/+ and PERK-/- MEFs were 
immunoprecipitated wlth a rabbit polyclonal anti-mPKR antibody (D-20), 
and subjected to phosphorylation in vitro in the presence of [32P]-yATP. The 
immunoprecipitated PKR was subjected to SDS-I0%PAGE and 
autoradiography (top panel). Protein extracts were subjected to immunoblot 
analysis with a rabbit polyclonal phosphothreonine 446 PKR antibody 
(second panel) or a mouse monoclonal Actin antibody (bottom panel). 
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Figure 37. VSV infection do es not elicit an ER stress response. 
Total RNA was isolated from VSV infected (MOI 10) PERK+/+ and PERK-/-
MEFs (lanes 1-12) or from thapsigargin treated cells (l/-lM, Sh; lanes 13 and 
14). 10 /-lg of RNA was used for northern blot analysis. The membrane-bound 
RNA was probed with radio-Iabeled cDNA corresponding to BiP/Grp78 (top 
panel), XBP-l (second panel) or CHOP/GADD153 (third panel). The bottom 
panel is a picture of the ethidium bromide stained gel depicting the 28S and 
18S rRNA as an indication for equalloading. 
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We have previously observed that pharmacological and physiological inducers of 
ER stress target p53 to the cytoplasm where it is degraded (263). Given the ability of ER 
stress to trigger the activation of eIF2a kinases, we hypothesized that eIF2a kinases may 
be involved in the downregulation of p53 mediated by ER stress. We first examined the 
expression levels of p53 and the phosphorylation of eIF2a on Ser51 in response to 
prolonged (16 hours) ER stress in different human tumor celIlines harboring wild type 
p53. We employed the fibrosarcoma cellline HTI080, the lung carcinoma epithelial cell 
line A549, the osteosarcoma cellline U20S, and the colon carcinoma cellline HCT116 
(Fig. 38A). AlI four human cell lines responded to both ER stress inducing agents 
tunicamycin (TM), and thapsigargin (TG) as indicated by the induction of eIF2a 
phosphorylation on Ser51 (Fig. 38A). 
In relation to our previous observations (263), the p53 protein levels decreased 
upon treatment with TM or TG (Fig. 38A). Short term ER stress led to the same 
conclusions when HTI080 cells were treated with TG for 4 hours (Fig. 38B, lanes 1 and 
2). Both, the induction of eIF2a phosphorylation and the downregulation of p53 were 
observed in HTI080 cells (Fig. 38B) and in the other human cancer celllines previously 
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mentioned (data not shown). For practical reasons, the remaining experiments were done 
with short term ER stress response between 2-4 hours. 
Next we investigated whether similar results can be obtained in the mouse 
fibroblast cellline Nlli 3T3 treated with TG for 4 hours. As expected, ER stress induced 
eIF2a phosphorylation in conjunction with p53 downregulation in NIH 3T3 cells (Fig. 
38C, lanes 1-2). These experiments suggest that both human and mouse cells may utilize 
a similar pathway to downregulate p53 upon ER stress. We previously showed that this 
ER stress-induced downregulation of p53 was due to the accelerated Mdm2-p53 
degradation pathway (260,263). Also, this downregulation can be rescued if the 
proteasome pathway is chemically inhibited with MG 132. We observed a recovery of 
p53 protein levels with MG132 above the basallevels in HT1080 (Fig. 38B, lanes 3-4) 
and NIH 3T3 (Fig. 38C, lanes 3-4) cells despite the induction of ER stress. These results 
support our previous c1aim that ER stress induces the degradation of p53 (263). 
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Figure 38. Downregulation of p53 upon ER stress in different celllines. 
(A) A549, HCTl16, U20S, HT1080 cens harboring wild type p53 were 
treated for 16h with tunicamycin (TM; 10 /lgjml) or thapsigargin (TG; l/lM). 
Total protein extracts were used to determine the protein levels of p53, 
ph?spho-ser51 of eIF2a, total eIF2a, PUMA, NOXA, phospho-Ser641j645-
glycogen synthase, total glycogen synthase by immunoblot analysis. 
(B, C) HT1080 cens (B) or NIH 3T3 cens (C) were treated with 1 /lM TG for 
4h in the presence or absence of MG132 (10 /lM). Cell extracts were 
subjected to immunoblot analysis with anti-p53, anti-phospho-Ser51-eIF2a 
and anti-eIF2a antibodies. 
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It has been demonstrated that PERK activation is induced upon ER stress, and it is 
the main eIF2a kinase that mediates the shutdown of protein synthesis (128). In order to 
assess the role that PERK plays in the downregulation of p53, PERK+1+ and PERK-1-
primary MEFs were treated with TG, and p53 levels were detected by immunoblot 
analysis. Thapsigargin treatment mediated the downregulation of p53 protein levels in 
PERK+1+ MEFs, however this decrease was not observed in the PERK-1- MEFs (Fig. 
39A). To further confirm the involvement of PERK in human cells, we knocked down 
PERK using the RNA interference (RNAi) approach (97) in HTI080 cells (Fig. 39B). We 
observed a dramatic decrease in PERK protein levels in the PERK RNAi cells (Fig. 39B, 
fourth panel, lanes 3-4 compared to lanes 1-2), and a failure to induce eIF2a 
phosphorylation (Fig. 39B, second panel) upon TG treatment indicating that PERK 
activation was impaired in these cells. This impairment of PERK was sufficient to rescue 
p53 protein levels even in the presence of TG (Fig. 39B, first panel). Both experiments 
suggest that PERK activation mediates p53 downregulation in response to ER stress. 
We next investigated whether other forms of stress that induce eIF2a 
phosphorylation are capable to downregulate p53. To this extent we decided to study if 
another eIF2a kinase such as PKR can lead to the same conclusions. PKR dimerizes and 
autophosphorylates in the presence of dsRNA produced during virus infection (59). To 
confirm the role of PKR in p53 downregulation upon dsRNA, we used the knockdown 
approach. Specifically, we used a stable NIH3T3 cell line expressing a short-hairpin 
RNA targeted against PKR mRNA (shPKR) in order to knockdown PKR protein levels 
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(Fig. 40A, second panel). We observed an induction of eIF2a phosphorylation after 
transfection of dsRNA in control cells but not in shPKR cells due to the lack of PKR 
expression (Fig. 40A, third panel). We found that by stably knocking down PKR, we 
were able to rescue the endogenous wild type p53 from the inhibitory effects of dsRNA 
transfection (Fig. 40A, top panel) providing evidence for a role ofPKR in this process. 
Similar to TG treatment, dsRNA transfection was able to downregulate p53 and 
induce eIF2a phosphorylation in RTl080 cells (Fig. 40B, lane 3) but not when dsRNA 
was added to the medium (Fig. 40B, lane 2). This confirms that intracellular or 
cytoplasmic dsRNA was required to induce PKR activation and promote p53 
downregulation. More so, the downregulation of p53 was rescued in the presence of 
MG132 (Fig. 40B, lane 6) further suggesting that the proteasome pathway is responsible 
for the p53 downregulation upon dsRNA transfection. Together these data suggest that 
eIF2a kinase activity induced by thapsigargin (PERK) or dsRNA (PKR) is sufficient to 
inhibit the expression ofp53. 
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Figure 39. Activation of PERK triggers the downregulation of p53 upon ER 
stress. 
(A) Primary PERK/- and PERK+/+ MEFs were treated with TG (1 /lM) for 4 h 
and total ceU extraets were used to determine p53 and aetin levels by 
immun ob lot analysis. 
(8) HT1080 cells were transiently transfeeted with non-specifie siRNA (GL-
2) or PERK siRNA (PERKi) and then treated with TG (1 /lM) for 4 h_ CeU 
extraets were subjeeted to immun ob lot analysis with anti-p53, anti-phospho-
Ser51-eIF2u, anti-eIF2u, and anti-PERK antibodies. 
185 
:R~iméilry PERK .1eFs 
+l+ ~/!" 
TG (1 JlM): !!'" .4h JO .4h 
HT1080 
GL-2 iREAKi 
~ReRK 
Figure 40. Activation of PKR by dsRNA triggers the downregulation of p53. 
(A) NIH 3T3 ceUs were stably transfected with non-specifie shRNA (CON) or 
with shRNA against PKR (shPKR) foUowed by transfection with dsRNA (10 
J.lg/ml) for 3h. CeU extracts were subjected to immunoblot analysis with anti-
p53, anti phospho-Ser51-eIF2a, anti-eIF2a, and anti-PKR antibodies. 
(8) HTI080 ceUs were either transfected with LipofectAMINE and dsRNA 
(10 J.lg/ml) or incubated with dsRNA (10 J.lg/ml) alone and pre-treated (30 
min) with or without MG132 (10 J.lM) for 4h. cen extracts were subjected to 
immun ob lot analysis with anti-p53, anti-phospho-Ser51-eIF2a, anti-eIF2a 
antibodies. 
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We previously reported that the ER stress response induces the nucleocytoplasmic 
transport and degradation of p53 (263). Since similar results were obtained between TG 
treatment and dsRNA transfection regarding p53 downregulation, we tested whether 
dsRNA also controls p53 localization. Immunohistochemistry analysis of untreated 
HTI080 cells show high levels of p53 localized in the nucleus (Fig. 41, top panel). 
Treatment with dsRNA had no effect on p53 localization (Fig. 41, second panel), whereas 
transfected dsRNA induced cytoplasmic localization of p53 (Fig. 41, third panel). The 
addition of MG132 was able to recover nuclear p53 (Fig. 41, panels 4-6) despite the 
activation of PKR mediated by transfected dsRNA as indicated by the phosphorylation of 
eIF2a (Fig. 40B, second panel). 
We also observed that the induction of eIF2a phosphorylation was lower in 
HTI080 cells transfected with dsRNA in the presence ofMG132 as opposed to dsRNA 
alone (Fig. 40B, second panel, lanes 6 compared to lane 3) for reasons not yet 
understood. This observation was not observed in NIH 3T3 cells treated with TG and/or 
MG132 (Fig. 38C) indicating that MG132 may have different effects on human cells than 
on mouse cells. It was previously shown that MG 132 induces eIF2a phosphorylation via 
GCN2 activation in mouse fibroblast cells (163).We also had a similar induction of 
eIF2a phosphorylation in NIH 3T3 cells treated with MG132 (Fig. 38C, second panel, 
lane 3). However, this induction failed to downregulate p53 despite any translational 
shutdown mediated by eIF2a phosphorylation. These data support our previous 
observations that p53 is subjected to proteasome mediated degradation since MG132 was 
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sufficient to recover and stabilize p53 protein ab ove basal levels.· Taken together, PKR 
activation induced by intracellular dsRNA promotes the nuc1ear export and degradation 
ofp53, and that the translation control mediated by eIF2a kinases may not be involved in 
this process. 
190 
Figure 41. dsRNA transfection induces the cytoplasmic localization of p53. 
HT1080 cells were treated (dsRNA) or transfected (Lipo + dsRNA) with 10 
/lg/ml dsRNA for 4h in presence or absence of MG132 (10 /lM). The 
localization of endogenous p53 was examined by immunofluorescence. CeU 
nuclei were visualized by staining with DAPI. 
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To determine whether the phosphorylation of eIF2a plays a role in the 
downregulation of p53 upon ER stress, we treated HTI080 cells with compound 3 
(SalO03), a derivative of salubrinal (39). Salubrinal is a drug that acts as a potent inhibitor 
of the PPI phosphatase thus preventing eIF2a dephosphorylation, a~d ultimately 
prevents protein synthesis independently of eIF2a kinase activity (39). We noticed that 
SalO03 treatment was capable of inducing eIF2a phosphorylation to the same extent as 
dsRNA transfection in HTI080 cells (Fig. 42A). Despite the robust accumulation of 
eIF2a phosphorylation, SalO03 treatment did not inhibit p53 levels (Fig. 42A) nor did it 
induce the cytoplasmic localization of p53 (Fig. 42B) in HTI080 cells as opposed to 
dsRNA transfection. This suggests that eIF2a phosphorylation in the absence of eIF2a 
kinase activity is not sufficient to decrease p53 levels or mediate its cytoplasmic 
localization. 
We further investigated whether the phosphorylation of eIF2a is responsible for 
p53 nuc1ear export upon ER stress. To this end, we used immortalized MEFs bearing a 
homozygous Ser5lAIa knock-in mutation of eIF2a (eIF2a A/A) (286). Isogenic wild 
type (eIF2a SIS) and eIF2aS5lA knock-in (eIF2a A/A) MEFs were treated with 
tunicamycin (TM) and/or with a genotoxic drug adriamycin (ADR) to determine if eIF2a 
MEFs respond to ER stress and DNA damage. As expected, TM induced eIF2a 
phosphorylation on ser51 in the eIF2a SIS MEFs whereas no detectable phosphorylation 
was observed in the eIF2a A/A MEFs (Fig. 43A). Due to the immortalization of the 
eIF2a MEFs, p53 was undetectable in the eIF2a SIS MEFs despite the treatment with 
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ADR, and appeared to be mutated or already stabüized in the eIF2a AI A MEFs since 
neither treatment affected p53 protein levels. To bypass this limitation, we transfected the 
eIF2a MEFs with a chimeric protein consisting of the human wild type p53, and the 
green fluorescent protein (GFP-p53). The cells were then subjected to TM or TG (Fig. 
43B). It was previously reported that the fluorescent GFP-p53 protein and the wild type 
p53 protein are recognized equally by several monoclonal p53-specific antibodies, have 
similar half-lives, and function comparably in transactivating a p53-responsive element 
as well as in suppressing the growth of tumor cells (243). In untreated conditions, GFP-
p53 was localized in the nucleus in both cell hnes (Fig. 43B). Upon ER stress, 
localization of GFP-p53 was both nuclear and cytoplasmic despite conditions in which 
eIF2a phosphorylation is not possible such as the case of the eIF2a AI A MEFs (Fig. 
43B). Together these results confirmed that although eIF2a kinases are activated upon 
ER stress or dsRNA, the phosphorylation of eIF2a played no role in the nuclear export or 
downregulation ofp53. 
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Figure 42. Salubrinal does not promote the downregulation or cytoplasmic 
localization of p53. 
(A) HTI080 cells were treated with SalO03 (75 !-lM) or transfected with 
dsRNA (10 !-lgjml). Cell extracts were subjected to immun ob lot analysis with 
anti-p53, anti-phospho-Ser51-eIF2u, and anti-eIF2u antibodies. 
(B) HTI080 cells were treated with SalO03 (75 !-lM) or transfected with 
dsRNA (10 !-lgjml) for 6h. The localization of endogenous p53 was examined 
by immunofluorescence. Cell nuclei were visualized by staining with DAPI. 
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Figure 43. The phosphorylation of eIF2a. does not control the 
downregulation of p53. 
(A) eIF2a SjS and eIF2a AJA MEFs were untreated or treated with 
tunicamycin (10 Ilgjml) andjor adriamycin (lIlM) for 4h. CeU extracts were 
subjected to immunoblot analysis with anti-p53, and anti-phospho-Ser51-
eIF2a antibodies. 
(8) GFP-p53 WT (0.5 Ilg) was transiently transfected into eIF2a SjS and 
eIF2a AjA MEFs. Twenty-four hours later, cells were left untreated or 
treated with TM (10 Ilgjml) or TG (lIlM) for 2h, and then examined for GFP-
p53 fluorescence. CeU nuclei were visualized by DAPI staining. 
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The lack of eIF2a phosphorylation in the involvement of the dowmegulation of 
p53 led us to question whether the inhibition of protein synthesis affected p53 mRNA 
translation. One of the most common methods to study translation mechanisms and 
regulation is polysome profiling using sucrose gradients (4). The method involves size 
separation of large cellular components on a sucrose gradient and monitoring the A254 
across the gradient. The A254 profile of the separated complexes contains information not 
only about polyribosomes (two or more ribosomes), but also about other translational 
machinery components, inc1uding the small ribosomal subunit (40S), large ribosomal 
subunit (60S), and single ribosome (80S). Changes in this profile are indicative of 
changes in translation. 
To study the behavior of specific mRNAs, the gradient is fractionated and the 
different fractions are analyzed by RT -PCR. hnportant information regarding translation 
of these mRNAs is obtained. The fraction of translationally active messages (those 
associated with ribosomes) can be deduced from the ratio between messages that 
sediment in the polysomal fractions versus those that sediment in the non-polysomal 
fractions. Changes in this ratio indicate changes in translation efficiency. 
We performed polysome profiling analysis of HTI080 cells to study the 
translation of the p53 mRNA (TP53) after TG, SalO03 treatment (Fig. 44A) or dsRNA 
transfection (Fig. 44B). Total RNA was isolated and sedimented through a linear sucrose 
gradient followed by fractionation. The distribution of RNA in the gradient fractions was 
determined by UV -spectroscopy (A254) and the RNA from each fraction was isolated 
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foIlowed by RT-PCR analysis using specific primers (Table 2) targeted against specific 
mRNA indicated in Figure 44. In each gradient, fractions 1 to 4 represent free mRNAs, 
whereas fractions 5 to 11 represent the ribosomal subunits (40S and 60S) and the single 
associated ribosome (80S or monosome). Fractions 12 to 20 represent the mRNAs 
associated with polysomes (2 or more ribosomes). 
After TG or SalO03 treatment, we show a significant inhibition in protein 
translation indicated by the peak increase ofribosomal subunits (fractions 5-11) and by a 
disruption of polysome peaks in fractions 12 to 20 (Fig. 44A). We analyzed the 
distribution of ATF4 mRNA as a control since it was previously shown to be translated 
under conditions that induce eIF2a phosphorylation (39,126,244,286). In untreated ceIls, 
the distribution of ATF4 mRNA is mainly associated with one or two ribosomes (Fig. 
44A, fractions 9-14, ATF4 panel). Treatment with TG or SalO03 c1early shows a shift of 
ATF4 mRNA associated with large polyribosomes (Fig. 44A, fractions 15-20, ATF4 
panels) indicating more efficient translation. 
Unlike the ATF4 mRNA, p53 transcripts exhibited similar mRNA sedimentation 
patterns as the one found in untreated ceIls (Fig. 44A, TP53 panels). We observed 1 or 2 
fraction changes in the distribution of p53 mRNA possibly due to the extensive 
disruption of the polysomes during translation inhibition. However this change appears to 
be negligible since aIl p53 transcripts were localized above fraction 15 where most 
polyribosomes are in conjunction with the enhanced translation of ATF4. This suggests 
that p53 mRNA is translated despite the shutdown of protein synthesis. In the case of 
GAPDH, TG and SalO03 treatment appear to induce changes in the distribution of its 
mRNAs towards monosomes (Fig. 44A, GAPDH panels). Although most of the GAPDH 
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mRNA appears in the polysome fractions, inhibition of protein synthesis shows sorne 
transcripts in the monosome portion of the profile (Fig. 44A, fractions 9-12, GAPDH 
panels), where the non-translated ATF4 mRNAs are located. 
Next, we inhibited protein synthesis by transfecting HTI080 cells with dsRNA 
(Fig. 44B) indicated by the increase of the 60S/80S peaks and the disruption of the 
polyribosome peaks. As expected, we observed a small shift of ATF4 mRNA towards the 
polyribosome fractions (Fig. 44B, ATF4 panels). Due to a larger polyribosome disruption 
upon dsRNA transfection, the p53 transcripts shifted more so towards the lower end of 
the polysome fractions as opposed to the other two treatments (compare TP53 panels of 
Fig. 44A with 44B). However, the lack of p53 mRNA in the ribosome/monosome 
fractions indicated that these mRNAs were still efficiently translated. The GAPDH 
mRNA also shifted towards the lower end of the polysome fractions and towards the free 
mRNA fractions suggesting that translation of GAPDH was affected upon dsRNA 
transfection (Fig. 44B, GAPDH panels). 
These results confirmed that p53 downregulation in response to various treatments 
that induce eIF2a kinase activity was not due to their ability to regulate p53 mRNA 
translation. Together, our data suggest that the downregulation of p53 involved another 
pathway that requires eIF2a kinase activity independent of eIF2a phosphorylation. 
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Figure 44. The downregulation of p53 is not controlled by translation. 
(A, B) HT1080 ceUs were treated with TG (A; 1 !-lM) for 2h or SalO03 (A; 75 
!-lM) for Sh or transfected with dsRNA (B; 10 !-lgjml) for 3h. CeUlysates were 
separated on a sucrose gradient and subjected to polysome profile analysis 
foUowed by fractionation and RNA extraction as described in materials and 
methods. The positions of the polysomes and ribosomal subunits (40S, 60S, 
and 80S) are indicated above each corresponding peaks. Translation 
efficiency of ATF4 mRNA, TP53 mRNA, and GAPDH mRNA were determined 
by RT -PCR using specifie primers and the RNA isolated from each polysome 
fractions. 
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Although we detennined that eIF2a phosphorylation and protein synthesis do not 
regulate p53 levels, we suspect that eIF2a kinas~: activity itse1f is required for this 
downregulation. However, many signaling pathways are activated in ER stressed or 
dsRNA treated cells, and it is therefore impossible to attribute the role of eIF2a kinase 
activity versus the activation of other pleiotropic pathways. To uncouple eIF2a kinase 
activity from stress, we took advantage of the fact that activation of eIF2a kinases is 
initiated by dimerization followed by trans-autophosphorylation. Nonnally this 
dimerization event is driven by the N-tenninus regulatory domain of aIl eIF2a kinases. 
Therefore we needed a system that allows us to monitor eIF2a kinase activity without 
inducing other stress-inducing pathways. 
In order to test the possibility and investigate specificaIly the role of eIF2a kinase 
activity in the regulation of p53, we employed a chimeric protein consisting of the 
bacterial Gyrase B protein (GyrB) fused to the kinase domain (KD) of human PKR 
(GyrB-PKR) (333). In the presence of the antibiotic coumennycin, the GyrB domains 
dimerize and induce the catalytic activity of the PKR kinase domain (Fig. 45A). Since the 
kinase domain of all eIF2a kinases is very similar in sequence and specificity (85), the 
GyrB-PKR system may faithfuIly represent not only PKR but aIl eIF2a kinases in tenns 
of induction of their catalytic activity. We previously demonstrated that conditional 
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activation of GyrB-PKR in HT1080 cells in the presence of coumennycin leads to the 
induction of eIF2a phosphorylation and inhibition of global protein synthesis (177). 
We used the HT1080/GyrB-PKR cells to look at the localization and expression 
of the endogenous wild type p53. The activation of wild type (WT) GyrB-PKR by 
coumennycin increased the cytoplasmiclocalization of p53 (Fig. 45B) as opposed to 
coumennycin-treated cells expressing the catalytically inactive GyrB-PKR K296H, in 
which localization of p53 remained nuclear (Fig. 45B). The nuclear localization of p53 
was rescued by leptomycin B, an inhibitor of nuclear export, in coumennycin treated 
GyrB-PKR WT cells (data not shown) (291,314). Moreover, coumennycin treatment 
resulted in the downregulation of p53 protein levels and the induction of eIF2a 
phosphorylation in cells expressing GyrB-PKR WT but not in cells expressing the 
catalytically inactive GyrB-PKR K296H (Fig. 45C). We also noticed that the p53 protein 
levels in coumennycin-treated GyrB-PKR WT cells were recovered in the presence of 
MG132 (Fig. 46A) and partially decreased eIF2a phosphorylation leve1s (similar to Fig. 
40B) through an as yet unidentified mechanism. Treatment with MG132 also prevented 
the cytoplasmic localization ofp53 (Fig. 46B) despite the activation of GyrB-PKR. 
Therefore inhibition of proteasome mediated degradation not only stabilizes p53 
but it also retains it in the nucleus as previously observed (Fig. 41). These results indicate 
that GyrB-PKR WT induced p53 degradation by enhancing its nucleocytoplasmic 
shuttling. 
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Figure 45. A conditional form of eIF2a. kinase downregulates p53. 
(A) A chimeric kinase-inducible PKR fusion protein (GyrB-PKR) was 
generated by swapping the dsRNA-binding domain (dsRBD) of PKR with part 
of the gyrase B (GyrB) bacterial protein. In the presence of the antibiotic 
coumermycin, the GyrB domains dimerize, and induce the 
autophosphorylation and catalytic activity of the PKR kinase domain (KDJ. 
(B) GyrB-PKR WT and K296H ceUs were treated with coumermycin (100 
ng/ml) for 4h, and the localization of endogenous wild-type p53 was 
examined by immunofluorescence. CeU nuclei were visualized by DAPI 
staining. (C) GyrB-PKR WT and K296H ceUs were treated with coumermycin 
(100 ng/ml) for 4h. Protein extracts were subjected to immunoblot analysis 
with anti-p53 (DO-l), anti-phospho-Ser51-eIF2a, anti-eIF2a., and anti-actin 
antibodies. 
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Figure 46. Disruption of the proteasome pathway rescues p53 from GyrB-
PKR activation. 
(A, B) GyrB-PKRWT ceUs were treated with coumermycin (100 ng/ml) for 
4h and pre-treated with or without MG132 (10 )lM), and protein extracts 
were subjected to immunoblot analysis (A) with anti-p53 (DO-l), anti-
phospho-Ser51-eIF2a, and anti-eIF2a, antibodies. (B) The localization of 
endogenous wild-type p53 was examined by immunofluorescence. CeU nuclei 
were visualized by DAPI staining. 
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We next investigated wh ether translation control affects TP53 in the GyrB-PKR 
system by performing polysome profile analysis. Coumermycin treatment increased the 
levels of free 40S and 60S ribosomal subunits as well as inhibited translation initiation 
indicated by the large 80S peak (Fig. 47 A, fractions 4-11). Translational inhibition 
correlated with a drastic disruption of the polysome fractions (Fig. 47 A, fractions 12-20). 
However the disruption of the polysomes did not affect the polysomal distribution ofp53 
mRNA in coumermycin treated GyrB-PKR cells (Fig. 47A, TP53 panels). The p53 
mRNA was co-sedimented with the translated ATF4 mRNA (Fig. 47A, ATF4 panels) 
upon conditions that induce eIF2a phosphorylation. This suggests that p53 and ATF4 
mRNA are both found in the polysomal pools where active translation occurs as 
previously observed (Fig. 44). The GAPDH mRNA c1early shows a shift towards the 
lower polysome pools and monosomes indicating a decrease in GAPDH translation (Fig 
47A, GAPDH panels). These results imply that activation of eIF2a kinase activity does 
not affect p53 mRNA translation and that the downregulation of p53 is translational 
independent. 
In order to confirm that eIF2a did not play a role in p53 degradation, we knocked 
down eIF2a by siRNA in the GyrB-PKR cells. We reasoned that by knocking down 
eIF2a we should not be able to rescue p53 from degradation. Expression of eIF2a siRNA 
in GyrB-PKR WT cells led to >90% decrease ofthe (~ndogenous eIF2a protein (Fig. 47B, 
third panel, lanes 3 and 4). When GyrB-PKR WT cells were subjected to coumermycin, 
p53 degradation occurred to the same extent in both cell types (Fig. 47B, first panel, lanes 
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2 and 4). This suggested that p53 downregulation occurs independently of eIF2a further 
supporting our previous findings (Fig. 42-43). These results pro vide evidence that eIF2a 
phosphorylation aione is not sufficient for the negative regulation of p53, further 
supporting the role that eIF2a kinases initiate a signaling pathway responsible for p53 
degradation upon ER stress. 
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Figure 47. The downregulation of p53 by GyrB-PKR is not controlled by 
translation. 
(A) GyrB-PKR WT ceUs were treated with coumermycin (100 ng/ml) for 4h. 
CeUlysates were separated on a sucrase gradient and subjected to polysome 
profile analysis followed by fractionation and RNA extraction as described in 
Materials and Methods. The positions of the polysomes and ribosomal 
subunits (40S, 60S, and 80S) are indicated above each corresponding peaks. 
Translation efficiency of ATF4 mRNA, TP53 mRNA, and GAPDH mRNA were 
determined by RT -PCR using specifie primers and the RNA isolated from 
each polysome fractions. 
(B) GyrB-PKR WT cells were transiently transfected with non-specifie siRNA 
(GL-2) or eIF2u (eIF2ui) and then treated with coumermycin (100 ng/ml) 
for 4h. CeU extracts were subjected to immun ob lot analysis with anti-p53, 
anti-phospho-Ser51-eIF2u, anti-eIF2u, and anti-actin antibodies. 
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We previously showed that ER stress-inducing phannacological cornpounds 
prornote the nuc1ear translocation of GSK3p, which in tum induces the phosphorylation 
and nuc1ear export ofp53 (263). It is weIl established that GSK3p is activated upon ER 
stress (263,305). Rowever, upstrearn signaling events Ieading to GSK3p activation are 
still unknown. We therefore treated RTI080 ceIls with TG, SalO03 or transfected thern 
with dsRNA and assessed the localization of GSK3p by irnrnunofluorescence (Fig. 48A). 
Since dsRNA and ER stress induce eIF2a kinase activityas opposed to Sa1003, they were 
the only two conditions that favored GSK3 p nuc1ear localization. This supports our 
notion that eIF2a phosphorylation was not involved in this process since SalO03 did not 
alter GSK3p localization and rernained perinuclear like in untreated ceIls (Fig. 48A). 
Sirnilar results were obtained in A549 ceIls (data not shown). 
We then rneasured GSK3 kinase activity in RTI080 ceIls by its capacity to 
phosphorylate the synthetic phospho-CREB substrate in vitro. GSK3 kinase activity 
increased after TG or dsRNA treatrnent in A549 (data not shown) and in RTI080 cells 
(Fig. 48B) but was unaffected in SalO03 treated cells. Moreover the increased nuc1ear 
Iocalization of GSK3p (Fig. 48A) correlated with the increase of its kinase activity (Fig. 
48B). Aiso the fact that localization and kinase activity of endogenous GSK3p was not 
affected by salubrinai treatrnent suggested that eIF2a phosphorylation aione is not 
responsible for GSK3 activation. 
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We next wanted to determine whether endogenous eIF2a kinases such as PERK 
and PKR are responsible for GSK3p activation. As PKR has been c1early implicated in 
virus infection (172) and PERK in the unfolded protein response in the ER (127), we 
used immortalized PERK-1- MEFs and the NIH3T3 PKR knockdown stable cell line 
(shPKR). These cells were respectively treated with TG or dsRNA, and the GSK3 
activity was assessed as in Figure 48B. Thapsigargin treatment induced GSK3 activity in 
PERK+1+ MEFs but not in PERK-1- MEFs (Fig. 49A) and dsRNA transfection increased 
GSK3 activity in control NIH 3T3 cells but not in shPKR cells (Fig. 49B). This induction 
of GSK3 kinase activity was abrogated in PERK+1+ MEFS and control NIH 3T3 cells 
when l-azakenpaullone (l-Aza) was used to inhibit GSK3 (Fig. 49). These results show 
that GSK3 activation is dependent on the activation of eIF2a kinases upon ER stress or 
dsRNA, and that GSK3p may be downstream to both PERK and PKR. These 
experiments advocate that eIF2a kinases downregulate p53 at least through a GSK3p 
dependent pathw~y. 
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Figure 48. PKR and PERK control GSK3~ localization and activity in 
response to TG and dsRNA. 
(A) HT1080 ceUs were treated with TG (1 /-lM), dsRNA (10 /-lg/ml) or Sa1003 
(75 /-lM) for 4 h and the localization of endogenous GSK3~ was examined by 
immunofluorescence. CeU nuclei were visualized by DAPI staining. For 
quantitative analysis see Materials and methods. 
(B) HT1080 ceUs were treated with TG (1 /-lM), dsRNA (10 /-lg/ml) or Sa1003 
(75 /-lM) for 4h and the activity of endogenous GSK3 was assessed by in vitro 
kinase assay as described in Materials and Methods. 
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Figure 49. PERK and PKR control GSK3(3 activity in response to TG or 
dsRNA. 
(A) PERK+/+ and PERK/- MEFs were treated with TG (1 /-lM), for 4h and the 
activity of endogenous GSK3 was assessed by in vitro kinase assay as 
described in Materials and Methods. 
(8) NIH 3T3 stable celllines expressing shRNA targeted against PKR (shPKR) 
cells were treated with dsRNA (10 /-lg/ml) for 4h and the activity of 
endogenous GSK3 was assessed by in vitro kinase assay as described in 
Materials and Methods. As a negative control of GSK3 activity, we used the 
GSK3p inhibitor 1-Aza-Kenpaullone (1 /-lM) in the kinase assays. 
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From the previous observations, we reasoned that GSK3p is downstream to eIF2a 
kinases in response to ER stress and dsRNA. Therefore the absence of GSK3p would not 
affect eIF2a kinase activity and would thus recover p53 protein levels. We previously 
showed that 10ss of GSK3p prevented p53 degradation in response to ER stress (260). 
We used GSK3p-l- primary MEFs to determine the p53 protein levels in responseto 
dsRNA (Fig. 50A). We observed 50-70% decrease in the p53 protein levels of dsRNA 
transfected GSK3p+l+ primary MEFs (Fig. 50A, top panel). However, p53 protein levels 
were partially rescued (~50% recovery) in GSK3p-l- MEFs (Fig. 50A). 
In order to exc1ude the possibility that eIF2a kinase activity was affected in 
GSK3p-l- MEFs, we tested whether these cells respond to ER stress or dsRNA to the 
same extent as their wild type counterparts. We determined that both cell types were able 
to induce eIF2a phosphorylation upon TG treatment (Fig. 50B) or dsRNA transfection 
(Fig. 50C). We conc1uded that absence of GSK3 p did not prevent eIF2a kinase activity, 
and that GSK3 p works downstream to PERK and PI(R. 
To confirm the downstream affect of GSK3p upon eIF2a kinase activation we 
used the GyrB-PKR cells. Treatment with l-Aza rescued p53 from GyrB-PKR activation 
by coumermycin treatment (Fig. 51A, top panel, compare lane 4 with lane 3). The 
phosphorylation of eIF2a was not abolished by l-Aza indicating that eIF2a kinase 
activity was not affected, and that the rescue of p53 was mainly due to the inhibition of 
GSK3p (Fig. 51A, fourth panel, lane 4). To validate this statement we investigated the 
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phosphorylation status of glycogen synthase, one of the well studied substrates of GSK3~ 
(180). Coumermycin treatment induced glycogen synthase phosphorylation indicating 
that GSK3~ activity was also stimulated by GyrB-PKR (Fig. 51A, second panel, lane 3). 
This was validated by performing GSK3 kinase assays similar to Fig. 48 and 49. GyrB-
PKR WT activation induced GSK3 kinase activity but not in the kinase dead GyrB-PKR 
K296H cells (Fig. 51B). GSK3 activity was fully inhibited with the addition of l-Aza 
(Fig. 5IB), and the phosphorylation of glycogen synthase was abolished in combination 
with l-Aza (Fig. 51A, second panel, lane 4). 
Similarly, HT1080, U20S, HCT116, and A549 cells treated with prolonged 
exposure (16h) to tunicamycin or thapsigargin induced glycogen synthase 
phosphorylation on Ser6411645, indicating that GSK3~ activity was maintained 
throughout the ER stress response (Fig. 38A). 
Overall, these data confirmed that GSK3~ is downstream to eIF2a kinases and is 
required for the downregulationof p53 in response to ER stress or dsRNA. The partial 
rescue of p53 observed in GSK3~-I- MEFs suggests that perhaps eIF2a kinases induce 
other pathways that may be involved in the degradation of p53 or that GSK3a may 
compensate for the loss ofGSK3~. 
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Figure 50. The downregulation of p53 by dsRNA and TG is mediated by 
GSK3f3. 
(A) Primary GSK3p+/+ and GSK3P-/- MEFs were treated with dsRNA (10 
/-LgfmL). CeU extracts were subjected to immunoblot analysis with anti-p53, 
anti-GSK3p, and anti-actin antibodies. The p53 levels were quantified and 
normalized to the actin levels and are presented as percentages underneath 
each lane. 
(B, C) Primary GSK3p+/+ and GSK3p-l- MEFs were treated with TG (B; 1 /-LM) 
or dsRNA (C; 10 /-LgfmL). CeU extracts were subjected to immunoblot analysis 
with anti-phospho-Ser51-eIF2u, and anti-eIF2u antibodies. 
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Figure 51. Inhibition of GSK3~ rescued p53 protein levels in GyrB-PKR 
cells. 
(A) GyrB-PKR WT ceUs were treated with coumermycin (100 ng/ml) in the 
absence or presence of the GSK3~ inhibitor l-Aza-KenpauUone (1 /-tM) for 4h. 
Protein extracts were subjected to immun ob lot analysis with anti-p53 (DO-
l), anti-phospho-Ser641/645-glycogen synthase, anti-glycogen synthase, 
anti-phospho-Ser51-eIF2a, anti-eIF2a, and anti-actin antibodies. 
(B) GyrB-PKR WT and K296H ceUs were treated with coumermycin (100 
ng/ml) for 4 h and the activity of endogenous GSK3 was assessed by Ïn vÏtro 
kinase assay as described in Materials and Methods. As a negative control of 
GSK3 activity, we used the GSK3~ inhibitor l-Aza-KenpauUone (1 /-tM) in the 
kinase assays. 
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1 IN 
PKR was initially characterized as a protein kinase with an important role in the 
control of mRNA translation through its capacity to induce eIF2a phosphorylation 
(61,172). The transcriptional induction of the pkr gene by type l IFNs provided further 
evidence that PKR is a mediator of the antiviral and anti-proliferative effects of IFNs 
(311). The c10ning of the human and mouse PKR cDNA (154,231,321,325) assisted in 
the identification of novel biological properties of the kinase in cultured cells. To date, 
numerous reports have assigned anti-proliferative and tumor suppressor functions in vitro 
to PKR and have implicated it in many signaling pathways that control gene expression at 
both translational and transcriptionalleve1s (61,172)" Since many of the important in vitro 
functions ofPKR were not verified in vivo, attempts were made to generate PKR-1- mice. 
The characterization of two different PKR-1- mice however did not yield the 
anticipated results. In addition, experiments with cells from the two PKR-1- mice have led 
to contradictory and confusing results conceming the PKR functions in vivo. Here, we 
demonstrate that neither of the two PKR-1- mice is complete1y devoid of PKR. The N-
PKR-1- mouse (356) expresses a dsRNA-binding defective but catalytically active PKR 
protein, whereas the C-PKR-1- mouse (2) expresses an altemative1y spliced form of the 
kinase with impaired catalytic properties but intact dsRNA-binding activity. 
In regard to cell signaling, it was previously shown that N-PKR-1- MEFs display 
an impaired NF-KR activation in response to dsRNA and this defect was restored after 
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priming with IFNa/p or IFNy possibly by the expression of a molecule that substitutes 
PKR function (356). Subsequent work with the N-PKR-1- MEFs conc1uded that PKR 
functions as an important signal transducer for the induction of IFN-stimulated genes 
through pathways that implicate interferon regulatory factor (IRF)-l and NF-KB (190). 
Moreover, N-PKR-1- MEFs were found to be resist:mt to apoptotic death in response to 
dsRNA, TNFa or LPS providing further evidence for the role of PKR in stress-induced 
apoptosis (83). Work with the N-PKR-1- MEFs also established a requirement of the 
kinase for p38 MAPK activation (114) and for serine phosphorylation of Statla in 
response to IFNs (266). Recent studies have demonstrated that the defective NF-KB 
activation by dsRNA in the N-PKR-1- MEFs is due to the impaired IKK activation and 
phosphorylation ofIKBa (56,364). 
The above signaling defects of N-PKR-1- cens were not found in C-PKR-1- cells 
(2). Specifically, IFN signaling and transcriptional induction of IFN-inducible genes is 
normal in C-PKR -1- cells (2) indicating that the lack of the catalytic activity of PKR does 
not -interfere with the Jak-Stat pathway. In accordance with this, we found that 
phosphorylation of Statl on serine 727 is not impaired in IFN-treated C-PKR-1- MEFs as 
opposed to N-PKR-1- MEFs (266). In regard to NF-KB activation, it has been documented 
that C-PKR-1- MEFs respond normally to dsRNA (157) or TNFa (2) suggesting that the 
catalytic activity of PKR is dispensable for NF-KB··mediated gene transcription. This is 
further supported by our data showing that induction of IKBa phosphorylation by dsRNA 
proceeds normally in C-PKR-1- MEFs compared to isogenic PKR+1+ MEFs (Fig. 26A). 
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The above striking differences between both PKR-1- mice may be attributed to the 
expression of the PKR forms. It is possible that the N-terminal dsRNA-binding domain of 
PKR is essential for mediating sorne signaling properties of PKR, and therefore the lack 
of this domain in ES-mPKR may account for the signaling defects reported for N-PKR-1-
MEFs. SpecificaIly, PKR through its N-terminus domain may participate in cell signaling 
as a scaffold protein by mediating protein-protein interactions and/or subcellular 
localization and compartmentalization of the molecule. This would explain the lack ofthe 
signaling defects that were reported for N-PKR-1- ceUs in C-PKR-1- MEFs, since the latter 
cell type expresses SF-mPKR with an intact dsRNA-binding domain. This would also 
imply that PKR may have the capacity to modulate cell signaling independently of its 
enzymatic activity. Interestingly, a kinase-independent role of PKR has been reported for 
signaling pathways leading to the transcriptional activation of NF -KB and Statl 
(37,158,344). 
Conceming viral infection, both PKR-1- mice exhibit a very modest susceptibility 
to viruses. SpecificaIly, N-PKR-1- mice are susceptible to infection with EMCV (356), 
whereas C-PKR-1- mice are susceptible to VSV infection only after intranasal inoculation 
(11,313). Interestingly, a recent report demonstrates that the increased susceptibility of C-
PKR-1- mice to VSV is dependent on the mouse strain, since animaIs with BALB/c 
genetic background are 5 orders of magnitude more sensitive to infection than those with 
129SvEv background (93). Nevertheless, PKR-1- mice bred onto resistant 129SvEv 
background still exhibited a 10 fold increased sensitivity compared to the strain-matched 
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PKR+1+ mice (93). These data raise the possibility that the signaling properties attributed 
to PKR may also be affected by mouse strain differences. 
We also found that eIF2a phosphorylation in response to vesicular stomatitis 
virus infection is not impaired in C-PKR-1- MEFs compared to isogenic PKR+1+ MEFs 
(Fig. 26B). This may indicate that the loss of the catalytic activity of PKR in C-PKR-1-
cells could be compensated by another eIF2a kinas(~ activated by virus infection. This is 
consistent with our previous observations that expression of the vaccinia virus K3L 
protein, which functions as a pseudo-substrate inhibitor of PKR (175), was still capable 
of enhancing translation from reporter gene constructs in transiently transfected C-PKR-1-
MEFs (206). The newly identified eIF2a kinases PERK and GCN2 might be implicated 
in this process although it is not yet known how these enzymes are regulated in virus 
infected cells despite sorne recent studies suggesting their involvement in RNA viruses 
(28,165) and in herpes simplex virus 1 (HSV-l) infection (50). 
In regard to an anti-viral role of PKR independently of eIF2a, the JNK and p38 
MAPK pathways have been recently implicated in virus replication (56,156). Although, 
activation of p38 MAPK was partially impaired in N-PKR-1- MEFs (114), our 
experiments with C-PKR-1- MEFs showed normal patterns of activation of both JNK and 
p38 MAPK pathways in response to VSV or Sendai Virus (SeV) infection (data not 
shown). 
The functional characterization of the ES-mPKR and SF1-mPKR proteins may 
provide sorne cIues to molecular mechanisms of PKR activation. For example, current 
models for PKR activation propose that dsRNA binding to the dsRBMs leads to 
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structural rearrangement of PKR relieving an auto-inhibitory interaction between the 
dsRBD and the kinase domain (KD) (135,240,347). This facilitates the dimerization of 
the PKR kinase domain and its subsequent activation via a trans-inter-dimer 
autophosphorylation mechanism prior to substrate recognition (75,88). Based on this 
model, auto-inhibition of the KD by the dsRBD in ES-mPKR is not possible, since this 
protein lacks the dsRBMI and half of the dsRBM2, and dimerization of the kinase 
domain itself could proceed independently of dsRNA-binding. Thus, the lack of an auto-
inhibitory action may explain, at least in part, the constitutive activity of ES-mPKR in 
vitro and in vivo. 
In regard to SF1-mPKR, its expreSSIOn III certain mouse tissues might be 
indicative of a specific function of this protein (Fig. 25). Since induction of PKR activity 
proceeds through dsRNA-binding, dimerization and inter-phosphorylation, a predicted 
function of the SF1-mPKR protein is the inhibition of mPKR activity in a dominant 
negative fashion, as previously demonstrated for a similar catalytic inactive PKR form 
expressed in a mouse pre-B leukemia cellline (1). However, expression of SF1-mPKR in 
normal tissues is very little compared to the full-Iength PKR suggesting that a dominant 
negative effect ofthis protein could possibly be local and/or RNA specific. Altematively, 
SF1-mPKR could function as an RNA-binding protein independently of PKR by 
modulating, for example, RNA editing (18), RNA trafficking (42), or RNA processing 
(179). 
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In conclusion, our data clearly demonstrate that both PKR-1- animal models are 
incomplete knockouts, and this may account for the differential responses of the two 
PKR-1- cell types to various intracellular and extracellular signaIs. Considering the crucial 
biological functions that have been attributed to PKl~ in tissue culture systems in vitro, it 
is apparent that a complete disruption of the pkr gene may be necessary to verify the 
biological functions ofthe kinase in vivo. 
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Our findings demonstrate an important role for PERK in VSV infection. We show 
that PERK-mediated eIF2a phosphorylation is indueed in VSV infected cells, and this is 
accompanied by an inhibition of virus replication and apoptosis. However, it remains 
possible that additional control mechanisms are modulated by PERK in VSV infected 
cells. In fact, we demonstrate that activation of PKR is impaired in cells lacking PERK 
suggesting a functional cross-talk between the two kinases with PKR functioning 
downstream to PERK. Previous data showed that treatment of cells with thapsigargin and 
TNFa renders PKR active providing evidence for a role of the kinase in ER stress 
(262,309). More recent research indicated that ER stressed cells can induce the activation 
and nuc1ear translocation of PKR (248). Consistent with these findings, our data show the 
induction of PKR in ER stressed cells and the lack of its activation in PERK-1- cells (Fig. 
35A). 
At present, we do not know how PKR becomes activated by PERK. One 
possibility is that active PERK directly phosphorylates and activates PKR in the 
proximity of the ER. Altematively, activation of PKR is mediated by another kinase that 
functions as an intermediate between the two eIF2a kinases (Fig. 52). Several studies 
have shown that the cellular inhibitor of PKR p58IPK (261), can also interact and inhibit 
PERK upon ER stress (334,353). This raises the possibility that the impaired PKR 
activation observed in ER stressed PERK-1- MEFs may be explained by the induction of 
unbound p58IPK. The lack of PERK in these cells may release more p58IPK to the 
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cytoplasm where it can target and further inhibit PKR. However it is not yet known 
whether VSV infection regulates p58IPK expression. 
Altematively, PERK activation by VSV may be mediated by the viral proteins 
themselves. The VSV glycoprotein (G) oligomerizes in the ER prior to its transport to the 
cell surface (363). Misfolded and unassembled VSV -G is retained in the ER (77) where it 
interacts with the chaperone BiP, the inhibitor of PERK. Although VSV infection does 
not elicit the UPR (Fig. 37), it was recently shown that IRE1 can sense and bind directly 
to misfolded proteins, and induce its dimerization and activation (69). Since PERK has a 
homologous sensor domain to IRE1 (128), it is possible that PERK activation can be 
induced by direct binding of the VSV -G protein. Even though BiP is present in the ER 
lumen in millimolar concentrations, activation of PERK (by the release from BiP) would 
require large concentrations of unfolded proteins to compete with the free BiP pool in the 
ER. However, enveloped viruses induce the production of ER membranes so that the cell 
can cope with the load of viral membrane protein production (95,115). It is unclear if 
VSV behaves similarly, but we can speculate that this process may explain for the lack of 
UPR signaling during VSV infection despite PERK activation. 
Nevertheless, VSV infection results in a powerful impairment of host gene 
expression due to the various combined actions ofthe virion components thus eliminating 
the majority of cellular ER-resident proteins. Combined with the limited load of viral ER-
resident proteins early in the VSV replication life cycle, this ensures chaperone 
sufficiency and thereby does not produce ER stress or the UPR pathway (Fig. 37). As the 
VSV glycoprotein (G) is produced later in the life cycle, VSV-G may physically 
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associate with PERK to regulate viral protein accumulation III a PERK-dependent 
manner, thereby maintaining ER homeostasis. 
As such, we conc1ude that VSV utilizes a novel pathway to activate PERK. 
Although this pathway is not currently known, we hypothesize that virus infection might 
induce protein-protein interactions and/or phosphorylation cascades leading to the 
activation of PERK in the ER. 
OF IN 
Regarding VSV-mediated apoptosis, our data implicate caspase-12 in this process 
(Fig. 32A). It was reported that upon ER stress, the cytosolic caspase-7 translocates to the 
ER surface, and associates with procaspase-12 thereby c1eaving its prodomain to generate 
an active caspase-12 (Fig. 11) (267). Interestingly, VSV infection was shown to induce 
the activation of caspase-7 (143) and this may account, at least in part, for caspase-12 
activation in infected cens. 
Previous findings have shown that caspase-12 has been implicated in apoptosis 
induced by BVDV infection (165) indicating that this protease may play a role in virus-
induced apoptosis in mouse cens. When PERK+1+ and PERK-1- MEFs were treated with 
general caspase inhibitors prior to VSV infection, PERK+1+ cens were rescued from VSV 
infection, as demonstrated by the absence of P ARP c1eavage (Fig. 32C). This suggested 
that caspases were involved in VSV -mediated 'apoptosis. However, PERK-1- MEFs were 
highly prone to P ARP c1eavage and VSV infection, despite caspase inhibition. This 
suggests that in the absence of PERK, the virus can utilize caspase-independent apoptotic 
pathways to induce P ARP c1eavage. This finding demonstrates that multiple caspase-
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dependent and caspase-independent cell death pathways may be activated during VSV 
infection, and that PERK plays a role in modulating caspase function and activation. It is 
now understood that P ARP is an important activator of caspase-independent cell death 
(149), and perhaps VSV can exploit sorne of these pathways to induce apoptosis. 
Undoubtedly, future experiments are needed to better characterize the fundamental 
pathways ofVSV-induced apoptosis. 
We have shown here that PERK appears to be a critical component of the innate 
immune response protecting the host against VSV infection. It does so, at least in part, 
through the activation of PKR. Thus, a cross-talk between PERK, PKR and possibly 
other eIF2a kinases is likely to exist and contribute to the antiviral mechanisms 
converging at the eIF2a phosphorylation level (Fig. 52). Although many virus es have 
evolved unique mechanisms to overcome PKR activation (171), it appears that sorne of 
these mechanisms also aim at inactivating PERK. For example, the ReV E2 protein 
(256) and the vaccinia virus K3L protein (306) are potent inhibitors of PERK as is the 
p58 PKR-inhibitor (p58IPK) induced in cells infected with influenza virus (353). Thus, 
further investigation of the role of the eIF2a kinase family members in virus infection 
may yield important information about the translational mechanisms of virus replication, 
and lead to the discovery of unique pathways controlled by each of the eIF2a kinases 
with important implications against virus infection and associated disease. 
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Figure 52. Model depicting a cross-talk between PERK and PKR upon VSV 
infection. 
VSV activates both PERK and PKR. Although PKR is thought to be activated 
by dsRNA produced during virus repli cation, the molecular mechanism(s) of 
PERK activation is not clear. Perhaps VSV infection induces protein-protein 
interactions or protein phosphorylation cascades resulting in PERK 
phosphorylation in the ER. PERK is upstream of PKR, and coordinated 
activation of both kinases is likely to be required for maximal eIF2a 
phosphorylation and full-scale shutdown of viral protein synthesis. PERK 
alone may not be sufficient to block virus replication unless PKR is present 
despite the sustained phosphorylation of eIF2a induced by PERK (thick 
arrow) in PKH.-/- MEFs. This is also consistent with the impaired anti-viral 
response observed in PKH.-/- MEFs after VSV infection. 
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Herein, we report that activation of eIF2a kinases plays a critical role in down-
regulating the p53 tumour suppressor protein, a key player in stress sensing and apoptotic 
signaling. We establish a novel functional cross-talk between the eIF2a kinases and p53. 
We demonstrated that eIF2a kinases participate in the nuclear export and proteasome-
dependent degradation ofp53 through a GSK3p-dependent but translational-independent 
pathway. A model illustrating our findings is shown in Figure 53. Thus, eIF2a kinase 
activation following ER stress or dsRNA regulates in parallel at least two distinct 
signaling pathways. The first is primarily dependent on eIF2a phosphorylation leading to 
a persistent inhibition of the global mRNA translation. The second is dependent on 
GSK3p activation resulting in the prolonged degradation ofp53. 
We identify GSK3p as a downstream effector of the eIF2a kinases which 
mediates p53 degradation (Fig. 49). GSK3p plays a role in a wide range of cellular 
processes and has been shown to phosphorylate many substrates including transcription 
and translation factors such as c-myc, eIF2B8 and p53 (64,89,263). Here, we show 
specifically that functional eIF2a kinases control GSK3p activity and its localization 
(Fig. 48A). This provides a new clue in our understanding of how thapsigargin (TG) 
induces GSK3p activity (305), and its nuclear localization (263) to mediate p53 nuclear 
export and degradation (260,263). One possibility is that GSK3p becomes activated by 
phosphorylation by kinase(s) that is (are) induced in response to PKRJPERK activation. 
Moreover, the eIF2a kinases may contribute to the control of factors that initiate GSK3p 
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activation and translocation. Here, we show that the eIF2a kinase/GSK3p pathway 
contributes to p53 degradation upon TG or dsRNA. Interestingly, it has been shown that 
DNA damage can induce the eIF2a kinase GCN2 (81) and that GSK3 p activation and 
nuclear localization upon DNA damage resulted in p53 stabilization (340). However, it is 
still unclear whether eIF2a kinases control GSK3 activity and localization upon DNA 
damage. This apparent opposite regulation on p53 by GSK3p can be explained by the 
fact that different stimuli induce different p53 phosphorylation patterns and these patterns 
could determine the outcome ofp53 stabilityand cellular response (281). 
OF 
Our data demonstrate that conditions activating eIF2a kinases induce p53 
downregulation without involving the translational shut-off of p53 mRNA despite the 
phosphorylation of eIF2a (Fig. 44 and 47). 
Our results are partially in agreement with conclusions of findings reported by 
Marques et al. (226), who also showed the downregulation of p53 by dsRNA signaling 
and PKR activation. In this study, the authors concluded that the reduction in p53 protein 
expression is regulated at the translationallevel. However, they observed similarly to us 
that p53 protein levels can be recovered by proteasome inhibition with MG 132 (Fig. 
40B), supporting a role of the proteasome pathway for the decrease of p53 protein levels. 
In order to justify this apparent contradiction, we employed a method that directly 
measures translation: polysome profiling. We did not observe any changes in the 
sedimentation pattern ofp53 mRNA in contrast to ATF4 mRNA (Fig. 44B) (125). Even if 
dsRNA induced a small shift ofp53 mRNA into lower polysomes, presumably due to the 
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disruption of high polysome fractions compared to TG treatment (Fig. 44A), the absence 
ofp53 mRNA in monosomes indicated that translation still proceeds. Moreover, the same 
conclusions were applied in our GyrB-PKR system, which mimics all eIF2a kinases in 
terms of induction of their catalytic activity (Fig. 47 A). Furthermore, our data using 
SalO03 and the eIF2a knock-in cells excluded the role of eIF2a phosphorylation per se in 
p53 nuclear export and degradation (Fig. 42-43). Therefore, we conclude that the 
downregulation of p53 by dsRNA is independent of eIF2a and translation. This raises the 
question whether the downregulation of p53 by the eIF2a kinases is specific to p53. It 
will be therefore interesting to see if other pro teins are regulated by a similar mechanism. 
One possibility for p53 mRNA to bypass eIF2a-dependent translation inhibition 
IS characterization of InternaI Ribosomal Entry Sites (IRES) that may mediate the 
translation of p53 as suggested recently (268,354). IRES-dependent translation upon 
eIF2a phosphorylation has been described for the CAT-l mRNA (351). Basically, the 
induction of CAT-l IRES activity requires both translation of a small upstream open 
reading frame (uORF) within the IRES and phosphorylation of eIF2a. Therefore, p53 
may be regulated similarly upon conditions that induce eIF2a kinase activity. 
IN THE THE 
Our results suggest that eIF2a kinases may regulate specific proteins that are 
resistant to the translational effects of eIF2a phosphorylation by inducing their 
degradation via the proteasome pathway. The implication of ER stress in modulating the 
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ER-associated degradation (ERAD) pathway has been previously described (329). 
However, the role of eIF2a kinases and translational control in regulating the ERAD 
pathway or protein degradation is currently not known despite sorne studies that link 
translation to degradation (98,253). This implies that in sorne circumstances eIF2a 
kinases may regulate protein degradation rather than protein synthesis depending on the 
type of stress exerted on the cell. Therefore it is conceivable to speculate that the eIF2a 
kinases may contribute to the regulation of protein turnover through their capacity to 
phosphorylate or activate other unidentified substrates. To date only Nrf2 and p53 have 
been described as substrates to PERK and PKR, respectively (72,73). 
The eIF2a kinases contribute to stress adaptation and their activation is primarily 
cytoprotective. This notion is supported by the fact that eIF2a kinases facilitate NF-KB 
activation in response to diverse stimuli including amino acid starvation, UV irradiation, 
and ER stress (158,162,164). NF-KB is a key factor involved in many biological 
responses including inflammatory response and cell survival (168). However, when 
adaptation is not possible, stressed cells are eliminated by apoptosis through the 
activation of the JNK pathway and caspases-7, -12, and -3 (174,280). Inhibition of p53 
activity by eIF2a kinases may represent an additional mechanism used by cells to adapt 
to various stress conditions that induce eIF2a kinase function. We previously showed 
that ER stress protects HCT116 cells from apoptosis in response to DNA damage and that 
ER stress impaired p53-dependent apoptosis (263). Recently published work by Li et al. 
report that ER stress-induced apoptosis resulted from p53-dependent activation of PUMA 
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and NOXA in MEFs (202). However, this conclusion is mainly based on immunoblot 
analysis performed with a p53 antibody (P Ab240) that is known to recognize only the 
mutant form ofp53 (109). 
In contrast, our analysis in primary MEFs demonstrated that p53 was rapidly 
degraded upon TG treatment (Fig. 39A). Moreover, our data showed that PUMA protein 
levels were not induced after prolonged treatment of ER stress in HCT116, HTI080, 
U20S and A549 cells (Fig. 38A). Similar results were found with NOXA except in 
U20S cells, suggesting that various cancer cells may utilize multiple pathways to 
regulate NOXA independently of p53 following ER stress (Fig. 38A). Consistent with 
our observations, Armstrong et al. showed that the induction of NOXA-mediated 
apoptosis upon TG treatment was p53-independent (6). Our findings are also in 
opposition with those by Zhang et al., who found that cytoprotective effects of ER stress 
resulted from the accumulation of p53 in HCT116 cells (365). By using the same 
conditions, our data clearly indicated that ER stress downregulates p53 protein levels in 
these cells (Fig. 38A). We have no explanation for these differences, however, our 
analysis using three additional cell lines was consistent with a recent report clearly 
showing that TG resulted in downregulation ofp53 (6). 
Moreover, our data showed an increase in phosphorylated glycogen synthase upon 
ER stress (Fig. 38A), a well known substrate correlating with GSK3~ activation, and a 
role of GSK3~ in p53 degradation as claimed in our previous conclusions (260,263). 
Consistent with our observations, Yamasaki et al. found that p53 was ubiquitinated and 
targeted for degradation in the cytoplasm by the ER-resident E3 ubiquitin ligase 
Synoviolin (352), whose expression is induced upon TG treatment (350). Taken together, 
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these data are consistent with the notion that p53 does not display any function or any 
transcriptional activity upon ER stress due to its degradation. 
5 3ANDTHE 
Our data suggest that dsRNA produced during virus replication may promote the 
downregulation of p53 protein levels in virus-infected cells. However, other studies have 
shown that the regulation of p53 during virus infection is dependent on the type of virus. 
For instance, VSV infection does not alter p53 protein levels whereas infection with 
encephalomyocarditis virus (ECMV), and human parainfluenza virus type 3 (HPIV3) 
downregulates p53 (226,320). Although these virus es have been shown to initiate an anti-
viral response mediated via activation of PKR by dsRNA intermediates (11), the overall 
signaling pathways induced by these different viruses may determine the fate of p53 
protein levels. 
AIso, IFNa/p treatment has been shown to induce p53 in order to contribute to the 
anti-viral response triggered by VSV infection (320). Studies have shown that two types 
of RNA helicases (RIG-I and MDA5) are essential for type 1 IFN production in response 
to distinct classes of RNA virus. RIG-I is required for the in vivo response to VSV, 
Newcastle disease virus (NDV), Sendai virus (SeV), and influenza virus (169,170). In 
contrast, MDA5 is the dominant receptor for poly(rl-rC), and is essential for the antiviral 
response to EMCV (113,170). 
Therefore, the IFN response generated by various types of virus es may be utilized 
by the cell to limit virus replication either through induction of early apoptosis by 
stabilizing p53 or by turning off viral protein synthesis through eIF2a kinase activation. 
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Although dsRNA contributes to p53 destabilization, this effect may be counterbalanced 
by the changes in the nucleus in virus-infected cells activating a pathway similar to the 
DNA damage response, leading to p53 stabilization. For example, it is suggested that 
RNA viruses may interact with the nucleolus and perturb cellular functions (142). 
Perturbation of the nucleolus has been shown to stabilize p53 through oncogenic stress. 
The nucleolus-Iocalized ARF protein has been shown to disrupt the Mdm2-p53 
interaction, thus favoring the stabilization and accumulation of p53 (108). Since viral 
proteins are produced prior to genome replication (or dsRNA production), one can 
assume viral proteins that disrupt the nucleolus can potentially stabilize p53. In tum, this 
mechanism could counteract the degradation of l'53 induced by dsRNA despite the 
activation ofPKR. 
Consequently, the nature of dsRNA recognitilon employed by the cell may explain 
the different ways in which differentially infected cells coordinate anti-viral immunity. 
AIso, dsRNA signaling is one of the many pro-apoptotic pathways induced in virus-
infected cells (279). Since, dsRNA is a by-product of virus replication, its ability to 
inhibit p53 raised sorne questions regarding the pro-apoptotic role of p53 in infected 
cells. The regulation of the anti-viral properties of p53 and the role of the eIF2a-
dependent apoptotic pathway may contribute to CUITent potential therapies such as the use 
of oncolytic virus es (20) aimed at destroying tumors carrying wild type p53. 
TO 
It is well established that ER stress is linked to tumorigenesis (220). A recent 
report showed that ER stress induced cellular senescence in primary melanocytes without 
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the requirement of a functional p53 protein (82), supporting a direct role of ER stress in 
tumour suppression. However, several reports showed that PERK activation and eIF2a 
phosphorylation are induced under hypoxia (184,186), a physiological inducer of ER 
stress, and promo tes tumor growth (31). Hypoxia is a condition that is common in solid 
tumors, making ER stress an important determinant of malignant progression. Although 
p53 induction under hypoxia is still controversial, sorne reports have provided evidence 
of the downregulation of p53 in conditions that were free from acidosis and maintained 
nutrient levels (254,288). 
Taken together, our findings are consistent with a model where induction of 
PERK is associated with p53 degradation in hypoxie conditions. Given the role of p53 in 
tumor suppression, its downregulation and inactivation in conditions where eIF2a 
kinases are activated could provide growth advantages to cells and promote 
transformation. Therefore, we can speculate that activation of PERK III 
pathophysiological conditions may provide explanation for tumor resistance to 
radio/chemotherapies in cells harbouring wild type p53. In this regard, it is intriguing to 
address the degree to which PERK-mediated p53 inactivation contributes to cancer 
progression, in conjunction with other inactilvating mechanisms (e.g. Mdm2 
amplification, cytoplasmic sequestration, loss of ARF). 
7 
In conclusion, our data provide a molecular basis for the destabilization of p53 
under conditions of eIF2a kinase activation. This allows the cell to adapt to disturbances 
in the normal function of the ER leading to p53 degradation, a necessary event to prote ct 
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cells against premature apoptosis. Further work is required to determine the intermediate 
signales) between eIF2a kinases and GSK3p. Such approach is crucial for the use of 
PERK and PKR as tools to discover therapeutic approaches for viral infection and cancer 
dysfunction. 
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Figure 53. Schematic model of eIF2a kinase mediated-p53 regulation in ER 
stressed cells. 
When ceUs are exposed to ER stress, the eIF2a kinases activate different 
signaling pathways, one involved in translational control, another one 
controlling the activation of GSK3p leading to the induction of p53 
phosphorylation on Ser315 and Ser376, as previously published. These 
phosphorylation events enhance the ubiquitination of p53 by Mdm2 and the 
cytoplasmic relocation of the tumour suppressor. As a result, p53 
degradation occurs in the cytoplasm. 
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Research presented within this document has provided evidence that two distinct 
PKR-1- mice express truncated PKR proteins that may contribute to the controversial 
evidence observed regarding downstream signaling pathways mediated by dsRNA. 
Furthermore, we provide evidence of novel' anti-viral and anti-apoptotic functions of 
PERK during VSV infection by regulating PKR activity. We also present new findings 
regarding the role of eIF2a kinases in promoting p53 downregulation independent of 
eIF2a-mediated translational inhibition. These studies are sorne of the first ones to 
demonstrate a role of eIF2a kinases in modulating p53 protein levels by promoting its 
nuclear export and degradation. Moreover, thisdocument pro vides new insights into the 
molecular mechanisms regarding resistance' to VSV infection, and the role of eIF2a 
kinases in the modulation ofp53 upon conditions that induce ER stress. The candidate's 
major contributions are summarized as follows: 
1. The candidate was the first to clone and characterize truncated proteins 
expressed in two distinct PKR-j- MEFs. These truncated proteins may 
contribute, at least in part, to the signaling differences observed between the 
two PKR-j- mice, and may explain the reason for the controversial evidence 
amongthem. 
2. The candidate demonstrated for the first time, the activation of PERK in VSV 
infected MEFs. These experiments demonstrated that VSV induces PERK 
activation and subsequent eIF2a phosphorylation. These results provide 
further evidence that other eIF2a kinases are involved in mediating the 
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inhibition of viral protein synthesis, and explain the redundant eIF2a 
phosphorylation observed in VSV-infected PKR-/- MEFs. 
3. Studies conducted by the candidate show, for the first time, that PERK may 
function upstream to PKR in VSV infection and upon ER stress. These data 
suggest that a cross-talk between two eIF2a kinases is required for 
resistance to VSV infection. This data may also explain the PKR activation 
observed du ring ER stress that remained elusive for almost one decade. 
4. The candidate was first to describe the role of PERK in dsRNA-mediated 
activation of PKR. This may provide evidence that PERK may contribute to 
the interaction between PKR and dsRNA by mediating conformational 
changes prior to PKR activation. 
5. Experiments performed by the candidate demonstrated that eIF2a kinases 
contribute to the downregulation of p53. This study provides further 
evidence to the transcriptional modulation functions mediated by eIF2a 
kinases. This suggests that eIF2a kinases play important roles in regulating 
transcription as weIl as translation. 
6. The candidate provides evidence for the first time that the downregulation of 
p53 upon ER stress or dsRNA is not translational but rather degradation. 
This study suggests that translational control does not play a role in p53 
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downregulation suggesting that eIF2a kinases may play a role in the protein 
degradation machinery. 
7. The candidate provides a novel finding that GSK3p activation is induced by 
eIF2a kinases. This suggests that the downregulation of pS3 upon ER stress 
mediated by GSK3p is regulated by eIF2a kinase· activity, and that eIF2a 
kinases may also play a role in glucose metabolism since GSK3p regulates 
glycogen synthesis. 
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1) TITULAIRE DE PERMIS 
PERMIS PORTANT SUR lES 
SUBSTANCES NUCLËAIRES ET 
LES APPAREILS A RAYONNEMENT 
04094-7-07.0 
licence Number 
Numéro de permis 
Conformément à l'article 24 (2) de la Loi sur la sûreté et la réglementation 
nucléaires, le prés'ent permis est délivré à: 
Il) PÉRIODE 
Hôpital Général Juif/ 
Jewish General Hospital 
Sir Mortimer B. Davis 
3755, chemin de la 
Côte Ste-Catherine 
Montréal (Québec) 
H3T lE2 
Canada 
Ci-après désigné sous le nom de «titulaire de permis» 
Ce permis est valide du 1er août 2002 au 31 juillet 2007. 
II) ACTIVITÉS AUTORISÉES 
Le présent permis autorise le titulaire à avoir en sa, possession, 
transférer, importer, exporter, utiliser et stocker les substances 
nucléaires et les équipements autorisés qui sont énumérés dans la 
section IV) du présent permis. 
Le présent permis est délivré pour le type d'utilisation: études de 
laboratoire - 10 laboratoires ou plus où des radio-isotopes sont 
utilisés ou manutentionnés (836) 
IV) SUBSTANCES NUCLÉAIRES ET ÉQUIPEMENT AUTORISÉ 
ARTICLE SUBSTJl:NCE SOURCE NON SCELLÉE ASSEMBLAGE DE LA ÉQUIPEM1!INT -
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
NUCLÉAIRE QUANTITÉ SOrJRCE SCELLÉE FABRICANT ET 
HllXIHALE QUANTITÉ HllXIHALE MODÈLE 
Carbone 14 400 MBq 5/0 s/o 
Ca.lcium 45 40 MBq s/o s/o 
Cérium 141 100 MBq 5/0 5/0 
Chrome 51 100 MBq s/o s/o 
Fer 55 100 MBq s/o s/o 
Fer 59 1 GBq s/o slo 
Hydrogène 3 2 GBq slo s/o 
Iode 125 1 GBq 5/0 slo 
l'hospho're 32 5 GBq slo slo 
Phosphore 33 100 MBq s/o slo 
Soufre 35 3 GBq slo slo 
Scandium 46 100 MBq s/o slo 
Strontium 85 20 MBq slo slo 
Césium 137 5/0 40 kBq slo 
Césium 137 slo 1480 kBq Beckman LS (series) 
Radium 226 slo 370 kBq PerkinElmer Wallac 1200 
series LS Counters 
Europium 152 slo 740 kBq PerkinElmer Wallac 1400 
series L5 Counters 
La quantité totale d'une substànce nucléaire non scellée possédée ne 
doit pas excéder la quantité maximale qui est indiquée pour une 
source non scellée correspondante. La quantité de substance nucléaire 
par source scellée ne doit pas excéder la quantité maximale indiquée 
par source scellée correspondante. Les sources scellées doivent être 
utilisées seulement dans l'équipement indiqué corrrespondant. 
V) ENDROIT(S) Où LÈS ACTIVITÉS AUTORISÉES PEUVENT ÊTRE EXERCÉES 
utilisées ou entreposées à (aux) 
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AOIATION DEVICES 
ICENCE 
CONDITIONS 
PERMIS PORTANT SUR LES 
SUBSTANCES NUCLÉAIRES ET 
LES APPAREILS A RAYONNEMENT 
endroit(s) suivant(s): 
Institut Lady Davis de Recherches 
Médicales 
3755 chemin Côte Ste-Catherine 
Montréal (Québec) 
1. Interdiction visant l'utilisation chez les humains 
04094-7-07.0 
Ucence Number 
Numéro de permis 
Page 2 
Le permis n'autorise pas l'utilisation des substances nucléaires dans 
ou sur le corps d'une personne. 
(2696-0) 
2. Classification des zones, pièces et enceintes 
Le titulaire de permis désigne chaque zone, pièce ou enceinte où on 
utilise plus d'une quantité d'exemption d'une substance nucléaire non 
scellée à un moment donné selon la classification suivante : 
(a) de niveau élementaire si la quantité ne dépasse pas 5 LAI, 
(b) de niveau intermédiaire si la quantité utilisée ne dépasse pas 50 
LAI, 
(c) de niveau supérieur si la quantité ne dépasse pas 500 LAI, 
(d) de confinement si la quantité dépasse 500 LAI; 
(e) à vocation spéciale, avec l'autorisation écrite de la Commission 
ou d'une personne autorisée par celle-ci. 
À l'exception du niveau élementaire, le titulaire de permis n'utilise 
pas de substances nucléaires non scelléE~s dans ces zones, pièces ou 
enceintes sans l'autorisation écrite de la Commission ou d'une 
personne autorisée par celle-ci. 
(2108-1) 
3. Liste des laboratoires 
Le titulaire de permis tient à jour une liste de toutes les zones, 
salles et enceintes dans lesquelles plus d'une quantité d'exemption 
d'une substance nucléaire est utilisée ou stockée. 
(2569-1) 
4. Procédures de laboratoire 
Le titulaire affiche en tout temps et bien en évidence dans les 
zones, les salles ou les enceintes où des substances nucléaires sont 
manipulées une affiche sur la radioprotection qui a été approuvée par 
la Commission ou une personne autorisée par la Commission et qui 
correspond à la classification de la zone, de la salle ou de 
l'enceinte. 
(2570-1) 
5. Surveillance thyroïdienne 
La personne 
a) qui utilise à un moment donné une quantité d'iode 125 ou d'iode 
131 volatiles dépassant : 
(i) 5 MBq dans une pièce ouverte, 
(ii) 50 MBq dans une hotte, 
(iii) 500 MBq dans une boîte à gants, 
(iv) toute autre quantité dans une enceinte de confinement approuvée 
par écrit par la Commission ou une personne autorisée par celle-ci; 
(b) qui est impliqué dans un déversement mettant en cause plus de 5 
MBq d'iode 125 ou d'iode 131 volatiles; 
(c) chez laquelle on détecte une contamination externe à l'iode 125 
ou l'iode 131; 
doit se prêter à un dépistage thyroïdien dans les cinq jours suivant 
l'exposition. 
(2046-7) 
6. Dépistage thyroïdien 
Le dépistage de l'iode 125 et de l'iode 131 internes se fait: 
(a) par mesure directe à l'aide d'un instrument capable de détecter 
kBq d'iode 125 ou d'iode 131; 
(b) par essai biologique approuvé par la Commission ou une personne 
autorisée par celle-ci. 
(2600-1) 
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7. Essai biologique thyroldien 
Si la charge thyroldienne dans une personne depasse 10 kBq d'iode 125 
ou d'iode 131, le titulaire de permis doit présenter immédiatement un 
rapport préliminaire à la Commission ou à une personne autorisée par 
celle-ci. Dans un délai de 24 heures, la personne en question doit 
subir des essaies biologiques par une personne autorisée par la 
Commission à offrir un service de dosimétrie interne. 
(2601-4 ) 
8. Dosimétrie des extrémités 
Le titulaire de permis veille à ce que toute personne qui manipule un 
contenant renfermant plus de 50 MBq de phosphore 32, de strontium 89, 
d'yttrium 90, de samarium 153 ou de rhénium 186 porte une bague 
dosimètre. Le dosimètre est fourni et lu par un service de dosimétrie 
autorisé par la Commission. 
(2578-0) 
9. Critères de contamination 
En ce qui a trait aux substances nucléaires figurant au tableau 
«Classification des radionucléides» du guide sur les demandes de 
permis, le titulaire de permis veille à ce que : 
(a) la contamination non fixée dans toutes les zones, pièces ou 
enceintes où on utilise ou stocke des substances nucléaires non 
scellées ne dépasse pas : 
(i) 3 Bq/cm2 pour tous les radionucléides de catégorie A, 
(ii) 30 Bq/cm2 pour tous les radionucléides de catégorie B, 
(iii) 300 Bq/cm2 pour tous les radionucléides de catégorie C, 
selon une moyenne établie pour une surface ne dépassant pas 100 cm2; 
(b) la contamination non fixée pour toutes les autres zones ne 
dépasse pas : 
(i) 0,3 Bq/cm2 pour tous les radionucléides de catégorie A, 
(ii) 3 Bq/cm2 pour tous les radionucléides de catégorie B, 
(iii) 30 Bq/cm2 pour tous les radionucléides de catégorie C, 
selon une moyenne établie pour une surface ne dépassant pas 100 cm2. 
(2642-2) 
10. Déclassement 
Avant le déclassement d'une zone, d'une p~ece ou d'une enceinte où 
s'est déroulée l'activité autorisée, le titulaire de permis veille à 
ce que : 
(a) la contamination non fixée pour les substances nucléaires 
figurant au tableau «Classification des radionucléides» du guide sur 
les demandes de permis ne dépasse pas : 
(i) 0,3 Bq/cm2 pour tous les radionucléides de catégorie A, 
(ii) 3 Bq/cm2 pour tous les radionucléides de catégorie B, 
(iii) 30 Bq/cm2 pour tous les radionucléides de catégorie C, 
selon une moyenne établie pour une surface ne dépassant pas 100 cm2; 
(b) la mise en disponibilité de toute zone, pièce ou enceinte 
contenant une contamination fixée soit approuvée par la Commission ou 
une personne autorisée par celle-ci; 
(c) toutes les substances nucléaires et tous les appareils à 
rayonnement ont été transférés conformément aux conditions du permis; 
(d) tous les panneaux de mise en garde contre les rayonnements ont 
été retirés ou ont été rendus illisible. 
(2571-2) 
11. Stockage 
Le titulaire 
a) veille à ce que seules les personnes autorisées par lui aient 
accès aux substances nucléaires radioactives ou aux appareils à 
rayonnement stockés; 
b) veille à ce qU'à tout endroit occupé à l'extérieur de la zone, de 
la salle ou de l'enceinte de stockage le débit de dose provenant des 
substances ou appareils stockés ne dépasse pas 2,5 microSv/h; 
c) a des mesures en place pour assurer que les limites de dose 
indiquées dans le Règlement sur la radioprotection ne sont pas 
dépassées en raison du stockage de ces substances ou appareils. (2575-0) 
12. Évacuation (laboratoires) 
Lorsqu'il évacue des substances nucléaires non scellées dans une 
décharge municipale ou un réseau d'égouts, le titulaire de permis 
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